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Abstract 
Psychotic experiences (PEs) are non-clinical traits, which at the extreme resemble 
symptoms of psychotic disorders, such as schizophrenia. PEs during adolescence 
have been associated with a range of psychiatric disorders, including 
schizophrenia, bipolar disorder, and major depression. Adolescent PEs are 
moderately heritable, however no genetic variant has been associated with 
adolescent PEs at genome-wide significance. There are limited and mixed findings 
regarding a common genetic overlap between adolescent PEs and psychiatric 
disorders.  
Following a systematic review of previous studies using genome-wide genetic data 
to investigate adolescent PEs, this thesis sets out to improve upon previous 
research through two main approaches: 1) the use of specific and quantitative 
measures of adolescent PEs, and 2) the combined analysis of multiple samples. In 
Chapter 2, a GWAS (genome-wide association study) is performed using specific 
and quantitative measures of adolescent PEs using the TEDS (Twins Early 
Development Study) sample. In Chapter 3, the procedure in which phenotypic data 
is normalised and controlled for covariates is investigated. The remainder of the 
thesis is based on the combined analysis of three European adolescent samples 
(TEDS and two others) with available PE data. In Chapter 4, the phenotypic data 
relating to PEs within each sample are harmonised to create four measures 
assessing specific PE traits that are comparable across samples. These four traits 
are Paranoia and Hallucinations, Cognitive Disorganisation, Anhedonia, and Parent-
rated Negative Symptoms. In Chapter 5, mega-GWASs of the four specific PE traits 
(N = 6,297-10,098) are performed across the three samples to highlight associated 
genetic variation. Chapter 6 then estimates the variance in specific PEs, and the 
covariance between PEs, that is attributable to common genetic variation. Chapter 
 4 
7 uses both polygenic risk scoring and LD-score regression to test for common 
genetic overlap between specific adolescent PEs and schizophrenia, bipolar 
disorder, and major depression.  
This thesis provides evidence that specific PEs during adolescence show common 
genetic effects, and have a common genetic overlap with psychiatric disorders, 
specifically schizophrenia and major depression. The findings of this thesis are 
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Chapter 1 - Introduction 
In this chapter, an in-depth overview of molecular genetic research on adolescent 
psychotic experiences (PEs) will be provided. The importance of adolescence as a 
developmental stage will be demonstrated, focusing on mental health. Adolescent 
PEs will be described in terms of behavioural features, presence in the general 
population, and their relationship with psychiatric traits and disorders occurring in 
adolescence and adulthood. The field of molecular genetics will then be introduced, 
focusing on the development of methods for identifying genetic factors underlying 
common traits/disorders and the nuances of genome-wide association studies. 
Evidence that adolescent PEs are heritable will be described before providing a 
systematic review of all studies investigating adolescent PEs using genome-wide 
molecular genetic data. The findings and limitations of previous genome-wide 
studies will present considerations from which the aims of this thesis will be 
derived. 
1.1 - Adolescence 
1.1.1 - Adolescence: A critical period 
Major physical and psychological changes occur during adolescence, the 
developmental stage between childhood and adulthood which is typically defined 
as 11-20 years of age (Dahl, 2004). These changes are in conjunction with 
substantial social changes driven in part by separation from ones parents, forming 
peer relationships, and taking on responsibility. The simultaneous transformation 
of these aspects of life makes adolescence a highly sensitive and complex 
developmental period (Steinberg, 2005). Due to the relatively low mortality during 
adolescence (World Health Organization, 2009b), adolescents are often thought to 
be in good health. However, adolescents are exposed to many risk factors, such as 
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substance use, and are commonly affected by non-lethal health problems, 
particularly relating to mental health (Patton et al., 2010), both of which can be 
influential for health outcomes later in life (World Health Organization, 2009a). For 
example, the World Health Organisation reported almost 35% of the global burden 
of disease occurs during or is attributable to adolescence (World Health 
Organisation, 2012). The importance of understanding adolescent health is further 
justified by its great potential to influence many aspects of society in the future 
(Sawyer et al., 2012). 
1.1.2 - Mental health in adolescence 
Mental health issues during adolescence have been reported as a major health 
concern (Patel, Flisher, Hetrick, & McGorry, 2007). More than 1 in 5 individuals 11-
16 years old have a psychiatric disorder, the most prevalent being anxiety and 
conduct disorder (Green, McGinnity, Meltzer, Ford, & Goodman, 2005). The 
debilitating nature of these psychiatric disorders during adolescence has harmful 
downstream consequences for mental and physical health. Psychiatric issues 
starting in adolescence, account for half of the psychiatric disorders in adulthood 
(P. B. Jones, 2013). Furthermore, a number of behavioural traits in healthy 
adolescents have been associated with the development of psychiatric disorders in 
adulthood (Hemphälä & Hodgins, 2014; Poulton et al., 2000). Many adult mental 
disorders are highly prevalent and have a high comorbidity with physical disorders 
such as diabetes, cardiovascular disease, asthma, and musculoskeletal disease 
(Australian Institute of Health and Welfare, 2011), suggesting that an improved 
understanding of adolescent mental health could lead to major health benefits. 
 32 
1.2 - Psychotic experiences (PEs) 
This section will first describe the term PEs and how they relate to the 
symptomatology of psychotic disorders. Then, previous research investigating PEs 
as a risk factor will be discussed, highlighting findings relating to adolescence. 
1.2.1 – Definition and relationship with psychotic disorders 
PEs (sometimes referred to as psychotic-like experiences or psychosis proneness) 
are defined as traits in the general population that at the extreme resemble 
symptoms of psychotic disorders, such as schizophrenia (American Psychiatric 
Association, 2013b; Ronald, 2015). Similar to the symptomology of psychotic 
disorders (Siever, Kalus, & Keefe, 1993), PEs contain a number of separable 
behavioural domains (Chen, Hsiao, & Lin, 1997; Ericson, Tuvblad, Raine, Young-
Wolff, & Baker, 2011; Fossati, Raine, Carretta, Leonardi, & Maffei, 2003; Ronald et 
al., 2014; Vollema & Hoijtink, 2000). Previous investigation of PEs in several 
general population samples using principal components analysis (PCA) has 
identified replicable PE domains congruent with the recognised symptom domains 
in psychotic disorders. Most often these PE domains have separated the positive, 
cognitive and negative symptom domains (Chen et al., 1997; Ericson et al., 2011; 
Fossati et al., 2003). Positive symptoms refer to the gain or addition in perceptions 
and experiences, and can be more finely separated into paranoia, hallucinations, 
delusions and grandiosity domains (American Psychiatric Association, 2013b). 
Cognitive symptoms, also referred to as cognitive disorganisation, often occur in 
individuals with psychotic disorders (American Psychiatric Association, 2013b) but 
certain aspects also overlap with other psychiatric disorders, such as attention 
deficit hyperactivity disorder (ADHD)(American Psychiatric Association, 2013a). 
Negative symptoms refer to the removal or subtraction of perceptions or 
experiences. Subdomains of negative symptoms include anhedonia, asociality, 
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apathy, alogia (poverty of speech), avolition and inattention (American Psychiatric 
Association, 2013b). Similar to the cognitive symptoms, certain aspects of these 
negative symptoms are features of psychotic disorders but also other psychiatric 
disorders. For example, anhedonia and avolition are also symptoms of major 
depression (American Psychiatric Association, 2013a). 
Although at the extreme, PE domains resemble symptom domains in psychotic 
disorders, PEs are different in a number of ways. Firstly, PEs are common in the 
general population, particularly adolescence (Fonseca-Pedrero, Paíno-Piñeiro, 
Lemos-Giráldez, Villazón-García, & Muñiz, 2009; Ronald et al., 2014; Van Os, 
Linscott, Myin-Germeys, Delespaul, & Krabbendam, 2009; Verdoux & van Os, 2002). 
Second, as opposed to the categorical outcome of a diagnosis, PEs can be viewed as 
quantitative traits, which vary in frequency and severity (Ronald et al., 2014; Van 
Os et al., 2009).  Third, PEs are not always associated with distress for the 
individual and should be viewed as a part of normal variation in the general 
population (McGrath et al., 2015; Ronald et al., 2014).  
There is a closely related group of traits referred to as schizotypal traits or 
schizotypy. These schizotypal traits differ to PEs in that they focus on differences in 
personality that reflect liability to psychotic disorders rather than the presentation 
of subclinical psychotic symptoms (Pedrero & Debbané, 2017). Schizotypal traits 
are not a focus of this thesis and will not be discussed further. 
1.2.2 - PEs as risk factors 
Although PEs are themselves not pathological, they have been associated with a 
number of mental health related factors and outcomes in adolescence and 
adulthood.  
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One adolescent mental health outcome associated with PEs is suicide. For example, 
PEs during adolescence have been identified as a risk factor for adolescent suicide 
attempts and ideation (Cederlöf et al., 2016; Kelleher et al., 2013; Kelleher, 
Cederlöf, & Lichtenstein, 2014). Suicide is a leading cause of mortality with 
approximately one million deaths by suicide per year worldwide (World Health 
Organization, 2012). The most recent study reporting an association between PEs 
and suicide was based on data collected by the Child and Adolescent Twin Study in 
Sweden (CATSS)(Cederlöf et al., 2016). This study reported that paranoia, 
hallucinations (auditory and visual), thought interference, and grandiosity at age 
15 or 18 all positively and significantly predicted suicide attempts later in 
adolescence (hazard ratios of 1.6-2.5). This study also demonstrated a positive and 
significant association between paranoia and hallucinations separately and 
subsequent diagnosis of substance abuse disorder during adolescence (hazard 
ratio of 2.7-3.0). Furthermore, the authors report that PEs (assessed at 15 or 18) 
preceded the suicide attempt or diagnosis when they included outcomes occurring 
anytime after 15. Although this study provides robust evidence for an association 
between certain positive PE domains, suicide attempts, and substance abuse 
disorder, it did not investigate the effect of cognitive or negative domains of PEs. 
There is also evidence for association between PEs and adult psychiatric disorders 
including psychotic (McGrath et al., 2016; Poulton et al., 2000; Van Os et al., 2009; 
Welham et al., 2009) and non-psychotic psychiatric disorders (McGrath et al., 2016; 
S. A. Sullivan et al., 2014). There is evidence of a bidirectional effect in that PEs can 
both precede and succeed the diagnosis of a psychiatric disorder (McGrath et al., 
2016), however the majority of studies have primarily focused on PEs occurring 
prior to diagnosis (Poulton et al., 2000; S. A. Sullivan et al., 2014; Van Os et al., 
2009; Welham et al., 2009). One of the first studies demonstrating a link between 
PEs prior to the onset of psychotic disorders specifically was based on the Dunedin 
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Multidisciplinary Health and Development Study(Poulton et al., 2000). This study 
reported that individuals at age 11 reporting prevalent PEs had a 16-fold increase 
in risk of developing schizophreniform-disorder by age 26. The most recent study 
investigating the relationship between PEs and the subsequent onset of a range of 
psychiatric disorders (not schizophrenia) reported a significant and positive 
association between PEs and several mood disorders, anxiety disorders, impulse-
control disorders, eating disorders and substance-use disorders, with odds ratios 
between 1.7 and 3.2 (McGrath et al., 2016). These studies have focused on the 
positive domain of PEs (mainly paranoia, hallucinations, and thought interference), 
with the effect of cognitive and negative PE domains on subsequent psychiatric 
outcomes less explored. A meta-analysis showed that unaffected first-degree 
relatives of schizophrenic individuals had increased cognitive deficits compared to 
the general population (Sitskoorn, Aleman, Ebisch, Appels, & Kahn, 2004). This 
provides evidence that cognitive deficits in a non-clinical sample have shared 
aetiology with psychotic disorders. There is also some recent evidence of an 
overlap in aetiology of negative symptoms during adolescence and schizophrenia 
based on a molecular genetic approach called polygenic risk scoring (H. J. Jones et 
al., 2016). This study will discussed further in Section 1.6. 
As previously mentioned, studies investigating PEs have focused on those 
occurring during adolescence. This is supported by the fact that adolescence is 
known to be influential in predicting mental health outcomes in general, but also 
the previous report that PEs during adolescence are associated with increased 
negative outcomes relative to PEs in childhood (Kelleher et al., 2012; Trotman et 
al., 2013). Collectively, the literature highlights the importance of PEs before the 
onset of psychiatric disorders, primarily in adolescence, suggesting that an 
understanding of adolescent PEs may provide insight into the aetiology of a range 
of psychiatric disorders.  
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1.2.3 - Assessment of adolescent PEs 
Adolescent PEs are assessed using either interviews or questionnaires. Clinical 
interviews are time consuming, expensive, and may introduce an inter-rater bias, 
making questionnaires an appealing alternative. The validity of assessing 
adolescent PEs using questionnaires has been previously explored by several 
studies.  
Self-report questionnaires of positive PEs lead to higher median estimates of 
prevalence than from interviews (Linscott & Van Os, 2013). However, when 
compared to the findings of clinical interviews, self-report questionnaire items 
assessing experiences of paranoia and hallucinations have good validity (Kelleher, 
Harley, Murtagh, & Cannon, 2009; Laurens et al., 2007). 
Self-report questionnaires are used to assess cognitive disorganisation in non-
clinical samples. A commonly used self-report questionnaire for assessing cognitive 
disorganisation in clinical and non-clinical samples is in the O-LIFE (Oxford-
Liverpool Inventory of Feelings and Experiences) (Mason, Claridge, & Jackson, 
1995). A previous study, comparing scores from the O-LIFE cognitive 
disorganisation questionnaire with scores from a clinical interview, reported that 
although patients with schizophrenia had higher cognitive disorganisation O-LIFE 
scores than healthy participants, there was no significant correlation between the 
cognitive disorganisation O-LIFE scores and the cognitive disorganisation scores 
from clinical interview (Cochrane, Petch, & Pickering, 2010). Although this 
comparison was based on schizophrenic patients instead of a non-clinical sample, 
this finding does not support the comparability of self-report measures of cognitive 
disorganisation to clinical interview based measures. 
The positive and cognitive domains during adolescence are typically assessed using 
self-report measures. However, the negative symptom PE domain during 
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adolescence is typically assessed using observer- (such as parent-) report 
interviews or questionnaires. This is due to evidence of a discrepancy between self- 
and observer-reported negative symptoms in schizophrenic patients, suggesting 
that self-report of negative symptoms is less reliable than observer-report 
(Hamera, Schneider, Potocky, & Casebeer, 1996; Selten, Wiersma, & van den Bosch, 
2000).  
1.3 - Molecular genetics 
In this section I will describe the function of deoxyribonucleic acid (DNA), genetic 
variation, and then the development of methods for identifying genomic regions 
associated with common given traits or diseases, leading up to the advent of the 
genome-wide association study (GWAS) era. 
1.3.1 – DNA 
One approach to understanding the mechanisms underlying a given trait or disease 
is through identification of associated differences within DNA. The sequence of 
DNA encodes information for the synthesis and regulation of proteins, the 
molecular machines that carry out biological processes. Regions of DNA that 
encode proteins are called protein-coding genes. Regions of DNA that do not 
encode proteins are called non-coding regions. A large proportion of non-coding 
DNA is thought to have other functions such as encoding RNA that is not translated 
into proteins but regulates the expression of other regions of the genome. In 
humans, DNA is organised into chromosomes of which we have two copies 
(diploid), one from our mother and one from our father. Twenty-two of the 
chromosome pairs are called autosomes (non-sex chromosome) and 1 
chromosome pair are the sex chromosomes called X and Y. Females have two X- 
chromosomes. Males have one X-chromosome and one Y-chromosome. 
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1.3.2 – Genetic variation 
99.5% of the DNA sequence in humans is identical between all humans (Levy et al., 
2007). The other 0.5% of DNA showing difference in sequence between individuals 
is termed genetic variation. Genetic variation is the result of random changes in the 
sequence of DNA (genetic mutations) that may or may not be passed on to future 
offspring dependant on the reproductive fitness of the organism. Broadly speaking 
de novo mutations (occurring within an individual) can either have a positive, 
neutral or negative effect on an organism’s reproductive fitness, affecting the 
extent to which the mutation is passed on to future generations and the mutation 
frequency in a population. There are many different types of genetic variation, from 
single nucleotide changes, referred to as either single nucleotide polymorphism 
(SNPs) or single nucleotide variations (SNVs), to large chromosomal 
rearrangements, such as large insertions, deletions and translocations. The larger 
the genetic variation (in terms of genomic length), the more likely it is to have an 
effect on the organism. The different versions of a given DNA sequence caused by 
genetic variation are referred to as alleles. As previously mentioned, humans are 
diploid, so they have two copies of each chromosome (except the sex chromosomes 
in males) and therefore, two alleles of genetic locus (region), one maternal and one 
paternal. The combination of alleles at a given locus is referred to as a genotype. At 
a given locus where there are only two possible alleles in the population (biallelic), 
the two alleles are often distinguished by their frequency in a given population. The 
allele that is more common in the population is called the major allele, and the 
allele that is less common in the population is called the minor allele. As a result, 
the frequency of a specific genetic variant is referred to as the minor allele 
frequency (MAF). 
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Another important feature of DNA is linkage disequilibrium (LD), the non-random 
association between alleles at different loci in a given population. If chromosomes 
were inherited without any recombination, de novo mutations, or rearrangements, 
then all existing genetic variation on a given chromosome would have a perfect 
pair-wise correlation of 1. However, due to the occurrence of recombination, de 
novo mutations, and large-scale chromosomal rearrangements, the correlation 
between genetic variants generally decreases as the genomic distance between 
them increases. Other factors that alter the correlation or LD between genetic 
variants include the rate of mutation, natural selection, and random genetic drift 
(Ardlie, Kruglyak, & Seielstad, 2002). There are different metrics used to measure 
the LD between two variants. The most widely used measure of LD between two 
variants in population genetics is r2, which can vary between 0 and 1 (1 = perfect 
correlation, 0 = no correlation).  
1.3.3 - Identification of genetic variants underlying rare and common disease 
One aspect of molecular genetics is the identification of genetic variation 
underlying different outcomes. This process can elucidate the function of genomic 
regions and the biological processes underlying a given phenotype. With this 
knowledge it is possible to predict, and if desired, prevent or treat health outcomes.  
This is particularly true for Mendelian traits where genetic variation affecting a 
single gene is responsible for determining the outcome. As a result, genetic 
variation underlying a Mendelian disease that reduces the organism’s reproductive 
fitness will be under strong negative selective pressure, leading to its reduced 
frequency in the population, and as a result, Mendelian diseases are very rare. Due 
to the rarity of Mendelian disease, and unifactoral aetiology, pedigrees (families) 
that show multiple occurrences of the disorder are used to identify the causal gene 
via a method called linkage analysis. Although linkage analysis is a very powerful 
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tool for identifying the causal variant for Mendelian diseases, it is not well suited to 
the identification of genetic variation associated with common diseases (N. J. Risch, 
2000).  
According to the common disease-common variant hypothesis (N. Risch & 
Merikangas, 1996), genetic factors underlying common diseases must themselves 
be common. However, in contrast to the large effect size variation in Mendelian 
diseases, common diseases are driven by many genetic (and environmental) 
factors with individually small effect sizes, allowing them to stably exist in the 
general population. The large number of small effect size genetic variants (termed 
polygenicity) underlying common diseases and traits has now been demonstrated 
repeatedly using both polygenic scoring and mixed linear model methodology 
(Dudbridge, 2016; Visscher, Brown, McCarthy, & Yang, 2012). As a result, 
association analysis testing for a correlation between genetic variation and 
common disease using unrelated individuals, an approach more appropriate for the 
identification of small effect size genetic variation, is the method of choice (N. J. 
Risch, 2000). Although the majority of variance in a common trait or disease is 
attributable to common genetic variation of small effect size, some variance can 
also be attributed to rarer genetic variation due to the presence of rare variation 
with small effect size, and very few individuals carrying large effect rare variants 
that lead to a Mendelian form of the common trait or disease (Manolio et al., 2009). 
Until recently, association studies were exclusively candidate gene studies that 
focused on specific genes based on functional plausibility for a given phenotype. 
The candidate gene approach has had some success in psychiatry, whereby genes 
implicated in neurobiological pathways are studied. For example, 5-HTT-LPR, a 
genetic variant within the serotonin transporter gene (5-HTT) has been associated 
with a number of psychiatric traits/disorders, first of which were affective 
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disorders (Collier et al., 1996). However, a key limitation of the candidate gene 
approach is its dependence on a priori hypotheses and our poor ability to identify 
plausible genes. 
1.4 – Genome-wide association studies (GWAS) 
In this section I will introduce the GWAS design, its improved ability to control for 
population stratification, the multiple testing problem of genome-wide analysis, the 
factors affecting statistical power, and finally the use of consortia to overcome 
sample size limitations. 
1.4.1 – The premise of GWAS 
Hypothesis-free genome-wide association studies (GWASs) became feasible 
following the availability of high resolution genetic maps of the human genome, 
such as from the HapMap project (Gibbs et al., 2003), and the development of high-
throughput genotyping technology (Ding & Jin, 2009). Unlike the traditional 
candidate gene approach where variants within regions of interest are tested for 
association, GWASs test for associations with genetic variation across the genome. 
The markers of genetic variation used in GWAS are common variants, typically 
single nucleotide polymorphisms (SNPs) or insertions/deletions (INDELS). Based 
on the common disease-common variant hypothesis, common variation is assumed 
to explain a larger amount of phenotypic variance (larger r2) than rare variation. An 
increase in r2 corresponds to increased statistical power (ability to reject a false 
null hypothesis). With such a limited understanding of the biological mechanisms 
and genetic architecture underlying psychiatric phenotypes, this hypothesis-free 
approach is more suitable than candidate gene studies. GWASs have highlighted 
many novel genomic regions associated with a range of phenotypes, enabling an 
improved understanding of the aetiology of many complex human diseases, and 
highlighted prevention and therapeutic strategies (Visscher et al., 2012). 
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GWASs typically use regression models to test for changes in minor allele copy 
number that correlate with a given phenotype. Additive effects of each minor allele 
copy (as opposed to dominant or recessive) have been shown to explain the 
majority of variance (Hill, Goddard, & Visscher, 2008). Therefore, individuals 
homozygous for the major allele are coded as 0, heterozygous individuals are coded 
as 1, and individuals homozygous for the minor allele are coded as 2. Linear 
regression is used for the analysis of quantitative phenotypes and logistic 
regression is used for the analysis binary phenotypes. Both these types of 
regression have underlying assumptions which if violated can result in increased 
type-I and II error rates. An assumption regarding linear regression is the 
normality of the residuals (Berry, 1993). This issue will be discussed further in 
Chapter 3. 
1.4.2 – Control of population stratification 
One advantage of the genome-wide approach compared to the candidate gene 
approach is the more sensitive control of population structure. In candidate gene 
studies population structure was either not controlled for or researchers would 
perform either genomic control or structured association. Genomic control is 
where the association statistic, typically the chi-square, is divided by an inflation 
factor (λ), the degree to which an implausible genetic variant is associated with the 
same trait (Bacanu, Devlin, & Roeder, 2000). However, this approach was not 
totally effective and doesn’t stop false negatives (Price et al., 2006). Structured 
association was an alternative approach that assigns individuals to discrete 
subpopulations based on allele frequencies at each locus (Pritchard, Stephens, & 
Donnelly, 2000). The main limitations of this approach were its sensitivity to the 
number of discrete clusters specified and the computational cost when using large 
datasets (Price et al., 2006). Another approach for controlling for population 
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structure is by including measures of ancestry as covariates in the model. The 
measures of ancestry are most commonly estimated by applying principal 
components analysis or multidimensional scaling to genome-wide common genetic 
variation (Price et al., 2006). These methods identify linearly uncorrelated axes of 
covariance (components) between all genetic variants. These components have 
been shown to be correlated with other ancestry measures and control for 
population stratification when included as covariates (Price et al., 2006). A more 
novel approach to control for population stratification is mixed linear modelling 
(Yang, Zaitlen, Goddard, Visscher, & Price, 2014). This approach involves creating a 
genetic relationship matrix (GRM) that describes the genome-wide structure 
within a sample, using a random effects model to estimate the phenotypic variance 
attributable to the GRM, and then estimating association statistics for each genetic 
variant that account for the phenotypic variance explained by the GRM. 
1.4.3 – The multiple testing problem and genome-wide significance 
Although genome-wide association studies provide some advantages, the 
hypothesis-free design leads to a large number of partially dependent (due to LD) 
and independent tests, which if unaccounted for will increase the type-1 error rate. 
The simple Bonferroni correction of significance is too stringent due to the 
correlation / LD between genetic variation making them non-independent. Several 
lines of evidence estimated that genome-wide analyses were performing 
approximately one million independent test in a European sample, and therefore a 
genome-wide significance threshold of p ≤ 5x10-8 should be adopted (Dudbridge & 
Gusnanto, 2008; Hoggart, Clark, De Iorio, Whittaker, & Balding, 2008; Pe’er, 




1.4.4 – Factors affecting power in GWAS 
GWASs, due to the heavy burden of multiple testing and the small effect size of 
individual genetic variants, are often limited in their ability to reject a false null 
hypothesis, also referred to as limited statistical power. Other than effect size, 
major factors affecting statistical power include sample size, total phenotypic 
variance that can be explained by tagged genetic variation (SNP-heritability) 
(Purcell, Cherny, & Sham, 2003), genetic and phenotypic heterogeneity (Manchia et 
al., 2013), and disorder/disease prevalence (Purcell et al., 2003). 
Studies often try to overcome sample size limitations by combining samples for 
mega-analysis, or by meta-analysing test statistics derived from several samples. 
Indeed, the approach of increasing sample size to improve power is effective. This 
was nicely demonstrated by GWASs of schizophrenia where each study had an 
increased sample size and a corresponding increase in the number of 
schizophrenia loci identified at genome-wide significance (Ripke et al., 2014; Ripke, 
O’Dushlaine, et al., 2013; Schizophrenia Psychiatric Genome-Wide Association 
Study (GWAS) Consortium, 2011). However, the approach of increasing sample size 
is not always the most effective approach for increasing statistical power. This was 
demonstrated by the 2013 mega-GWAS of major depressive disorder, which 
identified no replicable associated loci despite including over 9,000 major 
depressive disorder cases in the analysis (Ripke, Wray, et al., 2013). At the time this 
was the largest GWAS to find no significant locus, highlighting the importance of 
other factors affecting power.  
Major depressive disorder has several differences compared to other psychiatric 
disorders including higher prevalence, lower heritability, and increased phenotypic 
heterogeneity (Power et al., 2017). The issue of phenotypic heterogeneity is of 
particular importance as its effect on statistical power increases with sample size, 
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and phenotypic heterogeneity is something that can be reduced. One approach to 
reduce phenotypic heterogeneity is by stratification based on other patient 
information, such as age of onset. This has been demonstrated to increase 
statistical power in the face of reduced sample size using both ischaemic stroke 
phenotypes and major depression (Power et al., 2017; Traylor et al., 2013). 
Although diagnostic categories have great utility in a clinical setting, patients 
within them often have no unifying symptom and differing profiles of symptom 
severity. This is particularly true among psychiatric diagnoses. Therefore, another 
approach for the reduction of phenotypic heterogeneity is the use of measures that 
assess specific symptom domains using quantitative measures (Manchia et al., 
2013). The use of measures that assess specific phenotypes on a quantitative scale 
have been reported to reduce phenotypic heterogeneity and thereby increase 
statistical power (Kraemer, 2007).  
1.4.5 – GWAS consortia  
As previously mentioned, a major limitation of statistical power is sample size. The 
main approach for addressing sample size limitations, without starting a new 
larger scale study to investigate the phenotype of interest, is collaboration between 
research groups to pool resources. These collaborations usually occur in one of 
three ways: 1) Meta-analysis of summary statistics from multiple uncoordinated 
studies, 2) Meta-analysis of summary statistics from multiple coordinated studies, 
or 3) Mega-analysis of individual-level data from multiple studies. The main benefit 
of meta-analysis approaches is ability to include information from samples where 
the individual-level data is not available. Many samples often have restricting 
regulations over the sharing of individual-level data for data security purposes. 
Traditionally, the first approach was most common. However, the lack of a priori 
agreement of measures, statistical methods and quality control parameters led to 
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discrepancies between the studies, making it less appropriate to compare test 
statistics between studies. More recently, the second approach has become more 
common, whereby summary statistics from studies that have been coordinated are 
meta-analysed. This second approach, sometimes referred to as a multicentre 
study, is preferable to the first due to the predefined analysis pipeline improving 
the comparability between studies. The third approach is generally harder to carry 
out due to data sharing restrictions and computational requirements to analyse 
large samples. However, if the individual level data from each sample can stored in 
a single location with sufficient computational power, the mega-analysis approach 
offers two key advantages. Firstly, almost all statistical methods are based on 
asymptotic (or large sample) theory, and therefore become more robust as sample 
size increases. However, several studies have demonstrated that a well controlled 
meta-analysis give almost identical results to mega-analysis. Secondly, the handling 
and analysis of all the data on one site and by one experimenter enables the 
experimenter to go back to the raw data to perform more exploratory analyses 
more easily, and reduces the likelihood of discrepancy in the processing of each 
sample.  
1.5 - Genetics of adolescent PEs 
In order for a genetic approach to be appropriate for the investigation of PEs, there 
must be evidence that PEs are heritable. Furthermore, given adolescent PEs 
themselves are not pathological, there must be evidence that PEs are genetically 
associated with clinical phenotypes. In this section I will briefly outline methods 
used to calculate heritability and co-heritability estimates, and then present the 




1.5.1 – Estimating heritability and co-heritability 
Heritability is calculated by estimating the relationship between genotypic 
similarity and phenotypic similarity. This can be done using family-based designs 
where the average genotypic similarity between different family relationships is 
used. For example, in the twin design, the within pair differences of monozygotic 
(MZ) and dizygotic (DZ) twins are compared (Plomin, DeFries, Knopik, & 
Neiderheiser, 2013). Twin-based heritability estimates typically include the 
phenotypic variance explained by all additive genetic factors. The classic twin 
design assumes equal shared environment among both MZ and DZ siblings. The 
equal shared environment assumption has been questioned on the basis that twins 
who resemble one another more closely are likely to treated more similarly. 
However, studies investigating this assumption have reported that the equal 
shared environment assumption is accurate for most aspects of psychopathology 
(Martin, Boomsma, & Machin, 1997). 
Another approach is to use unrelated individuals and estimate the genotypic 
similarity between individuals using genotypic data (Yang, Benyamin, McEvoy, 
Gordon, Henders, & Others, 2010). This approach traditionally uses common 
genetic variation from a genotyping array (mainly SNPs), and so these estimates 
are referred to as the SNP-heritability. Estimating the SNP-heritability requires 
larger sample sizes than twin-based methods for accurate estimates with similar 
factors affecting power as mentioned in Section 1.4.4 (Visscher et al., 2014). A 
popular method for estimating the SNP-heritability is genomic-relatedness-matrix 
restricted maximum likelihood (GREML)(Yang, Benyamin, McEvoy, Gordon, 
Henders, & Others, 2010) in Genome-wide Complex Trait Analysis (GCTA)(Yang, 
Lee, Goddard, & Visscher, 2011), which consists of two analytical steps. First, all 
SNPs are used to calculate the genetic relationship matrix (GRM) of the sample. 
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Secondly, the GRM (independent variable) is used in a mixed linear model to 
estimate SNP-heritability of the phenotype (dependent variable). GCTA estimates 
the proportion phenotypic variance explained by additive genetic effects. 
Another method for estimating the SNP-heritability of the a phenotype is called LD-
score regression (Bulik-Sullivan et al., 2015). LD-score regression is a GWAS 
(genome-wide association study) summary statistic based method for estimating 
the phenotypic variance explained by additive genetic effects. This method uses 
linear regression to estimate the relationship between LD-score and the chi-square 
of genetic variants. The premise behind this approach is that the more genetic 
variation that an index variant is in LD with, the more likely it is to tag a causal 
variant, and therefore on average have a higher test statistic. Because LD is not 
correlated with population structure or other sources of confounding, this method 
is also able to distinguish polygenicity from confounding. 
Similar to methods estimating heritability, the genetic correlation between two 
phenotypes can be estimated using predicted genotypic similarity within families 
(Plomin et al., 2013), or estimated genotypic similarity using genotypic data from 
unrelated individuals (S. H. Lee, Yang, Goddard, Visscher, & Wray, 2012). In 
contrast to methods estimating heritability, where the phenotypic variance is 
partitioned into variance components, methods estimating genetic correlation 
partition the phenotypic covariance. 
1.5.2 – Heritability of PEs 
Twin-based analyses have estimated moderate twin heritability estimates for 
adolescent PEs (Ericson et al., 2011; Hur, Cherny, & Sham, 2012; Zavos et al., 2014). 
One study using separate measures to assess specific adolescent PE domains 
reported heritability estimates between 15% and 59% (Zavos et al., 2014). In fact, 
a meta-analysis of almost all twin studies reported that all reliably measured traits 
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are significantly heritable (Polderman et al., 2015). The previously mentioned 
Zavos et al. study also reported a significant genetic correlation of 0.3-0.6 between 
certain specific PEs (Zavos et al., 2014).  
Due to sample size limitations, existing SNP heritability estimates for PEs are less 
accurate but provide evidence that adolescent PEs are at least in part regulated by 
common genetic variation (Sieradzka et al., 2015). This study is discussed further 
in Section 1.6. These findings support the validity of a molecular genetic approach 
for understanding the factors affecting adolescent PEs.  
1.5.3 – Genetic association between PEs and clinical outcomes 
Several studies investigating this question reported that offspring reported 
increased adolescent PEs if their parents had been diagnosed with a psychiatric 
disorder, particularly schizophrenia and affective disorders (Binbay et al., 2012; R. 
B. Jones et al., 2016; Zavos et al., 2014). As discussed in the systematic review in 
Section 1.6, molecular genetic studies using polygenic risk score analysis have 
reported limited and mixed findings regarding the genetic overlap between 
adolescent PEs and psychiatric disorders (H. J. Jones et al., 2016; Sieradzka et al., 
2014; Zammit et al., 2014). Collectively, these findings provide limited evidence 
that adolescent PEs may share genetic pathways with major psychiatric disorders, 
but further research is required. 
1.6 - Genome-wide analysis of adolescent PEs – A systematic 
review 
Here, all genome-wide studies of adolescent PEs with the following aims will be 
summarised: 1) to identify genetic variation underlying adolescent PEs, 2) to 
estimate the variance in adolescent PEs attributable to common genetic variation 
using measured genotypes, and 3) to evaluate genetic associations between 
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adolescent PEs and psychiatric disorders. To identify all such papers, a series of 
search terms were used in PubMed to capture the following three criteria: 1) age 
group, 2) phenotype, and 3) type of analysis. The search was conducted using the 
following format: (adolescent OR adolescence OR teenager OR teenagers OR 
teenage OR teen OR child OR childhood OR children OR young adult) AND 
(psychotic OR psychosis OR schizotypy OR schizotypal OR psychotic experiences 
OR psychotic-like-experiences OR prodromal OR psychosis proneness OR paranoia 
OR hallucinations OR anhedonia OR negative symptoms OR cognitive 
disorganisation OR cognitive disorganization OR grandiosity OR delusions) AND 
(gwas OR genome-wide OR polygenic OR gcta OR greml OR snp-heritability OR ldsc 
OR ld score regression). The resulting publications were then selected for the 
review based on the following inclusion criteria: 
• Studies using genome-wide array or sequence data. 
• Studies focusing on at least one dimension of PEs. If other psychological 
traits are analysed, only the results referring to PEs are discussed. 
• Studies using adolescent sample or sample that overlaps with adolescence 
(10-20 years of age)  
• Studies in English. 
In addition to the systematic database search using PubMed, bibliographies of 
relevant research and review papers were investigated by hand to identify further 
relevant studies. 
1.6.1 - Results of systematic review 
Collectively, four publications were identified as genome-wide studies of 
adolescent PEs using the above search terms on 23rd of August 2017 (Table 1.1). 
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One study performed a genome-wide association analysis of PEs (Zammit et al., 
2014). This study used a binary phenotype of no positive symptoms or definite 
positive symptoms at either 12 or 18 and reported no genome-wide significant 
variation. 
One study estimated the SNP-heritability of PEs (Sieradzka et al., 2015). The study 
estimated the SNP-heritability of the full range of specific PEs at age 16 and 
reported evidence for a common genetic aetiology in some types of PEs (Cognitive 
Disorganisation, Grandiosity, Anhedonia, Paranoia). SNP-heritability was estimated 
using the GREML method in GCTA software. 
Three of these studies have used polygenic risk scoring to test for an association 
between schizophrenia and PEs assessed during adolescence (H. J. Jones et al., 
2016; Sieradzka et al., 2014; Zammit et al., 2014). Positive psychotic experiences 
have been reported to show no association with schizophrenia genetic risk three 
times based on two samples (H. J. Jones et al., 2016; Sieradzka et al., 2014; Zammit 
et al., 2014). The one and only study testing for an association with cognitive 
disorganisation showed no significant positive association (Sieradzka et al., 2014). 
Of the two studies testing for an association with negative symptoms, one showed a 
significant positive association (H. J. Jones et al., 2016), the other did not (Sieradzka 
et al., 2014). 
One study tested for a positive association between the full range of specific PEs 
and bipolar disorder (Sieradzka et al., 2014) and reported no significant positive 
associations. 
Two of these publications tested whether candidate genetic variation previously 
associated with schizophrenia plays a role in PEs during adolescence (Sieradzka et 
al., 2014; Zammit et al., 2014). No candidate variation achieved significance after 
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accounting for multiple testing. The strongest association was between Paranoia a 
gene called TCF4 (transcription factor 4)(Sieradzka et al., 2014). 
In summary, there is some evidence that adolescent PEs are in part influenced by 
common genetic factors. Studies of adolescent PE have reported some suggestive 
evidence that TCF4 is involved in the aetiology of adolescent PEs, but no genetic 
locus has been significantly associated with adolescent PEs. The evidence of a 
common genetic overlap with related psychotic disorders is inconclusive due to 
mixed findings across studies. The discrepancy between studies could be partly 
explained by differences in the measures used including the latent variable 
assessed and the degree of specificity. To improve the accuracy estimates of SNP-
heritability, the ability to identify associated genetic loci, and the robustness of 
evidence of genetic association between adolescent PEs and psychiatric disorders, 
greater statistical power is required. As previously discussed in Section 1.4.4 and 
Section 1.4.5, this could be achieved by pooling information from multiple samples 
and the use of both quantitative and specific measures. 
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Table 1.1. Summary of all publications performing genome-wide analysis of psychotic experiences during adolescence. 





Avon Longitudinal Study of Parents and 
Children (ALSPAC): N = 3,483 unrelated 
individuals assessed for PEs at 12 and 
18 years.  
 
Primary analysis: Individuals separated 
into two groups based on the presence 
of at least one definite PE at either 12 
or 18. The no PE and definite PE groups 
contained 3,059 and 424 individuals 
respectively. 
 
Secondary analysis: Individuals 
separated into two groups based on the 
presence of at least one probably PE at 
either 12 or 18. No PE and probable PE 







based on the Schedule 
for Clinical Assessment 
in Psychiatry (SCAN). 
Includes 11 questions 
assessing hallucinations, 
delusions and thought 
interference. 
Candidate variation analysis of 17 
SNPs that showed a genome-
wide significant association with 
schizophrenia, and or combined 
schizophrenia and bipolar 
phenotype.  
 
GWAS using logistic regression to 
compare allele frequencies 
between PE groups. 
 
Polygenic risk score analysis using 
logistic regression to compare 
schizophrenia genetic risk scores 
between PE groups. 
Schizophrenia genetic risk was 
based on schizophrenia GWAS 
summary statistics from the 
Psychiatric Genomics Consortium 
(PGC) 1. 
 
Candidate variation analysis 
returned no variant achieving 
significance after correction for 
multiple testing. 
 
GWAS identified no variant 
achieving p<5x10-8. 121 variants 
achieved p<5x10-5 representing 31 
independent signals. 
 
Polygenic risk scoring: No 
significant association between 
schizophrenia polygenic risk scores 
and definite/none PE groups in 





Table 1.1 cont. 
Study Sample Measure/s Method Results 
2. 
Sieradzka 























Discovery sample: Specific 
Psychotic Experiences 
Questionnaire (SPEQ): 
Contains six measures 















Polygenic risk scoring using linear 
regression to compare differences in 
schizophrenia genetic risk and bipolar 
disorder genetic risk with differences in 
specific PE domains. Schizophrenia and 
bipolar disorder genetic risks were based 
on schizophrenia (PGC 2) and bipolar 
disorder GWAS summary statistics 
respectively. A one-tailed hypothesis that 
there would be a positive association was 
used. 
 
Candidate variation analysis of 33 SNPs 
previously associated schizophrenia or a 
combined schizophrenia bipolar 
phenotype at genome-wide significance. 
This was initially carried out in TEDS, with 
any significant SNPs being replicated in 
the ALSPAC sample. 
 
Linear regression was used to compare 
differences in schizophrenia genetic risk 
based on genome-wide significant 
variation only. Schizophrenia genetic risk 
was calculated using an effect size 
weighted and unweighted approach.  
  
Polygenic risk score analysis returned no 
evidence of a positive association between any 
PE domain and schizophrenia genetic risk. 
Contrary to the one-tailed hypothesis, results 
indicated that schizophrenia genetic risk 
negatively predicts anhedonia and parent-rated 
negative symptoms, and bipolar disorder 
genetic risk negatively predicts anhedonia. 
 
Candidate variation analysis of previously 
implicated variation returned no variant 
achieving significance after correction for 
multiple testing. The strongest evidence for 
association was within TCF2. The association 
between candidate SNPs within TCF2 were not 
significant in the replication sample. However, 
there were differences in the phenotype used in 
the discovery and replications samples. 
 
Neither the weighted nor unweighted 
schizophrenia genetic risk score based on 
genome-wide significant genetic variation 
significantly predicted any PE domain. 
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Table 1.1 cont. 
Study Sample Measure/s Method Results 
3. 
Sieradzka 
et al., 2015  
TEDS: N = 2,152 
unrelated individuals 
assessed at 16. 
See Discovery sample 
information for study 2. 
 
SNP-based heritability was estimated 
using GREML in GCTA. The analysis was 
performed using both LD-pruning and 
MAF stratification to account for LD. The 
analysis was also performed without 
controlling for LD. 
The different approaches used to 
control for LD lead to different 
heritability estimates. MAF-stratified 
results were deemed most accurate. 
MAF-stratified heritability estimates 
provided evidence that differences 
in paranoia (6%), cognitive 
disorganisation (23%), grandiosity 
(10%) and anhedonia (32%) are in 
part attributable to common genetic 
variation. However, estimates have 
large standard errors and were non-
significant except for anhedonia. 
Hallucinations and Parent-rated 
Negative Symptom scales returned 




Table 1.1 cont. 







N = 5,444 unrelated individuals assessed for 
positive symptoms at 12 or 18 years. Definite 
and no positive symptom groups (N=419 and 
5,025 respectively) defined by at least one 
definite PE at either 12 or 18. 
 
N = 3,673 unrelated individuals assessed for 
negative symptoms at age 16.5. High/low 
negative symptom groups (N = 337 and 3,336 
respectively) were defined using a CAPE score 
threshold of 14.   
 
N = 4,106 unrelated individuals assessed for 
depression outcome likelihood at age 15.5. 
High/low groups (N = 373 and 3,733 
respectively) defined using a 15% likelihood of 
diagnosis.    
 
N = 4,107 unrelated individuals assessed for 
anxiety outcome likelihood at age 15.5. 
High/low groups (N = 444 and 3,663 




delusions, and thought 
interference) were 
assessed using the PLIKSi. 
(see study 1) 
 
Negative psychosis-like 
symptoms were assessed 
using 10 questions from 
the Community 
Assessment of Psychotic 
Experiences (CAPE) self-
report questionnaire. This 
measure assesses features 
such as apathy, anergia and 
asociality. 
 
Depressive and anxiety 
disorder outcomes were 
derived from the semi-
structured Development 
and Well-Being Assessment 
(DAWBA) interview. 
Polygenic risk score analysis 
using logistic regression tested 
for association between 
genetic risk for schizophrenia 
using PGC 2 schizophrenia 
GWAS summary statistics and 
positive symptoms, negative 
symptoms, anxiety and 
depression disorders. 
 
Sensitivity analyses were 
performed to determine 
whether effects varied when 
using different thresholds to 
distinguish groups or when 
participants were excluded 
based on a diagnosis of a 
psychotic disorder at 18 or a 
parental diagnosis. Effects of 
adjusting for parental history 
of schizophrenia or depression 
were also tested. 
 
A significant positive 
association between 
schizophrenia PRS and 
negative symptoms and 
anxiety disorder was reported. 
Positive symptoms showed a 
near significant positive 
association when using more 
relaxed p-value thresholds for 
the PRS but a near significant 
negative association when 
using a stringent p-value 
threshold for the PRS. 
 
Sensitivity analyses showed 
results as robust to across 
different thresholds used to 
determine groups. Results 
were also not dependent on 
any diagnoses of the 
participants or parental 
history of schizophrenia or 
depression. 
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1.7 - Future directions for genetic research of adolescent PEs 
This chapter has highlighted the importance and validity of understanding adolescent 
PEs using a genetic approach. Previous studies have demonstrated that at least some 
adolescent PEs are partly influenced by common genetic variation. However, no genetic 
variant has been associated with adolescent PEs at genome-wide. Furthermore, 
previous studies have also provided limited and mixed evidence for a genetic overlap 
between adolescent PEs and schizophrenia and other typically adult-onset disorders, 
requiring further investigation. One overarching limitation of all previous genome-wide 
studies of PEs is sample size, leading to limited statistical power to provide a robust 
genetic characterisation of adolescent PEs. Due to the predicted small effect size of 
associated genetic variation, larger sample sizes are required to identify specific genetic 
variation. Many of these studies have also suffered from low statistical power due to the 
effect of phenotypic heterogeneity by the use of binary and broad/non-specific 
measures of PEs. Phenotypic heterogeneity must be kept to a minimum to improve 
statistical power. To take this important area of research forward, further investigation 
is required using large samples assessed using specific and quantitative measures of 
PEs. 
1.8 - Aims 
Based on previous literature regarding the genetic factors affecting adolescent PEs and 
their relationship with psychiatric disorders, this thesis aims to further characterise 
genetic variation associated with adolescent PEs and the genetic overlap between 
adolescent PEs and related adult psychiatric disorders. This will be achieved using 
larger samples of adolescents assessed using both quantitative and specific measures of 
psychotic experiences. Specifically, this thesis will: 1) Harmonise genetic data from 
samples with adolescent PE data to enable combined analysis, 2) Harmonise measures 
of specific PEs between samples, 3) Estimate SNP-heritability of specific PEs. 4) Perform 
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GWAS of specific PEs to identify associated genetic variation and biological pathways. 5) 
Estimate the genetic correlation between specific PEs and typically adult-onset 




Chapter 2 - GWAS of adolescent psychotic 
experiences in the Twins Early Development Study 
2.1 - Introduction 
As discussed in Section 1.5.1, adolescent psychotic experiences (PEs) are heritable and 
have been associated with a number of psychiatric disorders. Therefore, investigation of 
the genetic factors associated with adolescent PEs could be informative about the 
developmental pathways associated with a range of psychiatric disorders. As discussed 
in Section 1.4.0, a successful approach for the identification of genetic loci associated 
with common traits is association testing, particularly on a genome-wide scale. 
As discussed in Section 1.6.1, there has been one previous GWAS of adolescent PEs 
(Zammit et al., 2014). This study used data from the Avon Longitudinal Study of Parents 
and Children (ALSPAC) study and tested for genetic associations with the presence of a 
definite PE at age 12 or 18. This study focused on the positive symptom domain by 
assessing individuals using the PLIKSi, which captures paranoia, hallucinations and 
delusions. No genome-wide significant (p<5x10-8) genetic association was identified 
with the dichotomous definite or none PE groups, although 31 linkage disequilibrium 
(LD) independent loci were reported as showing a suggestive association based on a 
significance threshold of p<5x10-5. Further investigation of genetic associations with the 
full range of PEs assessed using specific quantitative measures is required. 
Here, genome-wide association analysis was performed for six quantitative measures of 
specific PEs applied in an adolescent general population twin sample called the Twins 
Early Development Study (TEDS)(Haworth, Davis, & Plomin, 2013).  
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2.2 - Methods 
2.2.1 - Participants 
TEDS recruited twins born in England and Wales between 1994 and 1996, and assessed 
these individuals longitudinally (Haworth et al., 2013). TEDS originally recruited 13,488 
families who had responded with a written consent form. The Institute of Psychiatry 
ethics committee approved TEDS and their consent procedure (ref: 05/Q0706/228).  
In this study we used data collected as a part of the Longitudinal Experiences And 
Perceptions (LEAP) project, a study within TEDS investigating the aetiology of 
adolescent psychotic experiences. Families who had withdrawn from TEDS, had never 
returned any data or had issues with their known address were not invited to 
participate in LEAP. Of the 10,874 TEDS families invited to participate, 5,076 parents 
and 5,059 twin pairs provided data on quantitative dimension specific PEs at age 16 
years (mean = 16.32 years; standard deviation = 0.68). Participants were excluded 
based on lack of consent at first contact or for the present study, presence of severe 
medical disorder(s) including autism spectrum disorder, lack of zygosity information or 
experience of severe perinatal complications. 
2.2.2 - Measure of specific PEs 
This study used the Specific Psychotic Experiences Questionnaire (SPEQ) to assess 
dimension-specific psychotic experiences (Ronald et al., 2014). SPEQ assesses five self-
report subscales (Paranoia, Hallucinations, Cognitive Disorganisation, Grandiosity and 
Anhedonia) and one parent-rated subscale (Parent-rated Negative Symptoms). These 
subscales have high internal consistency, with Cronbach’s α ranging from .77 to .93, and 
test re-test reliability with a correlation of .65 to .74 across a 9-month interval 
(p=0.001). The SPEQ has been reported as a valid measure of adolescent PEs based on 
the opinion of expert clinicians, the correlations between the SPEQ subscales and 
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measures of anxiety, depression and personality, and a moderate to high correlation 
between the positive subscales of the SPEQ and a previously validated measure of 
positive PEs called the psychosis-like symptoms questionnaire (PLIKS-Q) (Ronald et al., 
2014). 
The validity of the SPEQ’ subscales has been confirmed by expert clinicians.    
2.2.3 - Phenotypic analyses 
Descriptive statistics for phenotypic measures were calculated using R.  
When performing association analyses it is desirable that the phenotypic values fit a 
normal distribution with a low amount of skew. Four of the specific PEs (Paranoia, 
Hallucinations, Grandiosity and Delusions, and Parent-rated Negative Symptoms) had a 
moderate level of skew (>1) and were therefore normalised. Normalisation was carried 
out using a rank-based inverse normal transformation called Van der Waerden 
transformation in SPSS. This method ranks the data points and then places them into 
quantiles of a normal distribution. The correlation of a measure before and after 
transformation was always >.91. 
2.2.4 - DNA collection and genotyping 
DNA collection and genotyping procedures were carried out by the TEDS research team 
prior to the beginning of this project. DNA was extracted from 4,440 TEDS unrelated 
children using buccal cheek swabs. In total, 3,665 samples were successfully hybridised 
to the AffymetrixGeneChip 6.0 SNP genotyping platform at the Affymetrix headquarters 
in Santa Clara, California, USA, as part of the TEDS Wellcome Trust Case Control 
Consortium 2 (WTCCC2) study of reading and mathematical abilities.  
Of these samples, 513 were excluded based on one or more of the following parameters: 
low call rate or heterozygosity outliers, atypical population ancestry, sample 
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duplication, relatedness to other sample members based on an identity by descent 
threshold of <5%, unusual hybridisation intensity, gender mismatches, and having less 
than 90% of genotypes called identically on the genome-wide array and Sequenom 
panel. This resulted in 3,152 unrelated individuals successfully genotyped consisting of 
1,446 males and 1,706 females. 
Of these 3,152 genotyped individuals, data on specific psychotic experiences was only 
available for 2,179 individuals. Of these 2,179 individuals, 837 had a genetically 
identical sibling for whom it was possible to infer the genotype of. Individuals with 
inferred genotypes are termed ‘pseudo-genotyped’. Given that both siblings of these 
genotyped monozygotic twin pairs have provided phenotypic information, they can both 
be included in the association analysis, providing family structure is accounted for. This 
gives a total sample of 3,016 genotyped individuals who have provided data on specific 
psychotic experiences (42.1% Male, 57.9% Female).  
It is possible that more distantly related individuals removed during quality control of 
the genetic data could have also been included in subsequent analyses. However, related 
individuals were removed before the data was received for this thesis. Nonetheless, the 
ability of currently available methods to account for the presence of identical siblings 
and more distant relatives simultaneously has not been validated.   
The AffymetrixGeneChip 6.0 SNP genotyping platform captured variation at 1,852,600 
sites across the genome. Prior to receiving the genetic data, it had been imputed using 
the 1000 Genomes Phase 1 V3 reference genome. The imputed genetic data was 
converted to ‘hard-call’ format using a certainty threshold of 0.9. Light quality control 
parameters had also been applied. For the purpose of this project, the following more 
stringent quality control parameters were applied by me:  Individual genotyping rate of 
>90%, Hardy-Weinberg Equilibrium of p>1x10-6, SNP genotyping rate of >98%, minor 
allele frequency threshold of >1%. This left 4,282,342 genetic variants for analysis. 
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2.2.5 - Association analysis 
Sex, age and eight principal components of population structure were used as 
covariates. All analyses used the phenotype residuals resulting from linear regression of 
the Van de Waerden transformed subscales on the 10 covariates in R using the ‘lm’ 
function. The eight principle components of population structure, previously calculated 
using principle components analysis by Maciek Trzaskowski (Trzaskowski, Eley, et al., 
2013), were included as covariates to control for population stratification. 
Genome-wide association analysis of all six specific psychotic experiences using related 
(i.e. MZ twin pairs) and unrelated individuals was performed in PLINK. Additional 
covariance arises between related individuals due to shared environmental factors. The 
non-independence of related individuals must be accounted for to estimate correct 
standard errors. This study used the generalised estimating equation (GEE) method, 
which creates a covariance matrix and then uses a Huber Sandwich Estimator equation 
to estimate the correct standard errors (Minică, Dolan, Kampert, Boomsma, & Vink, 
2015). This was implemented using the R package called ‘gee’. An exchangeable working 
correlation structure was used because the data was cross sectional with nothing to 
distinguish members within clusters, making them exchangeable, as the relationship 
between them is the same. The ‘gee’ package was implemented in PLINK using the R-
plugin function.  
Initially, only observed (i.e. not imputed) genetic variation was tested for an association 
to reduce the computation time. Regions containing genetic variation achieving or close 
to achieving genome-wide significance (p<5x10-8) were subsequently analysed using 
imputed genetic variation. Observed genetic variants achieving or close to achieving 
genome-wide significance were also analysed using MERLIN (Abecasis, Cherny, 
Cookson, & Cardon, 2002) to confirm validity of using GEE within PLINK. MERLIN uses a 
mixed effect model approach to account for related individuals. There is a body of 
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research comparing the two approaches for the control of non-independent 
observations, with neither method prevailing as superior (Hubbard et al., 2010; 
Subramanian & O’Malley, 2010).  
2.3 - Results 
2.3.1 - Descriptive statistics 
Descriptive statistics for the SPEQ measure are summarised in Table 2.1.  
2.3.2 - Genome-wide association analysis 
Independent genome-wide association analysis of the six specific psychotic experiences 
and genotyped SNPs collectively returned two variants (rs7830364 and rs7845752) 
achieving genome-wide significance (p < 5x10-8), representing two independent loci, 
both for cognitive disorganisation (Figure 2.1). Another two loci were close to genome-
wide significance for Parent-rated Negative Symptoms, with top variants (rs7587811 
and rs16876921) achieving p-values of 7.01x10-8 and 1.44x10-7. Figures 2.2-2.5 show 
the phenotypic mean per genotype for these four SNPs achieving or close to genome-
wide significance. Supplementary Figures 2.1-2.4 show regional associations for only 
observed genetic variation at these four loci. Collectively, these four loci were 
considered as regions of interest for subsequent analysis.  
 The three observed SNPs that showed the strongest associations with PEs (rs7830364 
and rs7845752 for Cognitive Disorganisation, and rs7587811 for Parent-reported 
Negative Symptoms) were tested for association using MERLIN to validate the approach 
of using GEE in PLINK. The two genome-wide significant SNPs for Cognitive 
Disorganisation achieved p<3x10-5 and the one near genome-wide significant SNP for 
Parent-reported Negative Symptoms achieved p=1.6x10-8. Given the instability of very 
small p-values, we consider this evidence that GEE in PLINK is a valid approach for 
accounting for related individuals. 
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Across all psychotic experiences, 73 variants achieved suggestive significance (p<1x10-
5), representing 47 LD independent loci (at least 250Kb apart). A summary of top SNPs 
in the independent loci associated at genome-wide and suggestive significance for each 
of the specific psychotic experiences is available in Table 2.2. Quality control procedures 
and control of family structure using GEE were deemed sufficient with observed p-
values showing a roughly uniform distribution between zero and one equating to 
inflation factors (λ) between 1.00 – 1.02.  
Analysis of the four independent regions of interest (surrounding rs7830364, 
rs7845752, rs7587811 and rs16876921) using the 1K Genome imputed TEDS dataset 
was supportive. The locus with the strongest evidence for association with cognitive 
disorganisation is on chromosome 8, containing 24 variants achieving genome-wide 
significance when including imputed variation, with the top variant being rs74921500 
at p = 8.57x10-9 (Figure 2.6). rs74921500 is within a protein-coding gene called CSMD1 
(CUB and Sushi multiple domains 1). The other locus achieving genome-wide 
significance with cognitive disorganisation had 3 variants achieving genome-wide 
significance when including imputed variation, with the top variant being rs7841444 at 
p = 1.68x10-8(Figure 2.7). rs7841444 is within LOC105375732, an uncharacterised non-
coding RNA, proximal to HAS2 (hyaluronan synthase 2) and HAS2-AS1 (hyaluronan 
synthase 2 – antisense 1). The locus most associated with parent-rated negative 
symptoms, just below genome-wide significance, had 5 variants in ~4Kb region 
achieving genome-wide significance when including imputed variation, all of which had 
a p = 2.69x10-8 (Figure 2.8). This region is within a protein-coding gene called SPAG16 
(sperm associated antigen 16). The other regions of interest (surrounding rs16876921) 
showing a strong association with parent-rated negative symptoms showed no 
additional evidence for association when including imputed variation due to a limited 
number of LD proxies. The top variant in this region was still the genotyped SNP 
(rs16876921) with p = 1.44 x10-7 (Figure 2.9). rs16876921 is within SEPSECS-AS1 (Sep 
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(O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase- Antisense 1), a non-
coding RNA with no known function. The variant is also 45Kb upstream of PI4K2B 
(phosphatidylinositol 4-kinase type 2 beta), a protein-coding gene important in the 
phosphatidylinositol pathway.   
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Table 2.1. Descriptive statistics for TEDS sample of related and unrelated 
individuals and six dimensions of adolescent psychotic experiences assessed using 
SPEQ.
 
Note. N, Sample size; SD, Standard Deviation. 
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Table 2.2. List of independent variants with p < 1x10-5 for each of the specific psychotic experiences. 
Paranoia         
Rank Index SNP Chromosome Position (bp) A1 MAF Beta p-value  Gene symbols 
1 rs12682930 9 110379567 T 0.06 -0.29 6.06x10-7 LOC105376205 
2 rs7582778 2 240350457 A 0.13 0.20 1.39x10-6 ~30Kb from HDAC4 
3 rs4128707 12 58288363 G 0.45 -0.13 4.13x10-6 LOC101927608 
4 rs12168697 22 41107688 T 0.44 0.13 6.85x10-6 ~30Kb from LOC105373039 
5 rs11638592 15 61468155 T 0.15 -0.17 9.48x10-6 RORA 
6 rs238215 20 47870506 T 0.24 0.14 9.52x10-6 ZNFX1 
7 rs7801276 7 148632720 T 0.49 0.12 9.95x10-6 ~6Kb from RNY5 
         
Hallucinations        
Rank Index SNP Chromosome Position (bp) A1 MAF Beta p-value  Gene symbols 
1 rs662968 15 50008443 G 0.45 -0.13 5.99x10-7 ~50Kb from DTWD1 
2 rs9467476 6 25368978 G 0.06 0.26 1.39x10-6 LRRC16A 
3 rs10777029 12 87731557 T 0.34 -0.12 3.04x10-6 ~6Kb from LOC105369879 
4 rs17204910 15 61451622 C 0.17 -0.15 4.66x10-6 ~350Kb from LOC105374394 
5 rs2740351 17 643426 G 0.44 0.12 5.08x10-6 FAM57A 
6 rs1501359 5 45337972 C 0.05 -0.24 6.93x10-6 HCN1 
7 rs11627856 14 48848243 G 0.11 -0.18 7.50x10-6 ~20Kb from STT3A pseudo 
8 rs2600855 3 62539014 A 0.13 -0.17 7.58x10-6 CADPS 
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Table 2.2 cont. 
Cognitive Disorganisation       
Rank Index SNP Chromosome Position (bp) A1 MAF Beta p-value  Gene symbols 
1 rs7830364 8 3682023 G 0.01 -1.22 1.24x10-8 CSMD1 
2 rs7845752 8 122695330 T 0.01 -1.65 2.98x10-8 
LOC105375732, ~35Kb 
from HAS2 
3 rs553850 9 37377959 A 0.14 -0.56 6.72x10-7 LOC105376035 
4 rs9315289 13 34852254 T 0.34 -0.41 1.28x10-6  ~70Kb from LOC105370158 
5 rs279779 1 16776804 C 0.41 0.38 3.97x10-6 NECAP2 
6 rs1946972 9 32874871 
C 
0.09 -0.60 5.02x10-6 
~80Kb from APTX and 
TMEM215 
7 rs17071637 6 110742197 
C 
0.05 -0.76 6.07x10-6 
~1Kb from LOC105377936 and 
~4Kb from SLC22A16 
8 rs508994 11 116280252 A 0.12 -0.51 8.25x10-6 ~250Kb from LOC101929011 
         
Grandiosity and Delusions       
Rank Index SNP Chromosome Position (bp) A1 MAF Beta p-value  Gene symbols 
1 rs12197499 6 36214491 A 0.11 0.20 1.15x10-6 PNPLA1, LOC105375036 
2 rs4790637 17 4411505 T 0.26 -0.14 3.20x10-6 SPNS2 
3 rs7026159 9 86850104 T 0.09 0.20 4.26x10-6 ~30Kb from SLC28A3 
4 rs17555239 15 25840403 T 0.41 0.12 5.88x10-6 ~15Kb from LOC105370737 
5 rs2211442 10 55536004 C 0.10 -0.19 6.91x10-6 ~15Kb from PCDH15 
6 rs7239816 18 67757790 C 0.07 -0.23 8.23x10-6 RTTN 
7 rs9541773 13 35252044 G 0.09 -0.20 8.30x10-6 LOC105370159 
8 rs17550688 9 8241736 A 0.10 -0.20 8.37x10-6 ~70Kb from PTPRD 
9 rs3791964 2 218720394 A 0.26 0.14 9.78x10-6 TNS1 
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Table 2.2 cont. 
Anhedonia         
Rank Index SNP Chromosome Position (bp) A1 MAF Beta p-value  Gene symbols 
1 rs319027 11 89249010 T 0.01 -3.10 1.33x10-6 NOX4 
2 rs2275706 1 220087703 T 0.02 -3.08 1.38x10-6 SLC30A10 
3 rs10435834 9 111640631 T 0.33 -1.05 3.49x10-6 IKBKAP 
4 rs4843658 16 87690403 C 0.12 1.46 5.45x10-6 JPH3 
         
Parent-rated Negative Symptoms       
Rank Index SNP Chromosome Position (bp) A1 MAF Beta p-value  Gene symbols 
1 rs7587811 2 214457257 C 0.01 0.56 7.01x10-8 SPAG16 
2 rs16876921 4 25179865 A 0.01 -0.40 1.44x10-7 SEPSECS antisense RNA 1 
3 rs16835045 3 129754605 G 0.05 0.31 1.38x10-6 ~0.5Kb from OR7E21P 
4 rs2518203 6 102305195 A 0.14 -0.17 1.60x10-6 GRIK2 
5 rs10818365 9 122454415 
T 
0.45 -0.12 1.91x10-6 
~150Kb from 
LOC105376250 
6 rs832539 5 56199386 T 0.27 0.14 2.11x10-6 LOC105378980 
7 rs1978648 2 43371542 T 0.27 0.14 2.24x10-6 LOC100506047 
8 rs4320122 4 120024874 C 0.29 0.14 3.88x10-6 LOC102723967 
9 rs12091513 1 115842658 A 0.03 -0.30 6.08x10-6 NGF 
10 rs6505386 17 32223728 G 0.15 -0.16 7.43x10-6 ASIC2 
11 rs12142944 1 84380880 T 0.03 -0.27 9.31x10-6 TTLL7 
Note. Each independent variant is labelled with the gene in which it is present or most proximal. A1, test allele; MAF, minor allele frequency; Beta, 
unstandardized effect size. 
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Figure 2.1. Manhattan plot and QQ-plot of specific psychotic experiences in 
adolescence in TEDS. 
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Figure 2.1 cont. Manhattan plot and QQ-plot of specific psychotic experiences in 
adolescence in TEDS. 
Note. Plots on the left show –log10(p) values for genotyped variation across the genome. 
Plots on the right show observed –log10(p) values against expected –log10(p) values based 
on a chi-squared distribution.
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Figure 2.2. Mean Cognitive Disorganisation scores by genotype at rs7830364.   
Note. Standard error bars are sandwich estimator corrected. G11, homozygous minor allele 
genotype; G12, heterozygous genotype; G22, homozygous major allele genotype; MAF, 




Figure 2.3. Mean Cognitive Disorganisation scores by genotype at rs7845752.  
Note. Standard error bars are sandwich estimator corrected. G11, homozygous minor allele 
genotype; G12, heterozygous genotype; G22, homozygous major allele genotype; MAF, 




Figure 2.4. Mean Negative Symptoms scores by genotype at rs7587811. 
Note. Standard error bars are sandwich estimator corrected. Negative symptoms scores 
have been transformed using Van de Waerden transformation. G11, homozygous minor 
allele genotype; G12, heterozygous genotype; G22, homozygous major allele genotype; 




Figure 2.5. Mean Negative Symptoms scores by genotype at rs16876921. 
Note. Standard error bars are sandwich estimator corrected. Negative symptoms scores 
have been transformed using Van de Waerden transformation. G11, homozygous minor 
allele genotype; G12, heterozygous genotype; G22, homozygous major allele genotype; 





Figure 2.6. Regional association plot of variation surrounding rs7830364 for 
Cognitive Disorganisation during adolescence. 
Note. The most strongly associated genotyped variant with Cognitive Disorganisation in this 
region is highlighted in purple (rs7830364). The colour of other points indicates the 
correlation (r2) of variants with rs7830364. This peak is within the protein-coding gene 
CSMD1. The ‘plotted SNPs’ bar at the top indicates the density of tagged SNPs in this region. 
This figure includes genotyped and 1K genome imputed variation. The arrow next to the 
gene name indicates the direction of transcription. The short vertical lines along the gene 




Figure 2.7. Regional association plot of variation surrounding rs7845752 for 
Cognitive Disorganisation during adolescence. 
Note. The most strongly associated genotyped variant with Cognitive Disorganisation in this 
region is highlighted in purple (rs7845752). The colour of other points indicates the 
correlation of variants with rs7845752. This peak is within an uncharacterised non-coding 
RNA proximal to HAS2 and HAS2-AS1. The ‘plotted SNPs’ bar at the top indicates the density 
of tagged SNPs in this region. This figure includes genotyped and 1K genome imputed 
variation. The arrow next to the gene name indicates the direction of transcription. The 




Figure 2.8. Regional association plot of variation surrounding rs7587811 for Parent-
reported Negative Symptoms during adolescence.  
Note. The most strongly associated genotyped variant with Parent-reported Negative 
Symptoms in this region is highlighted in purple (rs7587811). The colour of other points 
indicates the correlation of variants with rs7587811. This peak is within a protein-coding 
gene called SPAG16. This figure includes genotyped and 1K genome imputed variation. The 
arrow next to the gene name indicates the direction of transcription. The short vertical lines 




Figure 2.9. Regional association plot of variation surrounding rs16876921 for 
Parent-reported Negative Symptoms during adolescence.  
Note. The most strongly associated genotyped variant with Parent-reported Negative 
Symptoms in this region is highlighted in purple (rs16876921). The colour of other points 
indicates the correlation of variants with rs16876921. This variant is within a non-coding 
RNA called SEPSECS-AS1. This figure includes genotyped and 1K genome imputed variation. 
The arrow next to the gene name indicates the direction of transcription. The short vertical 
lines along the gene represent splice sites. 
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2.4 - Discussion 
This is the first GWAS of specific adolescent PEs assessed quantitatively. This study has 
identified the first genome-wide significant variation for Parent-reported Negative 
Symptoms and two genome-wide significant associations for Cognitive Disorganisation. 
There were an additional 47 independent loci achieving suggestive significance 
(p<1x10-5). 
The strongest association with Cognitive Disorganisation was within CSMD1, a protein-
coding gene thought to regulate complement activation and inflammation expressed 
throughout the central nervous system (Kraus et al., 2006). CSMD1 has been previously 
associated with cognitive ability and executive function in healthy males (Koiliari et al., 
2014), and psychotic disorders (Ripke et al., 2014; Xu et al., 2014), supporting its role in 
Cognitive Disorganization in adolescence and the overlapping aetiology of adolescent 
PEs and psychotic disorders in adulthood. Interestingly, CSMD1 has also been implicated 
in the autoimmune disorder multiple sclerosis (Baranzini et al., 2009) and the overlap 
between multiple sclerosis and schizophrenia (Andreassen et al., 2015).  
The other genome-wide significant locus for Cognitive Disorganisation was proximal to 
HAS2 and its antisense (HAS2-AS1). The HAS2 protein synthesises hyaluronan and has 
been implicated in breast cancer (P. Li et al., 2015; Okuda et al., 2012) and both osteo- 
and rheumatoid- arthritis (Chang, Yamada, & Yamamoto, 2005; Yoshida et al., 2004) but 
not with any neurodevelopmental phenotypes.  
The genome-wide significant locus for Parent-reported Negative Symptoms was within 
SPAG16, a gene encoding two proteins important for the microtubular backbone 
(axoneme) of tail of sperm and postmeiotic germ cells (Zhang et al., 2007). There is no 
evidence of SPAG16 function in neuropsychiatric traits/disorders except one study 
reporting a suggestive association with a visual endophenotype for schizophrenia and 
autism (Goodbourn et al., 2014). Otherwise, SPAG16 has been mainly implicated in 
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multiple sclerosis and rheumatoid arthritis (de Bock et al., 2014; Knevel et al., 2013), 
again consistent with the hypothesis of genetic overlap between adolescent PEs and 
autoimmune disorders. 
A role for immune-related pathways in the aetiology of psychiatric disorders, 
particularly schizophrenia, has been suggested by epidemiological studies for many 
years (Miller & Raison, 2016; Muller & J Schwarz, 2010) and has been more recently 
supported via molecular genetics (The Pathway Analysis Subgroup of the Psychiatric 
Genomics Network Consortium, 2015). Given the phenotypic evidence of association of 
psychiatric disorders with both adolescent PEs (see Section 1.2.2) and immune-related 
pathways, adolescent PEs and immune pathways may also be associated with one 
another. 
In order to increase sample size this study included the siblings of MZ individuals in the 
analyses using a generalised estimating equation to account for the additional 
covariance between related individuals(Minica, Boomsma, Vink, & Dolan, 2014; Minică 
et al., 2015). This method for accounting for related individuals was supported in this 
study as the inflation factor in all analyses was 1.00 - 1.02 and top associations were 
broadly replicated when using a mixed linear model approach applied in MERLIN 
(Abecasis et al., 2002). Although related individuals were included, the major limitation 
of this study is sample size. Integration of other adolescent samples both with genome-
wide variation and specific PEs phenotypes is required to improve statistical power and 
identify further genetic variation and gene pathways associated with adolescent PEs.  
 
In conclusion, the use of specific quantitative measures of adolescent PEs has 
successfully identified three genetic loci significantly associated with adolescent PEs. 
However, larger sample sizes are required to improve statistical power to detect further 
genome-wide significant variation, and as such efforts were not made to replicate these 
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associations at this stage. This study has also provided some indication that adolescent 
PEs and immune-related pathways may overlap in aetiology to some degree. 
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2.5 – Appendix 
 
Supplementary Figure 2.1. Regional association plot for observed variation only 
surrounding rs7830364 for Cognitive Disorganisation during adolescence. 
Note. The most strongly associated genotyped variant with Cognitive Disorganisation in this 
region is highlighted in purple (rs7830364). The colour of other points indicates the 
correlation of variants with rs7830364. This peak is within the protein-coding gene CSMD1 
(CUB and Sushi multiple domains 1). This figure includes only genotyped variation. The 
arrow next to the gene name indicates the direction of transcription. The short vertical lines 




Supplementary Figure 2.2. Regional association plot for observed variation only 
surrounding rs7845752 for Cognitive Disorganisation during adolescence. 
Note. The most strongly associated genotyped variant with Cognitive Disorganisation in this 
region is highlighted in purple (rs7845752). The colour of other points indicates the 
correlation of variants with rs7845752. This peak is within an uncharacterised non-coding 
RNA proximal to HAS2 (Hyaluronan Synthase 2) and HAS2-AS1. This figure includes only 
genotyped variation. The arrow next to the gene name indicates the direction of 




Supplementary Figure 2.3. Regional association plot for observed variation only 
surrounding rs7587811 for Parent-reported Negative Symptoms during 
adolescence. 
Note. The most strongly associated genotyped variant with Parent-reported Negative 
Symptoms in this region is highlighted in purple (rs7587811). The colour of other points 
indicates the correlation of variants with rs7587811. This peak is within a protein-coding 
gene called SPAG16 (sperm associated antigen 16).  This figure includes only genotyped 
variation. The arrow next to the gene name indicates the direction of transcription. The 
short vertical lines along the gene represent splice sites.  
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Supplementary Figure 2.4. Regional association plot for observed variation only 
surrounding rs16876921 for Parent-reported Negative Symptoms in adolescence. 
Note. The most strongly associated genotyped variant with Parent-reported Negative 
Symptoms in this region is highlighted in purple (rs16876921). The colour of other points 
indicates the correlation of variants with rs16876921. This variant is within a non-coding 
RNA called SEPSECS-AS1. This variant is also proximal to PI4K2B. This figure includes only 
genotyped variation. The arrow next to the gene name indicates the direction of 
transcription. The short vertical lines along the gene represent splice sites. 
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Chapter 3 - Investigating the effect of the procedures 
used when controlling for the normality assumption 
and covariates 
3.1 – Introduction 
As briefly mentioned in Section 1.4.1, the most common statistical method for assessing 
the association between a specific genetic variant and a given phenotype is either 
logistic or linear regression. This thesis aims to use quantitative measures in all primary 
analyses and linear regression will be used in Chapters 5-7. Therefore linear regression 
will be the focus of this chapter. This chapter represents a departure from phenotypic 
and genetic analyses of psychotic experience data (which will continue in chapters 4 
onwards) to explore a methodological issue. 
Linear regression, as well as many other statistical methods, has the underlying 
assumption that the residuals of the model are normally distributed (Berry, 1993). This 
assumption is important for the accurate approximation of significance. Violation of the 
normality assumption can lead to heteroskedasticity, the comparison of variables with 
unequal variance, which potentially increases both type-I error rates and reduced 
power (Feingold, 2002). In genetic studies, the normality of residuals is largely dictated 
by the distribution of the dependent (phenotypic) variable due to the very small effect 
size of individual genetic variants (Servin & Stephens, 2007).  
The normality assumption can either be satisfied by the transformation of the 
phenotypic variable (normalisation), or controlled for using heteroskedasticity robust 
methods such as generalized estimating equations (GEEs). One of the most popular 
approaches is the normalisation of the dependent variable. There are several 
transformations that can be used for this purpose, the most popular being log, power or 
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Box-Cox transformations, and rank-based inverse normal transformations (INTs), also 
referred to as quantile normalisations, such as the Van de Waerden transformation 
(Beasley, Erickson, & Allison, 2009). In many cases the use of log transformation is 
insufficient for normalising data. Conversely, rank-based INTs always create a perfect 
normal distribution when there are no tied observations. Previous studies have 
reported that although rank-based INTs can lead to loss of information, this approach 
controls power and type-I error rate (Peng, Robert, DeHoff, & Amos, 2007; K. Wang & 
Huang, 2002). However, a comprehensive review of rank-based INTs demonstrated that 
in certain scenarios, rank-based INTs do not control type-I error, although they remain 
useful in large samples where alternative methods, such as resampling, are less practical 
(Beasley et al., 2009). 
It is often desirable to adjust for covariates in analysis.  In genetic studies, principal 
components of ancestry are commonly included to reduce confounding by population 
structure. When a transformation to normality is used, the covariates may be included 
in the analysis model after transformation, or alternatively they may be regressed 
against the response prior to the residuals being transformed to normality. The latter 
approach has been used in a number of recent high profile studies (S. E. Jones et al., 
2016; Locke et al., 2015; Wain et al., 2015) and is also automated in the ‘rntransform’ 
function within GenABEL, a popular R package (Aulchenko, Ripke, Isaacs, & Van Duijn, 
2007).  One reason is that in collaborative consortia, it is more convenient to perform in-
house adjustments for covariates and transformations prior to data sharing. Another 
reason is that confounders may be considered to have their effects on the 
untransformed, rather than the normalised, variable. Finally, pre-adjustment for 
covariates will break many of the ties that are present in data derived from 
questionnaires or other rating scales that are usually represented by a small number of 
discrete values. 
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Although the approach of regressing covariate effects from the dependent variable prior 
to normalisation has some practical advantages, to the best of our knowledge, after 
extensive searches and reading of the surrounding literature, the effect of this 
procedure has not been documented. This chapter investigates whether applying rank-
based INT to residuals reintroduces a linear correlation with covariates. Three factors 
predicted to effect the outcome of this process are evaluated: original skew of the 
dependent variable, proportion of tied observations in the dependent variable, and the 
original correlation between the dependent variable and covariates. This chapter also 
investigates the consequence of an alternative procedure where the dependent variable 
is normalised (randomly splitting tied observations) prior to regressing out covariate 
effects. Both simulated and real data are used. 
3.2 – Methods  
3.2.1 - Simulation of phenotypic data 
Two types of phenotypic data were simulated: quantitative variables containing no tied 
observations (herein referred to as continuous variables) and quantitative variables 
containing tied observations (herein referred to as questionnaire-type variables). These 
variables were simulated to exhibit different degrees of skew ranging from -2 to 2. 
Skewed variables were created using the R ‘rbeta’ function, which randomly generates 
numbers following a beta distribution with two shape parameters to control the degree 
of skew. Each simulated variable contained 10,000 observations. To create tied 
observations in the questionnaire-type variables, the initially continuous data were 
collapsed into evenly distributed and discrete response bins. The number of response 
bins, determining the proportion of tied observations, was varied between 5 and 160 to 
capture the typical ranges of questionnaire-type data. 
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The R functions used to create continuous and questionnaire-type variables, called 
‘SimCont’ and ‘SimQuest’ respectively, are available in the appendix (Supplementary 
Notes 3.1 and 3.2). 
A normal distribution has skew = 0 but also kurtosis = 0. Given that the simulated 
variables were generated to follow a beta distribution, variables with a skew equal to 
zero may not have a kurtosis equal to zero. To ensure that the correction of kurtosis was 
not driving effects seen when skew is equal to zero, continuous and questionnaire-type 
variables were also generated using the ‘rnorm’ function in R to exhibit both a skew and 
kurtosis of zero. The functions used to create continuous and questionnaire-type with 
skew and kurtosis fixed to zero, called ‘SimContNorm’ and ‘SimQuestNorm’ respectively, 
are available in the appendix (Supplementary Notes 3.3 and 3.4). 
3.2.2 - Simulation of covariate data 
To create correlated covariate data, noise was added to each simulated phenotypic 
variable until the desired phenotype-covariate correlation was achieved. Phenotype-
covariate correlations (Pearsons) were varied between -0.5 and 0.5 to investigate the 
full range of possible dependent variable-covariate relationships. Noise was added to 
the questionnaire variables using the ‘jitter’ function in R. 
The R function used to create covariates for each phenotypic variable, called 
‘CovarCreator’, is available in the appendix (Supplementary Note 3.5). 
3.2.3 - Testing the effect of rank-based inverse normal transformation after regressing out 
covariate effects 
Linear regression of each covariate against the corresponding phenotypic variable was 
used to calculate phenotypic residuals, which are linearly uncorrelated with the 
covariates. The Spearman’s rank-based correlation between the phenotypic residuals 
and covariates was measured. Phenotypic residuals were then normalised using the 
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‘rntransform’ from the GenABEL package in R, which applies a rank-based INT similar to 
van de Waerden transformation. To determine whether the transformed residuals were 
still linearly uncorrelated with covariates, the Pearson correlation between the 
transformed residuals and covariates was calculated.  
3.2.4 - Testing the effect of applying rank-based inverse normal transformation (randomly 
splitting ties) before regressing out covariate effects 
This was carried out using the same simulated questionnaire-type and continuous 
variables and covariates. The raw questionnaire-type and continuous variables 
underwent rank-based INT using a modified version of the ‘rntransform’ function from 
GENABEL that randomly ranks any tied observations. The modified version of 
‘rntransform’, called ‘rntransform_random’, is available in the appendix (Supplementary 
Note 3.6). Linear regression of each covariate against the corresponding normalised 
questionnaire-type and continuous variables was used to calculate phenotypic residuals, 
which are linearly uncorrelated with the covariates.  
One concern with rank-based INT, particularly when randomly splitting ties, is that the 
linear relationship between the phenotypic variable and independent variables 
(including covariates) may be severely distorted. To determine the extent to which 
rank-based INT when randomly splitting ties distorts phenotypic variables, the Pearson 
correlations between the untransformed and transformed phenotypic variables were 
calculated. To determine the extent to which rank-based INT when randomly splitting 
ties distorts the relationship between the phenotypic variables and covariates, the 
Pearson correlation between the transformed phenotypic variables and covariates was 
calculated. 
Another concern with normalising the phenotypic variable before regressing out 
covariates is that the process of regressing out covariates may re-introduce skew in the 
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residuals. To determine the extent to which regressing covariates from normalised 
phenotypic variables re-introduced skew, the skew of the residuals was assessed. 
3.2.5 - Demonstration using real data 
To determine whether the predicted effects (when using simulated data) of performing 
rank-based INT before or after regressing out covariate effects are accurate, the same 
procedure was applied to real questionnaire data provided by the Twins Early 
Development Study (TEDS)(Haworth et al., 2013). TEDS data was acquired via the 
standard data request form procedure. The TEDS study has ethical approval from the 
Institute of Psychiatry ethics committee (ref: 05/Q0706/228). Data from two 
questionnaires were used measuring Paranoia and Anhedonia. Both of these measures 
are part of the SPEQ (Specific Psychotic Experiences Questionnaire)(Ronald et al., 2014). 
Unrelated individuals were included in subsequent analyses. Individuals with missing 
phenotypic data were excluded from all analyses. Sum scores of unrelated individuals 
were calculated by summing the response of each item. Each item of both the Paranoia 
and Anhedonia scales were coded as values from 0-5, with the total ranges of the 
Paranoia and Anhedonia scales being 0-75 and 0-50 respectively. Sum scores were 
calculated using different numbers of items (1, 2, 4, 8) to create different numbers of 
response bins (5, 10, 20, 40) as in the simulation study. The covariates used were age 
(continuous variable skew of -0.32) and sex (binary variable with skew of 0.22). Table 
3.1 shows the skew, number of response bins (proportion of ties) and correlation with 
covariates for each of dependent variable. The TEDS data were analysed using the same 




Table 3.1. Skew, range, and correlation with covariates for dependent variables 










Paranoia 5 1.357 0.055 0.018 
Paranoia 10 1.195 0.043 -0.026 
Paranoia 20 1.095 0.030 -0.022 
Paranoia 40 1.296 0.022 -0.059 
     
Anhedonia 5 1.868 -0.006 0.177 
Anhedonia 10 0.858 -0.025 0.127 
Anhedonia 20 0.651 -0.020 0.135 
Anhedonia 40 0.537 -0.013 0.205 
 
 
3.3 – Results 
3.3.1 - Simulated data 
3.3.1.1 - The effect of rank-based inverse normal transformation after regressing out 
covariate effects using simulated data 
As expected, regressing covariates against phenotypic variables created phenotypic 
residuals that were linearly uncorrelated with covariates.  Although there was no linear 
correlation, in almost all simulations a rank-based correlation existed between the 
residuals and covariates (Supplementary Figures 3.1-3.7). As a consequence, rank-based 
INT of residuals re-introduced a linear correlation between the phenotypic variables 
and covariates (Supplementary Figures 3.8-3.14). Three factors predicted to affect the 
extent to which rank-based INT of residuals re-introduced a correlation between the 
phenotypic variables and covariates were tested. These factors were the original skew 
of the phenotypic variable, the original correlation between the phenotypic variable and 
covariate, and the proportion of tied observations in the original phenotypic data. 
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First, in terms of skew, greater skew of the phenotypic variable was associated with a 
higher correlation between the normalised phenotypic residuals and the covariate data 
(Figure 3.1, Supplementary Figures 3.8-3.14). The direction of skew had no effect on the 
correlation between the normalised residuals and the covariate data. The effect of 
normalising residuals when skew was equal to zero remained when kurtosis was also 
fixed to zero (Supplementary Figure 3.15). 
Second, the direction of the original correlation between the original phenotypic 
variable and the covariates was reversed after rank-based INT of residuals. In 
questionnaire-type data, when the proportion of tied observations was high, the 
magnitude of correlation between the original questionnaire data and covariates had a 
negative relationship with the degree to which normalisation re-introduced the 
correlation with covariates (Supplementary Figure 3.8). However, this negative 
relationship reversed as the proportion of ties decreased (Supplementary Figure 3.16). 
This means when the proportion of tied observations was low (or in continuous data), 
the magnitude of correlation between the original questionnaire data and covariates 
had a positive relationship with the degree to which normalisation re-introduced the 
correlation with covariates.   
Third, in terms of the proportion of ties in the phenotypic variable, a decreased number 
of response bins in the questionnaire-type data (i.e. smaller range and more tied 
observations) resulted in an increased correlation between covariates and normalised 
residuals (Figure 3.1). However, even when there were 160 response bins, or the data 
were continuous, rank-based INT still re-introduced a correlation with covariates when 
the data had an original skew >0.5 (Supplementary Figures 3.13-3.14). 
As previously mentioned, although there is no linear correlation between phenotypic 
residuals and covariates, a rank-based correlation between the phenotypic residuals 
and covariates remained in almost all simulations. The factors affecting the magnitude 
 96 
of rank-based correlation between phenotypic residuals and covariates are the same as 




Figure 3.1. The relationship between the number of available responses (x-axis) 
and correlation between normalised residuals and covariate (y-axis) for different 
values of the skew in the raw phenotypic data.  
Note. Within this figure, the correlation between the untransformed phenotypic data and 






3.3.1.2 - The effect of rank-based inverse normal transformation (randomly splitting ties) 
before regressing out covariates using simulated data 
Rank-based INT of phenotypic variables, randomly splitting ties, before subsequent 
regression of covariates against the normalised phenotypic data, always resulted in 
phenotypic residuals with no linear correlation with covariates, and in the majority of 
simulations, skew less than 0.05.  
The process of rank-based INT whilst randomly splitting ties decreased the correlation 
with covariates by a small amount (median change of 5%)(Supplementary Table 3.1). 
The extent to which the covariate correlation decreased was dependent on the original 
correlation between the covariate and the dependent variable, the skew of the 
dependent variable, and the proportion of tied responses in the dependent variable 
(Supplementary Figures 3.19-3.24). 
The Pearson correlations between dependent variables before and after rank-based INT 
(randomly splitting tied observations) were between 0.77 and 1.00. An increased 
proportion of tied observations and increased skew led to a decreased correlation after 
rank-based INT (Supplementary Figure 3.25). 
Regressing covariates after normalising the dependent variables introduced a smaller 
degree of skew when covariates had either a low skew themselves or a low correlation 
with the dependent variable. The degree to which regressing covariate effects 
introduced skew was not dependent on the proportion of tied observations. Overall, 
regressing covariates introduced a small amount of skew to the dependent variable 
(0.00 – 0.11) unless the covariate had a correlation with the dependent variable over 
0.25 and a skew greater than 0.05 (Supplementary Figure 3.26). However, highly 
skewed covariates may introduce larger amounts of skew even when exhibiting a low 
correlation with the dependent variable. 
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3.3.2 - Real data 
3.3.2.1 - Effect of rank-based inverse normal transformation of residuals when using real 
data 
The observed effect of applying rank-based procedures to residuals within simulated 
questionnaire-type data was validated using real questionnaire data from TEDS. When 
using the age covariate (continuous) the magnitude and direction of effect of applying 
rank-based procedure to residuals were similar to those of simulated questionnaire-
type data (Supplementary Tables 3.2-3.3). The effect of rank-based procedures on 
residuals when using real questionnaire data was slightly reduced in comparison to 
effects observed when using simulated questionnaire-type data. 
When the sex covariate (binary) was used, the magnitude, and in some cases the 
direction, of the effect of rank-based procedures varied from effects observed in 
simulated data. Although regressing the effect of a binary covariate altered the outcome 
of rank-based procedures, application of rank-based procedures to residuals still re-
introduced a correlation with covariates (Supplementary Tables 3.4-3.5). Importantly, 
when a dichotomous variable was used, a large number of ties in the data still existed 
reducing the efficacy of rank-based INT. 
3.3.2.2 - Effect of rank-based inverse normal transformation before regressing out 
covariates when using real data 
The effect of rank-based INT (randomly splitting tied observations) before regressing 
out covariate effects in real questionnaire data was comparable to the effects observed 
when using simulated data. Rank-based INT, randomly splitting ties, and subsequent 
regression of covariates created residuals that were linearly uncorrelated with 
covariates and normally distributed (Supplementary Tables 3.6-3.7). The correlation 
between the dependent variable and covariate did vary slightly before and after rank-
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based INT (Supplementary Tables 3.6-3.7). Contrary to the observed effects when using 
simulated data, the correlation between the dependent variable and the covariate did 
not always decrease. The Pearson correlation between raw and normalised 
questionnaire data varied between 0.83 and 0.99 dependent on the skew of the raw data 
and the number of response bins (Supplementary Table 3.8). Similar to the results of 
based on simulated data, the effect of regressing covariates out of the normalised 
variables did not re-introduce skew greater than 0.02 in any situations (Supplementary 
Tables 3.6-3.7). 
3.4 – Discussion 
This study has demonstrated that regressing covariates against the dependent 
(phenotypic) variable and then transforming the resulting residuals to normality re-
introduces a correlation between the covariates and the normalised dependent variable. 
This effect occurs because the process of regressing covariates against the response 
variable leads to a covariate-based rank in the residuals, which is then used to 
redistribute the data (Figure 3.2). This effect of regressing covariates against response 
variables occurs when the response variable is continuous (contains no tied 
observations) or questionnaire-type (contains tied observations), however the effect 
increases as the proportion of tied observations increases. The degree to which the 
covariate correlation is re-introduced during rank-based INT is dependent on the 
original skew of the response variable, although when the data contain a large 
proportion of tied observations, a correlation with covariates is re-introduced even 




Figure 3.2. The effect of applying a rank-based INT to residuals of questionnaire-
type data, i.e. after regressing out covariates.  
Note. All correlations referred to in this figure are Pearson (linear) correlations. 
 
This study has also evaluated an alternative procedure for preparing data for parametric 
analyses, whereby the response variable undergoes rank-based INT, randomly 
separating ties, before regressing out covariate effects. The findings demonstrate that 
this alternative approach is preferable as it creates a normally distributed response 
variable with no correlation with covariates (Figure 3.3). The notion of normalising the 
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Skew = 1.50 
r = 0.00
Skew = 1.50 
r = -0.47





variable and its relationship with a 
continuous covariate. The 
questionnaire-type variable has a 
range of 5. A weak linear 
relationship exists between the 
questionnaire-type variable and 
covariate.
Questionnaire-type variable 
residuals after regressing out the 
relationship with the covariate. No 
linear relationship exists between 
the questionnaire-type residuals and 
covariate. Regressing out covariate 
effects has lead to the separation of 
many tied observations, creating a 
covariate-based rank within the 
questionnaire-type variable 
residuals.
After the rank-based INT of 
questionnaire-type variable 
residuals, the transformed 
questionnaire-type variable residuals 
show a strong linear correlation with 
the covariate. This correlation is 
stronger and in the opposite 
direction to the original correlation 
between the untransformed 
questionnaire-type variable and the 
covariate. 
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response variables before estimating its relationship with covariates may seem 
counterintuitive as the process of normalisation may disrupt the true relationship 
between variables. Although this may be true in some scenarios, when the variables are 
skewed and/or contain tied observations, the change in relationship between variables 
due to normalisation (Supplementary Tables 3.6-3.7) is small relative to the change in 
relationship when normalising residuals (Supplementary Tables 3.2-3.4). In contrast, 
regressing covariates after normalisation will leave no correlation between the 
variables, meaning that any confounding by those covariates will be eliminated. 
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Figure 3.3. The effect of applying a rank-based INT to questionnaire-type data 
before regressing out covariates.  
Note. All correlations referred to in this figure are Pearson (linear) correlations. 
 
Given the importance of phenotypic transformations, authors must describe the details 
of this process. Many studies do not clearly describe the details in which the data is 
processed, however there are some studies that have clearly applied rank-based INT to 
residuals (S. E. Jones et al., 2016; Locke et al., 2015; Wain et al., 2015). It is not thought 
that the results of these studies are seriously in error as they have either dealt with 
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variable and its relationship with a 
continuous covariate. The 
questionnaire-type variable has a 
range of 5. A weak linear 
relationship exists between the 
questionnaire-type variable and 
covariate.
Questionnaire-type variable after 
rank-based INT, randomly splitting 
tied observations. Relationship 
between the questionnaire-type 
variable remains intact.
Covariate effects have been 
regressed from the normalized 
questionnaire-type variable. There is 
no linear relationship between the 
residuals and the covariate, and the 
skew is close to zero.
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traits that have a very low skew and/or are continuous, or they have replicated their 
findings using binary outcomes based on untransformed data. However, it is thought 
that the potential problems with rank-based INT of residuals after correcting for 
covariates are not well known, and that researchers should be aware of these issues 
before applying such a procedure.  It is suggested that, when possible, researchers 
adjust for covariates after rather than before applying a normalising transformation, or 
employ other methods that do not assume normality. 
Although, this chapter concludes that normalisation of the dependent variable should be 
performed prior to the regression of covariates, regressing out covariates that are either 
highly skewed or highly correlated with the dependent variable, may introduce 
substantial skew to the residuals. However, this scenario is considered unlikely. 
One of the findings of this study was that rank-based INT of residuals often leads to an 
increased magnitude of correlation between the dependent variable and covariate than 
there was between the raw variables. This indicates that rank-based INT of residuals 
introduces an artificial correlation between the dependent variable and covariate. 
Another form of bias caused by conditioning variables on a covariate is called collider 
bias. A collider is a variable that is causally associated with two or more variables. If a 
variable is conditioned on an associated collider variable, it can introduce an artificial 
causal association with another variable associated with the collider variable. Real data 
examples of collider bias have been previously described (Cole et al., 2009). 
This study has demonstrated that rank-based INT of phenotypic residuals after 
adjusting for covariates can lead to an overcorrection of covariate effects leading to a 
correlation in the opposite direction between the normalised phenotypic residuals and 
covariates, and in questionnaire-type data, often of a greater magnitude. This finding has 
implications for all rank-based procedures and highlights the importance of clearly 
documenting how the raw data is handled. Normalisation of phenotypic data before 
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regressing out covariates has been explored as an alternative procedure and has been 
shown to produce normally distributed phenotypic residuals that are uncorrelated with 
covariates. Based on these results, subsequent parametric analysis in this thesis will use 
phenotypic data that has undergone rank-based INT (randomly splitting ties) prior to 
regressing out covariate effects. 
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3.5 – Appendix 
Supplementary Note 3.1. ‘SimCont’ – Function to simulate continuous variables. 
SimCont<-function(DesiredSkew, Seed=10101, NumOfSamp, StartingValue){ 
set.seed(Seed) 
 




sim <- scale(rbeta(NumOfSamp, y, 10)) 
 
if(skewness(sim) > DesiredSkew-0.0001 & skewness(sim) < DesiredSkew+0.0001) break 
 
if(skewness(sim) > DesiredSkew) {y<-y+0.001} 








sim <- scale(rbeta(NumOfSamp, 10, y)) 
 
if(skewness(sim) > DesiredSkew-0.0001 & skewness(sim) < DesiredSkew+0.0001) break 
 
if(skewness(sim) > DesiredSkew) {y<-y-0.001} 














Supplementary Note 3.2. ‘SimQuest’ – Function to simulate questionnaire-type 
variables. 






 for(y in seq(1:(n-1))){ 
 a[y]<-(abs((max(x)-min(x)))/n)*y 
 } 



















if(skewness(tied_sim) > DesiredSkew-0.0001 & skewness(tied_sim) < 
DesiredSkew+0.0001) break 
 
if(skewness(tied_sim) > DesiredSkew) {y<-y+0.001} 













if(skewness(tied_sim) > DesiredSkew-0.0001 & skewness(tied_sim) < 
DesiredSkew+0.0001) break 
 
if(skewness(tied_sim) > DesiredSkew) {y<-y-0.001} 














Supplementary Note 3.3. ‘SimContNorm’ – Function to simulate continuous 
variables with skew and kurtosis equal to zero. 





sim <- scale(rnorm(NumOfSamp)) 
 
if(skewness(sim) > -0.0001 & skewness(sim) < 0.0001 & kurtosis(sim) < 0.01 & 














Supplementary Note 3.4. ‘SimQuestNorm’ – Function to simulate questionnaire-
type variables with skew and kurtosis equal to zero. 





 for(y in seq(1:(n-1))){ 
      a[y]<-(abs((max(x)-min(x)))/n)*y 
      } 


















if(skewness(tied_sim) > -0.0001 & skewness(tied_sim) < 0.0001 & kurtosis(tied_sim) 














Supplementary Note 3.5. ‘CovarCreator’ – Function to create correlated covariates 




  cov<-jitter(x, factor = y, amount = NULL)  
   j<-cor(cov,x,use='complete.obs') 
   if(j < dis.cor-0.0001) {y<-y-1} 
   if(j > dis.cor+0.0001) {y<-y+1} 














Supplementary Note 3.6. ‘rntransform_random’ – Function to perform rank-based 
INT whilst randomly splitting tied observations. 
rntransform_random<-function (formula, data, family = gaussian)  
{ 
    if (is(try(formula, silent = TRUE), "try-error")) { 
        if (is(data, "gwaa.data"))  
            data1 <- phdata(data) 
        else if (is(data, "data.frame"))  
            data1 <- data 
        else stop("'data' must have 'gwaa.data' or 'data.frame' class") 
        formula <- data1[[as(match.call()[["formula"]], "character")]] 
    } 
    var <- ztransform(formula, data, family) 
    out <- rank(var, ties.method='random') - 0.5 
    out[is.na(var)] <- NA 
    mP <- 0.5/max(out, na.rm = T) 
    out <- out/(max(out, na.rm = T) + 0.5) 
    out <- qnorm(out) 
    out 
} 
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Supplementary Table 3.1. Difference in covariate correlation with the dependent variable before and after rank-based INT when splitting 
tied observations randomly. This is based on simulated data. 
Original Covariate 
Correlation 
Mean covariate correlation 
after normalisation 
Covariate correlation % 
difference after normalisation 
0.5 0.476 4.88% 
0.25 0.239 4.61% 
0.12 0.114 5.07% 
0.06 0.057 5.04% 
0.03 0.029 7.27% 
0.01 0.010 21.30% 
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Paranoia 5 1.357 0.055 -1.55x10-15 -0.275 8.91x10-6 
Paranoia 10 1.195 0.043 -1.89x10-15 -0.140 5.40x10-6 
Paranoia 20 1.095 0.030 -1.59x10-15 -0.079 1.59x10-5 
Paranoia 40 1.296 0.022 -1.42x10-15 -0.045 1.47x10-5 
       
Anhedonia 5 1.868 -5.73x10-3 5.81x10-16 0.462 8.91x10-6 
Anhedonia 10 0.858 -0.025 1.07x10-15 0.172 5.40x10-6 
Anhedonia 20 0.651 -0.020 1.06x10-15 0.081 1.59x10-5 
Anhedonia 40 0.537 -0.013 7.74x10-16 0.037 1.47x10-5 
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Paranoia 5 1.357 0.063 -0.266 
Paranoia 10 1.195 0.049 -0.123 
Paranoia 20 1.095 0.031 -0.061 
Paranoia 40 1.296 0.027 -0.025 
     
Anhedonia 5 1.868 -1.01x10-3 0.436 
Anhedonia 10 0.858 -0.027 0.146 
Anhedonia 20 0.651 -0.027 0.062 
Anhedonia 40 0.537 -0.016 0.031 
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Supplementary Table 3.4. Outcome of rank-based INT after regressing effect of a dichotomous covariate (sex) from real questionnaire data. 




















Paranoia 5 1.357 0.018 -1.00x10-16 -0.264 0.624 
Paranoia 10 1.195 -0.026 -8.74x10-17 0.125 0.209 
Paranoia 20 1.095 -0.022 -2.93x10-16 0.065 0.097 
Paranoia 40 1.296 -0.059 -5.60x10-16 -7.96x10-3 0.077 
       
Anhedonia 5 1.868 0.177 4.78x10-16 -0.212 0.624 
Anhedonia 10 0.858 0.127 4.07x10-16 -0.040 0.209 
Anhedonia 20 0.651 0.135 4.09x10-16 0.049 0.097 
Anhedonia 40 0.537 0.205 -1.77x10-16 -5.51x10-3 0.077 
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Paranoia 5 1.357 0.018 -0.269 
Paranoia 10 1.195 -0.031 0.118 
Paranoia 20 1.095 -0.026 0.054 
Paranoia 40 1.296 -0.066 -0.020 
     
Anhedonia 5 1.868 0.200 -0.187 
Anhedonia 10 0.858 0.124 -0.025 
Anhedonia 20 0.651 0.140 0.065 




Supplementary Table 3.6. Effect of rank-based INT (randomly ranking tied observations) on the relationship between real questionnaire 





















Skew of Residuals 
of Normalised 
Dependant 
Paranoia 5 1.357 0.055 0.054 -2.52x10-15 -3.87x10-3 
Paranoia 10 1.195 0.043 0.043 -2.99x10-15 -2.56x10-3 
Paranoia 20 1.095 0.030 0.029 -1.96x10-15 -1.67x10-3 
Paranoia 40 1.296 0.022 0.023 -1.66x10-15 -3.67x10-4 
       
Anhedonia 5 1.868 -0.006 -0.013 1.01x10-15 5.34x10-4 
Anhedonia 10 0.858 -0.025 -0.028 1.56x10-15 3.27x10-4 
Anhedonia 20 0.651 -0.020 -0.024 1.24x10-15 1.67x10-3 




Supplementary Table 3.7. Effect of rank-based INT (randomly ranking tied observations) on the relationship between real questionnaire 

























Paranoia 5 1.357 0.018 0.012 7.14x10-16 -2.81x10-4 
Paranoia 10 1.195 -0.026 -0.033 5.17x10-16 1.54x10-3 
Paranoia 20 1.095 -0.022 -0.026 5.96x10-17 1.36x10-3 
Paranoia 40 1.296 -0.059 -0.065 -4.01x10-16 1.18x10-3 
       
Anhedonia 5 1.868 0.177 0.175 4.80x10-16 -0.017 
Anhedonia 10 0.858 0.127 0.127 5.92x10-16 -0.010 
Anhedonia 20 0.651 0.135 0.136 4.94x10-16 -1.35x10-3 
Anhedonia 40 0.537 0.205 0.206 -7.20x10-17 -3.32x10-3 
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Supplementary Table 3.8. Effect of rank-based INT of real questionnaire variable when randomly ranking tied observations. Shows Pearson 






Paranoia 5 1.357 0.889 
Paranoia 10 1.195 0.939 
Paranoia 20 1.095 0.957 
Paranoia 40 1.296 0.949 
    
Anhedonia 5 1.868 0.833 
Anhedonia 10 0.858 0.958 
Anhedonia 20 0.651 0.980 





Supplementary Figure 3.1. Effect of regressing out covariate effects from 
questionnaire-type data with a range of 5 before rank-based non-parametric 
analyses.  
Note. X-axis shows the skew of the original phenotypic data. Y-axis shows the Spearman 
rank-based correlation between residuals and covariates. Colours indicate the original 




Supplementary Figure 3.2. Effect of regressing out covariate effects from 
questionnaire-type data with a range of 10 before rank-based non-parametric 
analyses.  
Note. X-axis shows the skew of the original phenotypic data. Y-axis shows the Spearman 
rank-based correlation between residuals and covariates. Colours indicate the original 





Supplementary Figure 3.3. Effect of regressing out covariate effects from 
questionnaire-type data with a range of 20 before rank-based non-parametric 
analyses.  
Note. X-axis shows the skew of the original phenotypic data. Y-axis shows the Spearman 
rank-based correlation between residuals and covariates. Colours indicate the original 





Supplementary Figure 3.4. Effect of regressing out covariate effects from 
questionnaire-type data with a range of 40 before rank-based non-parametric 
analyses.  
Note. X-axis shows the skew of the original phenotypic data. Y-axis shows the Spearman 
rank-based correlation between residuals and covariates. Colours indicate the original 





Supplementary Figure 3.5. Effect of regressing out covariate effects from 
questionnaire-type data with a range of 80 before rank-based non-parametric 
analyses.  
Note. X-axis shows the skew of the original phenotypic data. Y-axis shows the Spearman 
rank-based correlation between residuals and covariates. Colours indicate the original 





Supplementary Figure 3.6. Effect of regressing out covariate effects from 
questionnaire-type data with a range of 160 before rank-based non-parametric 
analyses.  
Note. X-axis shows the skew of the original phenotypic data. Y-axis shows the Spearman 
rank-based correlation between residuals and covariates. Colours indicate the original 





Supplementary Figure 3.7. Effect of regressing out covariate effects from 
continuous data before rank-based non-parametric analyses.  
Note. X-axis shows the skew of the original phenotypic data. Y-axis shows the Spearman 
rank-based correlation between residuals and covariates. Colours indicate the original 
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Effect of Regressing Out Covariates on Rank−based Correlation
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Supplementary Figure 3.8. Effect of rank-based INT of questionnaire-type data 
residuals (after regressing out covariates) with range of 5.  
Note. The relationship between the original skew of the raw questionnaire-type data (x-
axis), the original correlation between the raw questionnaire-type data and covariate data 
(colour coded), and the correlation between normalised questionnaire-type residuals (y-
axis). This figure is based on simulated data.  
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Supplementary Figure 3.9. Effect of rank-based INT of questionnaire-type data 
residuals (after regressing out covariates) with range of 10.  
Note. The relationship between the original skew of the raw questionnaire-type data (x-
axis), the original correlation between the raw questionnaire-type data and covariate data 
(colour coded), and the correlation between normalised questionnaire-type residuals (y-
axis). This figure is based on simulated data. 
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Supplementary Figure 3.10. Effect of rank-based INT of questionnaire-type data 
residuals (after regressing out covariates) with range of 20. 
Note. The relationship between the original skew of the raw questionnaire-type data (x-
axis), the original correlation between the raw questionnaire-type data and covariate data 
(colour coded), and the correlation between normalised questionnaire-type residuals (y-





Supplementary Figure 3.11. Effect of rank-based INT of questionnaire-type data 
residuals (after regressing out covariates) with range of 40.  
Note. The relationship between the original skew of the raw questionnaire-type data (x-
axis), the original correlation between the raw questionnaire-type data and covariate data 
(colour coded), and the correlation between normalised questionnaire-type residuals (y-





Supplementary Figure 3.12. Effect of rank-based INT of questionnaire-type data 
residuals (after regressing out covariates) with range of 80. 
Note. The relationship between the original skew of the raw questionnaire-type data (x-
axis), the original correlation between the raw questionnaire-type data and covariate data 
(colour coded), and the correlation between normalised questionnaire-type residuals (y-
axis). This figure is based on simulated data. 
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Supplementary Figure 3.13. Effect of rank-based INT of questionnaire-type data 
residuals (after regressing out covariates) with range of 160.  
Note. The relationship between the original skew of the raw questionnaire-type data (x-
axis), the original correlation between the raw questionnaire-type data and covariate data 
(colour coded), and the correlation between normalised questionnaire-type residuals (y-





Supplementary Figure 3.14. Effect of rank-based INT of continuous data residuals 
(after regressing out covariates).  
Note. The relationship between the original skew of the raw continuous data (x-axis), the 
original correlation between the raw continuous data and covariate data (colour coded), and 
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Normalization Effect when Continuous
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Supplementary Figure 3.15. Effect of rank-based INT when kurtosis and skew are 
























































































Comparing Normalization Effect in 
 when Kurtosis = 0
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Supplementary Figure 3.16. Effect of proportion of ties and magnitude of original 
covariate correlation on the confounding effect of normalising the dependent 
variable residuals. 
Note. The number of response bins (x-axis) is a measure of the proportion of tied 
observations. As the number of available responses increases, the proportion of tied 
observations decreases. The y-axis is the absolute correlation between normalised residuals 
and the covariate, and therefore indicates the degree to which normalisation reintroduces 
the covariate correlation with residuals. Colour indicates the original correlation between 
the covariate and simulated variables. This figure is based on simulated variables with a 
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Effect of normalizing residuals when
original skew is 1
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Supplementary Figure 3.17. The relationship between the number of available 
responses in the dependent variable (x-axis) and the absolute Spearman rank-
based correlation between normalised residuals and covariate (y-axis) for different 
values of the skew.  
Note. Within this figure, the Pearson correlation between the raw dependent variable and 
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Effect of normalizing residuals when
original covariate correlation is 0.06
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Supplementary Figure 3.18. Effect of proportion of ties and magnitude of original 
covariate correlation on the Spearman correlation between dependent variable 
residuals and the covariate. 
Note. The number of response bins (x-axis) is a measure of the proportion of tied 
observations. The y-axis is the absolute Spearman rank-based correlation between residuals 
and covariates. Colour indicates the original Pearson correlation between the covariates and 
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Effect of normalizing residuals when
original skew is 1
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Supplementary Figure 3.19. Difference in covariate correlation with dependent 
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Original Covariate Correlation = 0.5
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Supplementary Figure 3.20. Difference in covariate correlation with dependent 






















−2 −1 0 1 2




















































































Original Covariate Correlation = 0.25
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Supplementary Figure 3.21. Difference in covariate correlation with dependent 
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Original Covariate Correlation = 0.12
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Supplementary Figure 3.22. Difference in covariate correlation with dependent 
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Original Covariate Correlation = 0.06
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Supplementary Figure 3.23. Difference in covariate correlation with dependent 
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Original Covariate Correlation = 0.03
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Supplementary Figure 3.24. Difference in covariate correlation with dependent 
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Original Covariate Correlation = 0.01
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Supplementary Figure 3.25. Correlation between the dependent variable before 
















































































Effect of normalizing raw variables separating ties randomly
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Supplementary Figure 3.26. Magnitude of skew reintroduced when regressing out 
covariate effects from normalised dependent variables.  







































































Effect of Regressing Out Covariates on Skew
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Chapter 4 - Harmonising Subscales of Specific 
Psychotic Experiences Across TEDS, ALSPAC and 
CATSS 
4.1 – Introduction 
As discussed in Section 1.6.1, the main limitations of previous molecular genetic studies 
of adolescent psychotic experiences (PEs) are sample size and the lack of specific and 
quantitative measures, both of which increase statistical power. As described in Section 
1.4.5, the best approach for increasing sample size, apart from starting a new larger 
scale study to investigate the phenotype of interest, is collaboration between research 
groups to pool data. Particularly in behavioural or psychiatric research, a likely 
consequence of combining multiple samples is an increase in phenotypic heterogeneity 
due to a number of factors including (but not limited to) the use of different measures, 
environmental differences, and cultural differences. The complex interplay of 
environmental and cultural differences between samples is difficult to control for and is 
therefore best avoided by selecting highly comparable samples, based on features such 
as geographical region, culture and age. The use of different measures between samples 
is potentially less of an issue when using widely used diagnostic protocols carried out by 
health care professionals. However, as previously discussed in Section 1.4.4 these 
diagnostic protocols often lead to binary case-control categories, often containing large 
degrees of phenotypic heterogeneity. In order to gain the relative improvements in 
statistical power and interpretation of specific and quantitative measures, careful 
consideration of the measures used in each sample must occur. Some measures of 
specific behaviours have been employed in multiple samples enabling the direct 
comparison of individuals from different samples. For example, a recent meta-analysis 
of several personality traits was able to combine several samples that had been assessed 
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via several overlapping questionnaires (Van den Berg et al., 2014). To account for 
differences between samples for the same questionnaires, this study used item response 
theory. However, the direct comparison of behavioural traits assessed in different 
samples often isn’t possible due to samples regularly employing bespoke questionnaire 
measures. An alternative approach is to look within the relevant questionnaires from 
each sample to identify individual items that are comparable across samples. 
A key aim of this thesis is to pool data from samples with sufficient PE data to enable 
combined analysis. Three European samples with adolescent PE data available have 
been identified: the Twins Early Development Study (TEDS), the Avon Longitudinal 
Study of Parents and Children (ALSPAC), and the Child and Adolescent Twin Study in 
Sweden (CATSS). However, different measures have been used in each sample. This 
chapter describes the process of harmonising the measures in the three samples onto 
common scales of specific PEs. Figure 4.1 is a schematic representation of the 
phenotypic harmonisation procedure. The procedure can be broken down into three 
stages: 1) Using the TEDS’ Specific Psychotic Experiences Questionnaire (SPEQ) as a 
template, identify items in ALSPAC and CATSS samples that assess specific PEs. 2) 
Perform psychometric analysis of PE items within ALSPAC and CATSS to derive 
measures of specific PEs and assess their reliability. 3) Adapt the TEDS measures of 
specific PEs to improve comparability with measures in ALSPAC and CATSS, and then 
assess them psychometrically. 
4.2 - Methods 
4.2.1 - Samples 
Adolescent PEs had been previously assessed in three general population samples called 
TEDS (Haworth et al., 2013), ALSPAC (Boyd et al., 2012) and CATSS (Anckarsäter et al., 
2011). Each of these samples used different measures of adolescent PEs. Below is a 
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description of the three studies. The available items assessing adolescent PEs are 
described in Section 4.2.2. 
TEDS – This sample recruited twins born in England and Wales between 1994 and 1996 
and assessed these individuals longitudinally. TEDS originally recruited 13,488 families, 
who responded with a written consent form. The Institute of Psychiatry ethics 
committee approved TEDS and their consent procedure (ref: 05/Q0706/228). More 
information can be found on the following website: http://www.teds.ac.uk. 
ALSPAC – This sample includes 14,062 children born to pregnant residents of the 
former Avon region in South West England who had an expected date of delivery 
between the 1st of April 1991, and the 31st of December 1992. Informed consent has 
been received from all participants within this study. Ethical approval for this study was 
obtained from the ALSPAC Law and Ethics Committee and the Local Research Ethics 
Committees. More information can be found on the following website: 
http://www.bristol.ac.uk/alspac. 
CATSS – The CATSS sample includes all twins born in Sweden since the 1st of July 1992. 
Currently, data is available for ~5,350 twins at age 18 from the ‘CATSS-18’ subset. All 
participants are informed of the information being collected and are repeatedly given 
the opportunity to withdraw. The study has ethical approval from the Karolinska 
Institute Ethical Review Board. More information can be found on the following website: 
http://www.ki.se/en/meb/the-child-and-adolescent-twin-study-in-sweden-catss. 
4.2.2 - Exclusion criteria 
Exclusion criteria were chosen based on those used in previous studies of behavioural 
traits (Docherty et al., 2010). Each samples’ data dictionary was searched to identify 
variables relating to the exclusion criteria. The relevant variables from each sample 
were then matched across samples where possible (Table 4.1). After exclusion criteria 
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were applied, TEDS, ALSPAC and CATSS respectively provided 4,869, 14,177, and 5,407 
unrelated individuals (Table 4.2). These figures do not account for the availability of 
adolescent PE data, as the PE items used in this study are yet to be identified. 
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Table 4.1. Exclusion variables applied in each sample. These exclusion criteria are standard practice for genome-wide association studies of 
behavioural and cognitive traits (Docherty et al., 2010). 
 
TEDS ALSPAC CATSS 
Exclusion 
criteria 
• Unknown zygosity 
• Unknown sex at age 16 
• Low birth weight 
• Short gestational age 
• Maternal drinking during pregnancy 
• Long stay in hospital after birth 
• Diagnosis of autism 
• Cerebral palsy 
• Genetic, chromosomal or inherited disorders 
• Brain damage or disorders affecting the brain 
• Severely deaf 
• Developmental delay 
• Complete blindness 
• Death of either twin 
 
• Unknown sex 
• Low birth weight 
• Short gestational age 
• Maternal drinking during pregnancy 
• Long period in hospital after birth 
• Diagnosis of autism 
• Cerebral palsy 
 
 
• Severely deaf 
• Developmental delay 
• Unknown zygosity 
• Unknown sex 
• Low birth weight 
• Birth trauma 
 
 
• Diagnosis of autism 
• Cerebral palsy 
• Chromosomal abnormalities 
• Brain damage 
• Deafness 
 
• Complete blindness 
 
 
Table 4.2. Number of individuals from TEDS, ALSPAC and CATSS. Figures shown before and after exclusion criteria have been applied. 
 TEDS ALSPAC CATSS 
Related individuals 
before exclusions 
10324 15445 10742 
Unrelated individuals 
before exclusions 
5162 15243 5669 
Unrelated individuals 
after exclusions 
4869 14177 5407 
 150 
4.2.3 - Measures 
TEDS - The SPEQ consists of six subscales including Paranoia, Hallucinations, 
Grandiosity and Delusions, Cognitive Disorganisation, Anhedonia, and Parent-rated 
Negative Symptoms. Details of the SPEQ subscales are available at the following 
references (Ronald et al., 2013, Sieradzka et al., 2014). Items within the SPEQ are listed 
and annotated in Supplementary Table 4.1. 
ALSPAC - This study used the Psychotic Like Experiences Questionnaire (PLIKS-Q) at 
age 16 to assess adolescent PEs. The PLIKS-Q only assesses some positive PE symptoms 
including paranoia, hallucinations, and thought insertion. The PLIKS-Q was applied 
within the ‘Life of a 16+ Teenager’ questionnaire. This questionnaire included a number 
of other scales assessing behaviour, all of which were interrogated to identify any items 
relevant for the assessment of other specific PEs. Items assessing parent-reported 
negative symptoms were searched for in the corresponding parent questionnaire called 
‘Your Son/Daughter 16+ Years On’. 
Items within the PLIKS-Q consisted of an initial question, and then several follow up 
questions regarding the individuals’ experience (example in Supplementary Note 4.1). It 
was decided to include frequency information provided by the first follow up question 
(part a). Including the frequency of experience information provided several advantages 
including an improved ability to separate the individuals based on the prevalence of the 
experience, but also matching the frequency type information collected by both TEDS 
and CATSS positive symptom items. 
CATSS - Adolescent PEs were assessed at age 18 using the APSS (Adolescent Psychotic-
like Symptom Screener). Similar to PLIKS-Q, APSS only captures information on some 
positive PE symptoms (paranoia, hallucinations, and grandiosity and delusions). All 
scales applied to these individuals were interrogated to identify items assessing other 
adolescent PEs.  The more relevant scales include Child Mania Rating Scale (CMRS), 
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Adult ADHD Self-Report Scale (ASRS), and Centre of Epidemiologic Studies Depression 
Scale (CES-D). Parent-reported negative symptoms were looked for within the parent 
report Adult Behaviour Checklist (ABCL), and the Autism – Tics, ADHD and other 
Comorbidities Inventory (A-TAC). 
4.2.4 - Analyses 
Derivation of comparable subscales of specific PEs across the three studies was achieved 
via three analytical stages (Figure 4.1). 
Stage 1: Identification of items assessing specific adolescent PEs in ALSPAC and 
CATSS samples using the TEDS’ SPEQ measure as a template.  
The data dictionaries for ALSPAC and CATSS were manually searched for all items 
assessing latent PE traits in common with those captured by the TEDS’ SPEQ. The 
relevant items where then labelled according to the specific PE domain that it assessed. 
This process was carried out under the guidance of two expert clinicians (Dr Alastair 
Cardno and Professor Daniel Freeman), both with prior experience of creating measures 
for specific PEs during adolescence. 
Stage 2: Psychometric analysis of PE items in ALSPAC and CATSS to create and 
assess measures of specific PEs. 
This stage was performed separately for ALSPAC and CATSS. Principal components 
analysis (PCA) was used to investigate the correlation structure between PE items, 
highlighting how items cluster into dimensions of PEs.  
PCA is a method that uses the correlation between variables to identify axes of variance 
within the data (Jolliffe, 2002). This dimension reduction of data enables the 
construction of scales to measure underlying latent variables. PCA was performed using 
the R function ‘prcomp’ from the ‘stats’ package with the ‘center’ and ‘scale’ options set 
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to ‘TRUE’ (R Core Team, 2015). Based on evidence from scree plots of variance 
explained by principal components, components were extracted and rotated to improve 
interpretation of the data. Oblique rotation was used in light of previous evidence of 
some correlation between specific PEs (Ronald et al., 2014). Extraction and rotation of 
components was performed using the R function ‘principal’ from the ‘stats’ package (R 
Core Team, 2015). 
Measures of specific PEs were based on the PE dimensions identified by PCA and the 
clinicians’ advice. Some specific PE domains can be broken down further into 
subdomains, e.g. negative symptoms consist of five distinct behaviours including alogia 
(poverty of speech), avolition, asociality, inattention, avolition, and blunted affect. If 
there was an excess of items assessing one specific aspect of a PE domain, the 
appropriate number of items would be removed based on clinicians’ advice and the 
factor loadings from PCA. 
The Cronbach’s alphas of these specific measures were then calculated to assess 
reliability. This was performed using the R function ‘alpha’ from the ‘psych’ package 
(Revelle, 2015) with the following parameters: ‘cumulative = FALSE, max = 10,na.rm = 
TRUE, check.keys = TRUE, n.iter =1, delete=TRUE’. 
Stage 3: Adaptation of TEDS’ specific PE measures to improve comparability with 
ALSPAC and CATSS measures. 
A number of items were removed from the TEDS PE measures to ensure that the 
measures in TEDS assessed latent traits in common with those captured by the 
measures in ALSPAC and CATSS. PCA of the remaining PE items in TEDS was then 
performed to highlight specific PE domains. The number of items assessing each aspect 
of each PE domain was adjusted to ensure comparability with the measures in ALSPAC 
and CATSS samples. Calculating the Cronbach’s alphas then assessed the reliability of 
the derived measures. 
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Figure 4.1. Schematic representation of the phenotypic harmonisation process. 
4.3 - Results 
4.3.1 – Stage 1: Identifying PE items in ALSPAC and CATSS that matched SPEQ items 
ALSPAC: Items assessing paranoia and hallucinations matched well with items within 
the TEDS’ SPEQ. Grandiosity was not sufficiently assessed in ALSPAC to create a scale 
corresponding the TEDS’ grandiosity and delusions scale. Although there were no 
available measures that were designed to specifically assess anhedonia or parent-rated 
negative symptoms, items from other psychopathology-relevant measures that captured 
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latent traits resembling these specific PE domains could be used. This is possible due to 
the wide range of measures administered to the ALSPAC participants, and the overlap 
between psychological traits, such as social problems. However, cognitive 
disorganisation was not sufficiently captured within this cohort at age 16. In total, 19 
items corresponded to SPEQ items with their content validity confirmed by clinicians. 
See Table 4.3 for selected items.  
CATSS: Similar to ALSPAC, items assessing paranoia and hallucinations matched well 
with items within the TEDS’ SPEQ, however, grandiosity was not assessed sufficiently to 
create a scale corresponding the TEDS’ grandiosity and delusions scale. Similar to the 
situation in ALSPAC, although there were no available measures in CATSS that were 
designed to specifically assess cognitive disorganisation or parent-rated negative 
symptoms, items from other psychopathology-relevant measures that captured latent 
traits resembling these specific PE domains could be used. However, anhedonia was not 
sufficiently captured within CATSS. In total, 25 items corresponded well to SPEQ items 
with their content validity confirmed by clinicians. See Table 4.4 for selected items.  
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Table 4.3. List of items assessing adolescent psychotic experiences in the ALSPAC 
sample.  








0 = Not at all, 1 = Once or twice, 2 = Less than once a month, 3 = More 
than once a month, 4 = Nearly every day 
para1 a: 
Some people believe that other people can read their thoughts. Have 
other people ever read your thoughts? 
para1 b: 
How often have other people read your thoughts since your 15th 
birthday? 
para2 a: Have you ever thought you were being followed or spied on? 
para2 b: How often has this happened since your 15th birthday? 
para3 a: 
Have you ever believed that you were being sent special messages 
though the television or the radio, or that a programme had been 
arranged just for you alone? 
para3 b: How often has this happened since your 15th birthday? 
halluc1 a: Have you ever heard voices that other people couldn't hear 
halluc1 b: 
How often have you heard voices that other people couldn't hear since 
your 15th birthday? 
halluc2 a: 
Have you ever seen something or someone that other people could not 
see? 
halluc2 b: 
How often have you seen something or someone that other people 
could not see since your 15th birthday? 
Note: 
Composite scores for each item were created by adding the Part A and 
Part B responses. 
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Table 4.3 cont. 
  
ALSPAC Life of a 16+ Teenager Questionnaire - Section D: Your Current Feelings 
Leading 
statement: 
For each of the following questions, please mark the box that best 
describes the way you have felt over the past month: 
Response 
options: 
0 = No, never, 1 = Yes, sometimes, 2 = Yes, often, 3 = Yes, nearly always 
anhed1: 
Have you felt that you experience few or no emotions at important 
events, such as on your birthday? 
anhed2: Have you felt that you are lacking 'get up and go'? 
anhed3: Have you felt that you have only a few hobbies or interests? 
ALSPAC Life of a 16+ Teenager Questionnaire - Section H: Your Current Feelings 
Leading 
statement: 
In the past two weeks… 
Response 
options: 
0 = Not true, 1 = Sometimes true, 2 = True 
anhed4: I have been having fun. (Reversed) 
anhed5: I didn't enjoy anything at all. 
anhed6: I felt so tired that I just sat around and did nothing. 
anhed7: I have had a good time. (Reversed) 




0 = Often, 1 = Sometimes, 2 = Hardly ever, 3 = Never 
negsym1: 
How often does he/she tell you about things that happen at 
school/college/work? 
negsym2: 
How often does he/she tell you about things that happen while 
he's/she's been out? 
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Table 4.3 cont. 




In the past 6 months… 
Response 
options: 
0 = Not true, 1 = Somewhat true, 2 = Certainly true, NA = Don't know 
negsym3: He/She has at least one good friend. 
negsym4: He/She is easily distracted, his/her concentration wanders. 
negsym5: He/She sees tasks through to the end has good attention span. 
negsym6: He/She did not respond when told to do something. 




0 = No, 1 = Yes 
negsym7: 
Thinking back over the last month, has she been feeling tired or felt she 
had no energy? 
Note. A few items in this list may not be retained in the final scale due to results of stage 2 of 
analysis. Items are labelled based on content validity against the SPEQ subscales. para = 






Table 4.4. List of items assessing adolescent psychotic experiences in the CATSS 
sample.  
Adolescent Psychotic-like Symptom Screener (APSS) 
Leading 
statement: 
Have you ever… 
Response 
options: 
0 = Never or rarely, 1 = Sometimes, 2 = Often, 3 = Very Often 
para1: Thought you were being followed or spied on? 
para2: 
Thought you were being sent special messages through the 
television? 
para3: Thought other people could read your thoughts? 
halluc1: Seen things other people cannot see? 
halluc2: Heard voices that nobody else can hear? 
Adult ADHD Self-Report Scale (ASRS) 
Response 
options: 
0 = Never, 1 = Rarely, 2 = Sometimes, 3 = Often, 4 = Very often 
cogdis1: 
How often do you have trouble wrapping up the fine details of a 
project, once the challenging parts have been done? 
cogdis2: 
When you have a task that requires a lot of thought, how often do 
you avoid or delay getting started? 
cogdis3: 
How often do you have difficulty keeping your attention when you are 
doing boring or repetitive work? 
cogdis4: 
How often do you have difficulty concentrating on what people say to 
you, even when they are speaking to you directly? 
cogdis5: How often are you distracted by activity or noise around you? 
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Table 4.4 cont. 
Adult Behaviour Checklist  (ABCL) - Parental Report 
Leading 
statement: 




0 = Not true, 1 = Somewhat true, 2 = Very or often true 
negsym1: Fails to finish things he/she should do 
negsym2: Underactive, slow moving, or lacks energy 
negsym3: Doesn’t get along with other people 
negsym4: Would rather be alone than with others 
negsym5: Not liked by others 
negsym6: Refuses to talk 
negsym7: Has trouble making or keeping friends 
negsym8: Secretive, keeps things to self 
negsym9: Withdrawn, doesn't get involved with others 
negsym10: Stares blankly 
negsym11: Feels tired without good reason 
negsym12: Enjoys being with people 
negsym15: Can’t concentrate, can’t pay attention for long 
Autism - Tics, ADHD and other Comorbidities (A-TAC) -Parental Report 
Response 
options: 
0 = No, 1 = Yes, to a certain degree, 2 = Yes 
negsym13: 
Does the twin have difficulties expressing emotions and reactions 
with facial gestures, prosody, or body language? 
negsym14: Does the twin have difficulties to make and keep friends? 
Note. A few items in this list may not be retained in the final scale due to results of stage 2 of 
analysis. Items are labelled based on content validity against SPEQ subscales. para = 




4.3.2 - Stage 2: Psychometric analysis of identified PE items within ALSPAC and CATSS 
ALSPAC: Using a scree plot to interpret PCA results, the majority of variance in these 
items was explained by three components (Figure 4.2). Therefore, extraction of three 
principal components was performed to improve interpretability. The three principal 
component model fit the data well with a root mean square of the residuals (RMSR) of 
0.08. Using a cut-off of ±0.3 to interpret loadings, all paranoia and hallucination items 
loaded onto a single component, anhedonia items all loaded onto a single component 
and five out of seven parent rated negative symptom items loaded onto single 
component. Based on the items loading within the three components (Table 4.5), the 
components (or latent variables) were named paranoia and hallucinations, anhedonia 
and parent-rated negative symptoms. It was agreed in consultation with clinicians that 
the two poorly loading parent-rated negative symptom items, negsym3 and negsym7 
(‘at least one good friend’ and ‘feeling tired or has no energy’) were measuring key 
aspects of the construct and should be kept despite poor loadings.  
Calculation of Cronbach’s alpha for the subscales showed that paranoia and 
hallucinations, and anhedonia subscales had good reliability, with standardised alphas 
of 0.69 and 0.73 respectively. As a result of the two poorly loading items for parent-
rated negative symptoms (negsym3 and negsym7), this subscale only achieved an alpha 
of 0.60 (Table 4.6). If one of the poorly loading items was removed from the subscale 
then the standardised alpha increased to ≥0.63. However, with the understanding that 
these behavioural traits do not necessarily behave well psychometrically, all items were 
retained due to good content validity. 
CATSS: PCA showed that the majority of variance among these 25 items was explained 
by three principal components (Figure 4.3). Therefore, extraction of three principal 
components was performed with oblique rotation to improve interpretability (Table 
4.7). The three principal component model fit the data well with an RMSR of 0.06. 
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Similar to ALSPAC, using a loading cut-off of ±0.3, all paranoia and hallucination items 
loaded onto a single component. This latent variable captured by this component was 
therefore named paranoia and hallucinations. All cognitive disorganisation items loaded 
at ±0.3 on a single component. Of the 15 parent-rated negative-symptom items, 13 
loaded onto a single component using a cut- off of ±0.3. The other two had loadings of 
0.24 and 0.20 with fairly high cross loading onto the cognitive disorganisation 
component. The poorly loading parent-rated negative symptom items were retained in 
the scale due to good content validity. Of the 15 parent-rated negative symptoms, seven 
assessed asociality, whereas only two assessed each of the other aspects of negative 
symptoms (poverty of speech, inattention, avolition, and blunted affect). Although PCA 
identified these items as assessing a single latent factor, based on previous literature 
and the advice of clinicians, it was deemed important that each specific aspect of 
negative symptoms have an equal contribution to an individuals’ overall score. 
Therefore, 5 asociality items were removed from the scale leaving negsym7 and 
negsym9, the two best-matched items across samples that also had the highest loading 
on the negative symptom component in PCA. The results of PCA changed minimally 
when re-run after removal of the excess asociality negative symptom items (see 
Supplementary Figure 4.1 and Supplementary Table 4.2).  
Calculation of Cronbach’s alphas for the subscales showed that the reliability of the 
positive symptom, cognitive disorganisation subscale and parent-rated negative 
symptom subscales was good with standardised alphas of 0.73, 0.79 and 0.76 




Figure 4.2. Scree plot of ALSPAC psychotic experience items. 
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Table 4.5. Principal component loadings of psychotic experience items in ALSPAC.  
 
Component 1 Component 2 Component 3 
para1.comp -0.02 0.61 -0.02 
para2.comp 0.09 0.63 0.02 
para3.comp -0.03 0.57 0.00 
halluc1.comp 0.02 0.67 -0.02 
halluc2.comp 0.00 0.74 -0.01 
anhed1 0.50 0.18 0.05 
anhed2 0.61 0.17 0.05 
anhed3 0.57 0.15 0.03 
anhed4 0.65 -0.18 -0.04 
anhed5 0.57 0.10 0.03 
anhed6 0.47 0.16 0.03 
anhed7 0.72 -0.14 -0.04 
negsym1 0.05 -0.13 0.67 
negsym2 0.03 -0.11 0.68 
negsym3 0.09 -0.03 0.14 
negsym4 -0.07 0.12 0.64 
negsym5 -0.01 0.06 0.69 
negsym6 0.00 0.05 0.56 
negsym7 0.18 0.02 0.12 
Note. Shows the presence of three underlying latent variables that have been labelled as 
paranoia and hallucinations (Component 2), anhedonia (Component 1), and parent rated 
negative symptoms (Component 3). Numbers in bold and italic highlight a principal 
component loading of ±0.3. The RMSR is 0.08 indicates this model provides a good fit. 
  
 164 
Table 4.6. Cronbach's alpha for the paranoia and hallucinations, anhedonia and 
parent-rated negative symptoms subscales identified within ALSPAC.  
Paranoia and Hallucinations 
Full 0.69 
excl. para1.comp 0.66 
excl. para2.comp 0.64 
excl. para3.comp 0.66 
excl. halluc1.comp 0.64 
excl. halluc2.comp 0.61 
Anhedonia  
Full 0.73 
excl. anhed1 0.70 
excl. anhed2 0.67 
excl. anhed3 0.69 
excl. anhed4 0.71 
excl. anhed5 0.69 
excl. anhed6 0.71 
excl. anhed7 0.69 
Parent-rated Negative Symptoms 
Full 0.60 
excl. negsym1 0.54 
excl. negsym2 0.54 
excl. negsym3 0.63 
excl. negsym4 0.54 
excl. negsym5 0.51 
excl. negsym6 0.54 
excl. negsym7 0.64 
Note. Table shows alpha when excluding each item of the scale. Parent-rated negative 
symptom scale has a poor alpha due to negsym3 and negsym7. These items have good 




Figure 4.3. Scree plot of CATSS psychotic experience items. 
  
 166 
Table 4.7. Principal component loadings of psychotic experience items in CATSS. 
 
Component 1 Component 2 Component 3 
para1 -0.10 0.12 0.70 
para2 -0.03 -0.16 0.64 
para3 0.01 0.00 0.78 
halluc1 0.03 0.02 0.72 
halluc2 0.09 0.02 0.73 
cogdis1 -0.03 0.68 0.01 
cogdis2 -0.01 0.72 -0.10 
cogdis3 -0.02 0.71 0.05 
cogdis4 -0.01 0.70 0.06 
cogdis5 -0.04 0.72 0.03 
negsym1 0.24 0.43 -0.07 
negsym2 0.55 0.18 -0.03 
negsym3 0.35 0.11 0.04 
negsym4 0.72 -0.05 0.00 
negsym5 0.48 0.00 -0.01 
negsym6 0.52 0.05 0.08 
negsym7 0.81 -0.07 0.01 
negsym8 0.62 0.04 0.03 
negsym9 0.74 0.01 0.01 
negsym10 0.33 0.05 0.12 
negsym11 0.32 0.34 0.10 
negsym12 0.39 0.02 -0.02 
negsym13 0.45 0.08 -0.15 
negsym14 0.76 -0.06 -0.02 
negsym15 0.20 0.39 0.05 
Note. Highlights the presence of three underlying latent variables that have been labelled 
called positive symptoms (Component 3), cognitive disorganisation (Component 2), and 
parent rated negative symptoms (Component 1). 
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Table 4.8. Cronbach's alpha for the paranoia and hallucinations, cognitive 
disorganisation and parent-rated negative symptoms subscale identified within 
CATSS. 
Paranoia and Hallucinations 
Full 0.73 
excl. para1 0.67 
excl. para2 0.73 
excl. para3 0.67 
excl. halluc1 0.67 
excl. halluc2 0.67 
Cognitive Disorganisation 
Full 0.79 
excl. cogdis1 0.77 
excl. cogdis2 0.75 
excl. cogdis3 0.74 
excl. cogdis4 0.75 
excl. cogdis5 0.76 
Parent-rated Negative Symptoms 
Full 0.76 
excl. negsym1 0.74 
excl. negsym2 0.72 
excl. negsym6 0.74 
excl. negsym7 0.73 
excl. negsym8 0.72 
excl. negsym9 0.72 
excl. negsym10 0.74 
excl. negsym11 0.74 
excl. negsym13 0.75 
excl. negsym15 0.75 
Note. Table shows alpha when excluding each item of the scale.   
 168 
4.3.3 - Stage 3: Adaptation and psychometric analysis of TEDS’ SPEQ scale based on the 
subscales available in ALSPAC and CATSS 
The SPEQ has many more items assessing paranoia and hallucinations than in ALSPAC 
and CATSS. This means that some aspects of the SPEQ paranoia and hallucinations 
subscales were not assessed in ALSPAC and CATSS. For example, ALSPAC and CATSS 
only assessed visual and auditory hallucinations, whereas in TEDS other types of 
hallucinations were measured, including olfactory and tactile hallucinations. To 
overcome this potential issue, TEDS’ SPEQ items were removed if they assessed aspects 
of subscales that were not assessed in ALSPAC and CATSS subscales. Adaptations to the 
TEDS paranoia and hallucinations scales resulted in three items assessing paranoia and 
five items assessing hallucinations. No items had to be excluded from the anhedonia, 
cognitive disorganisation or parent-rated negative symptoms scales, leaving ten items 
assessing each of these subscales (Table 4.9). These adaptations to the SPEQ were 
carried out in consultation with expert clinicians who were involved in the original 
development of the SPEQ.  
PCA showed that the majority of variance in these remaining items was explained by 
four components (Figure 4.4). Extraction and rotation of these four components showed 
that the paranoia and hallucinations items fell into a single component (Table 4.10) and 
the other three subscales (cognitive disorganisation, parent rated-negative symptoms 
and anhedonia) remained distinct corresponding to the results of ALSPAC and CATSS 
psychometric analysis. The composition of these PCA results resembled ALSPAC and 
CATSS PCA results closely. Paranoia and hallucinations items were therefore considered 
as measuring a single latent variable. 
Although PCA identifies items within a component as assessing a single latent variable, 
given the prior knowledge that paranoia and hallucinations are separable latent traits, 
the numbers of items assessing these two domains were balanced across samples to 
 169 
ensure that when the individual phenotypic scores are calculated, these two domains 
would be weighted equally across samples. In CATSS and ALSPAC there are three items 
assessing paranoia and two items assessing hallucinations. In each of these studies one 
hallucination item assesses auditory hallucinations, and the other assesses visual 
hallucinations. In the TEDS paranoia and hallucinations scale, there are three items 
assessing paranoia, but five items assessing hallucinations. Given the prior knowledge 
that paranoia and hallucinations are separable traits, this imbalance in the number of 
paranoia items and hallucination items may result in an over-representation of 
hallucinations in TEDS individuals compared to CATSS and ALSPAC individuals. In order 
to promote phenotypic homogeneity across the samples the TEDS hallucination items 
were condensed into two items, one assessing auditory (labelled as Aud_Hall) and the 
other assessing visual (labelled as Vis_Hall). In order to preserve the valuable 
information provided by multiple items assessing both visual and auditory 
hallucinations, the mean across auditory hallucination items will act as a single item 
assessing auditory hallucinations. Similarly, the mean of the two visual hallucination 
items will be used as a single item assessing visual hallucinations. This procedure was 
not carried out for anhedonia, cognitive disorganisation or parent-rated negative 
symptom scales, as the items within them are measuring a more unidimensional trait 
meaning the number of items available in each sample will introduce less heterogeneity. 
After converting hallucinations items into two items, the Cronbach’s alpha of the 
paranoia and hallucinations scale was 0.72 (Table 4.11). 
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Table 4.9. List of SPEQ items that match items available in ALSPAC and CATSS.  




How often have you thought… 
Response 
options: 
0 = Not at all, 1 = Rarely, 2 = Once a month, 3 = Once a week, 4 = 
Several times a week, 5 = Daily 
para4 I might be being observed or followed 
para12 People might be conspiring against me 
para15 I can detect coded messages about me in the press/TV/internet 
halluc1 Hear noises or sounds when there is nothing about to explain them? 
halluc3 Hear sounds or music that people near you don't hear? 
halluc5 See things that other people cannot 
halluc7 Sees shapes, lights, or colours even thought there is nothing really 
there? 





0 = Very false for me, 1 = Moderately false for me, 2 = Slightly false for 
me, 3 = Slightly true for me, 4 = Moderately true for me, 6 = Very true 
for me 
Item 1: When something exciting is coming up in my life, I really look forward 
to it. 
Item 2: When I'm on my way to an amusement park, I can hardly wait to ride 
the rollercoasters. 
Item 3: When it think about eating my favourite food, I can almost taste how 
good it is. 
Item 4: I don’t look forward to things like eating out at restaurants. 
Item 5: I get so excited the night before a major holiday I can hardly sleep. 
Item 6: When I think of something tasty, like chocolate biscuit, I have to have 
one. 
Item 7: Looking forward to a pleasurable experience is in itself pleasurable. 
Item 8: I look forward to a lot of things in my life. 
Item 9: When ordering something off a menu, I imagine how good it will taste. 
Item 10: When I hear about a new movie starring my favourite actor, I can't wait 
to see it. 
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0 = Yes, 1 = No 
Item 1: Are you easily confused if too much happens at the same time? 
Item 2: Do you frequently have difficulty in starting to do things? 
Item 3: Are you a person whose mood goes up and down easily? 
Item 4: Do you dread going into a room by yourself where other people have 
already gathered and are talking? 
Item 5: Do you find it difficult to keep interested in the same thing for a long 
time? 
Item 6: Do you find it difficult in controlling your thoughts? 
Item 7: Are you easily distracted from work by daydreams? 
Item 8: Do you ever feel that your speech is difficult to understand because the 
words are all mixed up and don't make sense? 
Item 9: Are you easily distracted when you talk read or talk to someone? 
Item 10: Is it hard for you to make decisions? 
Item 11: When in a crowded room, do you often have difficulty in following a 
conversation? 







0 = Not at all true,  1 = Somewhat true, 2 = Mainly true, 3 = Definitely 
true 
Item 1: Usually gives brief, one word replies to questions, even if encouraged 
to say more. 
Item 2: Often does not have much to say for him/herself. 
Item 3: Has few or no friends.  
Item 4: Is often inattentive and appears distracted. 
Item 5: Often does not pay attention when being spoken to. 
Item 6: Often sits around for a long time doing nothing. 
Item 7: Has a lack of energy and motivation. 
Item 8: Has very few interests or hobbies. 
Item 9: Often fails to smile or laugh at things others would find funny. 
Item 10: Seems emotionally "flat", for example, rarely changes the emotions 
he/she shows.  
Note. Cognitive Disorganisation, Anhedonia, and Parent-rated Negative Symptoms scales 





Figure 4.4. Scree plot of SPEQ items in TEDS that match psychotic experience items 
available in the ALSPAC and CATSS samples.   
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Table 4.10. Principal component loadings of psychotic experience items in TEDS. 
 
Component 1 Component 2 Component 3 Component 4 
para4 0.01 0.52 -0.01 0.09 
para12 0.08 0.50 0.03 0.05 
para15 0.05 0.40 -0.05 0.00 
halluc1 -0.02 0.67 -0.01 0.10 
halluc3 -0.01 0.78 -0.01 -0.02 
halluc5 0.00 0.79 -0.01 -0.07 
halluc7 -0.01 0.74 0.00 0.01 
halluc8 0.01 0.67 0.04 0.00 
cogdis1 -0.01 -0.03 -0.06 0.63 
cogdis2 0.04 -0.02 0.07 0.60 
cogdis3 0.01 0.06 0.00 0.48 
cogdis4 0.06 0.06 0.01 0.44 
cogdis5 0.00 -0.07 0.04 0.54 
cogdis6 -0.07 0.18 0.03 0.51 
cogdis7 -0.01 0.05 -0.05 0.54 
cogdis8 -0.01 0.15 0.03 0.45 
cogdis9 0.02 0.01 -0.05 0.61 
cogdis10 -0.03 -0.03 -0.01 0.54 
cogdis11 0.04 0.03 0.06 0.51 
anhed1 0.05 0.04 0.60 0.08 
anhed2 -0.01 -0.06 0.64 -0.01 
anhed3 0.06 0.05 0.35 0.21 
anhed4 0.02 0.01 0.45 0.02 
anhed5 -0.01 0.03 0.63 -0.10 
anhed6 -0.04 0.02 0.54 -0.23 
anhed7 0.00 -0.05 0.67 0.01 
anhed8 0.05 0.06 0.61 0.21 
anhed9 -0.02 -0.02 0.69 -0.01 
anhed10 -0.02 0.00 0.56 -0.06 
negsym1 0.54 0.03 0.00 -0.02 
negsym2 0.69 0.05 0.02 -0.10 
negsym3 0.74 -0.01 0.02 -0.06 
negsym4 0.71 -0.01 0.07 -0.04 
negsym5 0.66 -0.02 -0.10 0.04 
negsym6 0.72 0.00 -0.01 0.07 
negsym7 0.65 -0.03 0.02 0.05 
negsym8 0.47 0.06 0.09 -0.04 
negsym9 0.64 0.01 -0.04 0.04 
negsym10 0.65 0.00 -0.04 0.07 
Note. The correlation between principal components supports the use of oblique rotation. 
The RMSR is <0.08 indicating this model provides good fit. 
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Table 4.11. Cronbach’s alpha of paranoia and hallucinations (after converting 
hallucinations into two items), cognitive disorganisation, anhedonia and parent-
rated negative symptom scales in the TEDS sample using matched items. 
Paranoia and Hallucinations 
Full 0.72 
excl. para4 0.68 
excl. para12 0.68 
excl. para15 0.73 
excl. Aud_Hall 0.62 
excl. Vis_Hall 0.65 
Cognitive Disorganisation   
Full 0.77 
excl. cogdis1 0.75 
excl. cogdis2 0.75 
excl. cogdis3 0.76 
excl. cogdis4 0.76 
excl. cogdis5 0.76 
excl. cogdis6 0.75 
excl. cogdis7 0.76 
excl. cogdis8 0.76 
excl. cogdis9 0.75 
excl. cogdis10 0.76 
excl. cogdis11 0.76 
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Table 4.11 cont. 
Anhedonia   
Full 0.78 
excl. anhed1 0.76 
excl. anhed2 0.75 
excl. anhed3 0.78 
excl. anhed4 0.77 
excl. anhed5 0.75 
excl. anhed6 0.77 
excl. anhed7 0.75 
excl. anhed8 0.76 
excl. anhed9 0.75 
excl. anhed10 0.76 
Parent-rated Negative Symptoms 
Full 0.85 
excl. negsym1 0.84 
excl. negsym2 0.83 
excl. negsym3 0.83 
excl. negsym4 0.83 
excl. negsym5 0.83 
excl. negsym6 0.83 
excl. negsym7 0.83 
excl. negsym8 0.85 
excl. negsym9 0.83 
excl. negsym10 0.83 
Note. Table shows alpha when excluding each item of the scale. 
4.4 - Discussion 
This chapter has identified items within three non-clinical adolescent samples assessing 
a broad range of specific PEs. These PE items have been demonstrated to fall into 
distinct PE domains, comparable to those previously reported (Ronald et al., 2014; 
Wigman et al., 2012), and comparable across the samples within this study. The expert 
clinicians consulted here advised that the PE scales derived within each sample are 
capturing comparable latent traits across the samples in spite of the PE items within 
each sample not being identical. The outcome of this phenotypic harmonisation is the 
derivation of reliable, comparable, quantitative, and specific PE measures within three 
large-scale non-clinical adolescent samples. These specific PE measures enable the 
combined analysis of Paranoia and Hallucinations, and Parent-rated Negative Symptoms 
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across three samples, and Cognitive Disorganisation and Anhedonia across two samples. 
This provides an opportunity for combined analysis of multiple samples and improved 
statistical power. Therefore these measures will be used in all subsequent chapters. 
The phenotypic harmonisation process raised two important points for consideration.  
Firstly, the ALSPAC and CATSS samples were not directly assessed for certain specific PE 
domains (cognitive disorganisation, anhedonia, and negative symptoms). However, the 
traits/symptoms relating to different areas of psychopathology frequently overlap, and 
therefore, items within measures from other areas of psychopathology could be used. 
For example, the cognitive disorganisation domain of PEs was not directly assessed in 
CATSS. However, the CATSS sample had administered the Adult Self-report ADHD Scale 
(ASAS) containing several items that assessed problems in attention and concentration 
that resembled items within the Cognitive Disorganisation measure in the SPEQ (Ronald 
et al., 2014). This approach was facilitated by the large range of measures administered 
to participants of ALSPAC and CATSS, capturing a broad range of traits relating to 
psychopathology. Consultation with expert clinicians was crucial for validating the 
derived measures as both content valid and well matched across samples.  
A second but related issue is determining the number of items within each measure 
assessing specific aspects of the trait. This is important for both content validity within 
samples and for ensuring the comparability of the measures across samples. For 
example, the negative symptoms PE domain contains several aspects of behaviour 
including alogia (poverty of speech), asociality, inattention, avolition, and blunted affect. 
Although PCA identified these items as assessing a single latent factor, based on 
previous literature and the advice of clinicians, it was deemed important that each 
specific aspect of negative symptoms have an equal contribution to an individuals’ 
overall score. Therefore there must be a similar proportion of items assessing each 
specific aspect of the negative symptoms domain. As previously described, this issue 
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was particularly important for the Parent-rated Negative Symptoms measures in the 
CATSS sample. Of the 15 items assessing parent-rated negative symptoms, seven 
assessed asociality, leading to an increased weighting of asocial behaviour relative to 
other aspects of the domain. Therefore, five asociality items were removed to ensure a 
more equal contribution of the different aspects of the negative symptoms PE domain, 
and ensuring comparability across samples. 
Although this approach has provided opportunities for the analysis of several specific 
PEs across several samples, it has not been possible to create Grandiosity measures for 
ALSPAC and CATSS samples. As a result, this domain of PEs will not be included in 
subsequent analyses. Furthermore, Cognitive Disorganisation was not assessed in 
ALSPAC, and Anhedonia was not assessed in CATSS, meaning these PE domains will only 
be analysed across the two samples with available data. This study has been able to 
identify a sufficient number of items to highlight the dimensional structure of PEs. 
However, due to the high correlation between paranoia and hallucinations, and the 
small number of items for these traits in ALSPAC and CATSS, PCA was unable to 
separate these specific domains, and it was decided to study these two domains as one.  
A consideration is the inability to assess the phenotypic correlation of PE measures 
between samples. Phenotypic heterogeneity is likely to exist given that these samples 
were assessed separately using different items (although highly similar in some 
situations). Molecular genetic methods for estimating the genetic correlation between 
traits could be used to estimate the extent to which these phenotypes have a genetic 
overlap. However, methods for the estimation of genetic correlation are underpowered 
when looking between these samples. Another approach to indicate sample 
heterogeneity is to compare SNP-heritability estimates for a trait within versus across 
samples. This will be investigated further in Chapter 6. 
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In conclusion, this chapter has derived scales within each sample assessing four 
common latent traits: Paranoia and Hallucinations (TEDS, ALSPAC and CATSS), 
Anhedonia (TEDS and ALSPAC), Cognitive Disorganisation (TEDS, CATSS), and Parent-
rated Negative Symptoms (TEDS, ALSPAC and CATSS). The results of PCA, the approval 
of expert clinicians, and the similarity of items across samples, collectively support the 
validity of these scales as assessing adolescent PEs that are both dimension specific and 
in common across samples. These scales of will be used study specific PEs across TEDS, 
ALSPAC and CATSS in subsequent chapters.  
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4.5 – Appendix 





How often have you thought… 
Response 
options: 
0 = Not at all, 1 = Rarely, 2 = Once a month, 3 = Once a week, 4 = 
Several times a week, 5 = Daily 
para1 I need to be on my guard against others 
para2 There might be negative comments being spread about me 
para3 People are deliberately trying to irritate me 
para4 I might be being observed or followed 
para5 People are trying to upset 
para6 People are looking at me in an unfriendly way 
para7 People are being hostile towards me 
para8 Bad things are being said about me behind my back 
para9 Someone has bad intentions towards me 
para10 Someone has it in for me 
para11 People would harm me if given the opportunity 
para12 People might be conspiring against me 
para13 People are laughing at me 
para14 I am under threat from others 





How often have you thought… 
Response 
options: 
0 = Not at all, 1 = Rarely, 2 = Once a month, 3 = Once a week, 4 = 
Several times a week, 5 = Daily 
halluc1 Hear noises or sounds when there is nothing about to explain them? 
halluc2 Feel that someone is touching you but when you look nobody is there? 
halluc3 Hear sounds or music that people near you don't hear? 
halluc4 Detects smells which don't seem to come from your surroundings? 
halluc5 See things that other people cannot 
halluc6 Experience unusual burning sensations or other strange feeling in or on 
your body that can't be explained? 
halluc7 Sees shapes, lights, or colours even thought there is nothing really 
there? 
halluc8 Hear voices commenting on what you're thinking or doing? 
halluc9 Notice smells or odours that people next to you seem unaware of? 
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0 = Yes, 1 = No 
Item 1: Are you easily confused if too much happens at the same time? 
Item 2: Do you frequently have difficulty in starting to do things? 
Item 3: Are you a person whose mood goes up and down easily? 
Item 4: Do you dread going into a room by yourself where other people have 
already gathered and are talking? 
Item 5: Do you find it difficult to keep interested in the same thing for a long 
time? 
Item 6: Do you find it difficult in controlling your thoughts? 
Item 7: Are you easily distracted from work by daydreams? 
Item 8: Do you ever feel that your speech is difficult to understand because the 
words are all mixed up and don't make sense? 
Item 9: Are you easily distracted when you talk read or talk to someone? 
Item 10: Is it hard for you to make decisions? 






0 = Very false for me, 1 = Moderately false for me, 2 = Slightly false for 
me, 3 = Slightly true for me, 4 = Moderately true for me, 6 = Very true 
for me 
Item 1: When something exciting is coming up in my life, I really look forward 
to it. 
Item 2: When I'm on my way to an amusement park, I can hardly wait to ride 
the rollercoasters. 
Item 3: When it think about eating my favourite food, I can almost taste how 
good it is. 
Item 4: I don’t look forward to things like eating out at restaurants. 
Item 5: I get so excited the night before a major holiday I can hardly sleep. 
Item 6: When I think of something tasty, like chocolate biscuit, I have to have 
one. 
Item 7: Looking forward to a pleasurable experience is in itself pleasurable. 
Item 8: I look forward to a lot of things in my life. 
Item 9: When ordering something off a menu, I imagine how good it will taste. 
Item 10: When I hear about a new movie starring my favourite actor, I can't wait 
to see it. 
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Supplementary table 4.1 cont. 







0 = Not at all true,  1 = Somewhat true, 2 = Mainly true, 3 = Definitely 
true 
Item 1: Usually gives brief, one word replies to questions, even if encouraged 
to say more. 
Item 2: Often does not have much to say for him/herself. 
Item 3: Has few or no friends. 
Item 4: Is often inattentive and appears distracted. 
Item 5: Often does not pay attention when being spoken to. 
Item 6: Often sits around for a long time doing nothing. 
Item 7: Has a lack of energy and motivation. 
Item 8: Has very few interests or hobbies. 
Item 9: Often fails to smile or laugh at things others would find funny. 
Item 10: Seems emotionally "flat", for example, rarely changes the emotions 
he/she shows . 
Note. Items are labelled according to specific PE subscale. para = paranoia, halluc = 
hallucinations, grandi = grandiosity and delusions, cogdis = cognitive disorganisation, anhed 




Supplementary Table 4.2. Loadings of CATSS PE items from principal components 
analysis after removal of excess parent-reported asociality items. 
 
Component 1 Component 2 Component 3 
para1 -0.13 0.14 0.70 
para2 -0.04 -0.16 0.64 
para3 0.01 0.00 0.78 
halluc1 0.04 0.01 0.72 
halluc2 0.13 0.01 0.72 
cogdis1 -0.04 0.69 0.02 
cogdis2 0.00 0.73 -0.10 
cogdis3 -0.02 0.72 0.05 
cogdis4 0.01 0.70 0.06 
cogdis5 -0.03 0.73 0.03 
negsym1 0.31 0.39 -0.09 
negsym2 0.63 0.12 -0.04 
negsym6 0.61 -0.02 0.06 
negsym7 0.69 -0.08 0.02 
negsym8 0.70 -0.03 0.02 
negsym9 0.75 -0.03 0.00 
negsym10 0.46 -0.01 0.10 
negsym11 0.37 0.31 0.08 
negsym13 0.48 0.04 -0.16 






Supplementary Figure 4.1. Scree plot of CATSS PE items after removal of excess 
parent-reported asociality items. 
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Supplementary Note 4.1. Example of PLIKS-Q item in ALSPAC’ Life of a 16+ 





Chapter 5 - Genome-wide association study of specific 
psychotic experiences using TEDS, ALSPAC and 
CATSS samples 
5.1 – Introduction 
As discussed in Section 1.6, prior to this thesis there was only one genome-wide 
association study (GWAS) of adolescent psychotic experiences (PEs)(Zammit et al., 
2014). This previous GWAS, based on data collected in the ALSPAC study, reported no 
variant significantly associated with a binary outcome on a broad positive symptom 
measure. The statistical power of this study was restricted by its use of a binary and 
non-specific measure, and a limited sample size (N=3,483). In Chapter 2, a second GWAS 
of adolescent PEs was performed, which used quantitative measures of specific PEs 
assessed in the TEDS sample (N=2,978 – 2,997). Although this second GWAS also had 
limited statistical power due to a small sample size, the use of quantitative and specific 
PEs could potentially reduce phenotypic heterogeneity compared to the previous study. 
This second GWAS reported three genome-wide significant loci for specific PEs. To gain 
further statistical power, larger sample sizes are required. As described in Section 4.1, 
the main approach to increasing sample size is the pooling of resources across samples 
with the relevant phenotypic data. In Chapter 4, data from three European general 
population samples (TEDS, ALSPAC and CATSS) were analysed to create specific 
measures of PEs that were comparable across samples. This lead to the creation of four 
specific PE measures that were assessed in at least two of the three samples: Paranoia 
and Hallucinations, Cognitive Disorganisation, Anhedonia, and Parent-rated Negative 
Symptoms. TEDS, ALSPAC and CATSS have collected genome-wide genotypic data for a 
subset of their participants, providing an opportunity to perform the largest GWAS of 
specific adolescent PEs to date. 
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This chapter aims to identify genetic loci associated with specific adolescent PEs by 
performing genome-wide association analysis of the four specific PEs assessed across 
TEDS, ALSPAC, and CATSS. Initially, the genotypic data from each study was harmonised 
via genotypic imputation to a common reference panel and the application of quality 
control parameters. Subsequently, the identification of associated genetic variation was 
performed across all three samples simultaneously (mega-GWAS). In addition, this 
chapter aimed to identify genes associated with specific adolescent PEs using two 
approaches (MAGMA and PrediXcan). 
5.2 – Methods 
5.2.1 – Samples 
The three samples used in this chapter have been previously described in Section 4.2.1. 
The exclusion criteria applied within each sample have been detailed in Section 4.2.2.  
5.2.2 – Measures 
The measures used in this chapter are based on the results of Chapter 4. Lists of items 
for each measure within each sample are in Supplementary Tables 5.1-5.4.  
To understand the relationship between the PE domains used in this study and other 
related behavioural and cognitive domains, the correlations between PEs and anxiety 
symptoms, depressive symptoms and cognitive ability were assessed. These 
correlations were assessed primarily using the TEDS sample as only this sample 
assessed anxiety symptoms, depressive symptoms and cognitive ability at the same time 
point as PEs. Only the correlation between self-report depressive symptoms and PEs 
was calculated in all three samples, as this was the only trait of interest that was 
measured in all three samples at the same time point as PEs.  
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TEDS assessed anxiety symptoms using the Childhood Anxiety Sensitivity Index (self-
report) (Silverman, Fleisig, Rabian, & Peterson, 1991) and Anxiety-Related Behaviours 
Questionnaire (parent-report)(Hallett, Ronald, Rijsdijk, & Eley, 2009), depressive 
symptoms using the Mood and Feelings Questionnaire (self- and parent-report)(Angold, 
Costello, Messer, & Pickles, 1995), and general cognitive ability using the Mill Hill 
Vocabulary score and Raven’s Progressive Matrices (Raven, Raven, & Court, 1996, 
1989). Self-report depressive symptoms were assessed using the Short Mood and 
Feelings Questionnaire (Angold et al., 1995) in the ALSPAC sample, and the Center for 
Epidemiological Studies-Depression measure in the CATSS sample (Radloff, 1977). 
5.2.3 – Handling missing phenotypic data 
Individuals with >50% missingness for a given measure were excluded from subsequent 
analysis of that measure. The remaining missing phenotypic data for each measure was 
imputed using multiple imputation in R (Buuren & Groothuis-Oudshoorn, 2011).  The 
specified method of imputation was predictive mean matching (‘meth = pmm’). Each 
missing value was replaced with the average of 10 imputations (‘m=10’) using 50 
iterations (‘maxit = 50’). 
5.2.4 – Calculation of phenotypic sum scores 
Individual scores for each measure were calculated using sum scores. To ensure the 
equal contribution of each item to the sum score, item response values were rescaled to 
values between 0 and 1. 
5.2.5 – Normalisation of phenotypic data and controlling for covariate effects 
Sum scores for each psychotic experience subscale were normalised using inverse rank-
based normalisation (data ties ranked randomly) and then standardised. This approach 
of normalisation before controlling for covariate effects was investigated in Chapter 3. 
The R function used to normalise the phenotypic data (called rntransform_random, 
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Supplementary Note 3.6) was an adaptation of the rntransform function from GenABEL 
that randomly ranks tied observations. The normalised scores were then regressed 
against the following covariates: sex, age, age2, sex*age, sex*age2, study, and the top 8 
principal components of ancestry. Principal components of ancestry were jointly 
calculated across all three samples using PLINK1.9 (https://www.cog-
genomics.org/plink2) based only on observed genetic variation (number of linkage 
disequilibrium (LD) independent genetic markers = 49,596). 
All stages of this phenotypic preparation procedure and calculation of ancestry 
covariates (Section 5.2.3 – 5.2.5) were carried out for the purposes of this thesis. 
5.2.6 – DNA collection and genotyping 
TEDS: DNA was extracted using buccal cheek swabs. Genotyping was performed using 
Affymetrix GeneChip 6.0 SNP genotyping platform at the Affymetrix Santa Clara, 
California, USA, as part of the TEDS Wellcome Trust Case Control Consortium 2 
(WTCCC2) study of reading and mathematical abilities. Samples were excluded based on 
one or more of the following parameters: low call rate or heterozygosity outliers, 
atypical population ancestry, sample duplication or relatedness to other sample 
members, unusual hybridisation intensity, gender mismatches, and having less than 
90% of genotypes called identically on the genome-wide array and Sequenom panel. 
This resulted in 3,152 unrelated individuals being successfully genotyped consisting of 
1,446 males and 1,706 females. Individuals from monozygotic (MZ) twin pairs could be 
used to impute the genotype of their sibling based on the assumption that MZ twins are 
genetically identical. Given that both siblings of these genotyped MZ twin pairs provided 
phenotypic information, they were both included in subsequent analyses, accounting for 
family structure (Minică et al., 2015). 
ALSPAC: DNA was extracted from umbilical cord blood. Genotyping was performed 
using the Illumina HumanHap550 quad genome-wide SNP genotyping platform by 
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23andMe subcontracting the Wellcome Trust Sanger Institute, Cambridge, UK and the 
Laboratory Corporation of America, Burlington NC, USA. Samples were excluded based 
on the following criteria: incorrect gender assignments, heterozygosity outliers, low call 
rate, cryptic relatedness and being of non-European ancestry as detected by a 
multidimensional scaling analysis seeded with HapMap 2 individuals. Subsequently, 
8,365 unrelated individuals survived quality control consisting of 4,285 males and 4,080 
females. 
CATSS: DNA was extracted from saliva. Genotyping was performed using the Illumina 
Infinium PsychArray-24 BeadChip and carried out by SNP&SEQ Technologies in 
Uppsala, Sweden. Samples were excluded based on one or more of the following 
parameters: Low call rate, excess heterozygosity, sample duplication, erroneous within 
family relatedness, cryptic relatedness, gender mismatches, being non-European as 
detected by principal components analysis seeded by the 1KG EUR (1000 genomes 
European) reference. This resulted in 17,898 individuals successfully genotyped. This 
number includes dizygotic (DZ) twin pairs. As in TEDS, the genotypes of MZ siblings 
were imputed if their co-twin was genotyped. If both siblings of these genotyped twin 
pairs provided phenotypic information, they were both included in subsequent analyses, 
while accounting for family structure.  
All DNA collection and genotyping was carried out prior to this project. MZ sibs had not 
been inserted into the genotypic data prior to this study. 
5.2.7 – Genotype imputation and quality control procedure 
This genotype imputation and quality control process was carried out for this study. 
Genotype imputation and harmonisation was performed using only autosomes. The 
reference panel chosen for imputation was the 1KG Phase 3 version 5 dataset. Stringent 
quality control and strand alignment (ambiguous SNPs excluded) was performed prior 
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to imputation. The data was phased using ShapeIt V2 and subsequently imputed in 5Mb 
sections using Impute2 (B. Howie, Marchini, & Stephens, 2011; B. N. Howie, Donnelly, & 
Marchini, 2009). In all cases the call accuracy of imputation was between .90 and .99. 
SNPs with poor INFO scores were removed (INFO < .3). For ease of subsequent analysis, 
the dosage levels of imputed SNPs were converted to ‘hard calls‘ using a threshold of 
>0.9 with the intention of following up associations of interest accounting for 
imputation probabilities. 
The ‘hard call’ genotype data from each sample were merged per chromosome using 
PLINK1.9. A light SNP-missingness threshold (>20%) was applied to remove SNPs that 
were neither imputed nor observed in the samples. A second round of stringent SNP- 
and individual-level QC was then applied: SNP missingness > 2%, individual missingness 
>5%, minor allele frequency (MAF) < 1%, Hardy-Weinberg equilibrium p < 1x10-6. After 
QC 4,487,870 common variants were captured in each of the samples. 
5.2.8 – Mega-genome-wide association analysis 
After phenotypic and genotypic harmonisation, the three samples were combined to 
enable genome-wide association mega-analysis of four specific PEs with the following 
sample sizes (including siblings): Paranoia and Hallucinations = 8,665, Anhedonia = 
6,579, Cognitive Disorganisation = 6,297, and Parent-rated Negative Symptoms = 
10,098. Genome-wide association analysis of all four PE domains using related (i.e. 
monozygotic and dizygotic twin pairs) and unrelated individuals was performed in 
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007). As 
described in Chapter 2, additional covariance arises from related individuals; this was 
accounted for using the method of generalised estimating equations (GEE) (Minica et al., 
2014; Minică et al., 2015) in R specifying an exchangeable correlation matrix.  
Power calculations showed that the mega-GWASs of PEs had a sufficient sample sizes to 
detect reasonable effect sizes (Table 5.1). Power calculations show that the r2 (effect 
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size) that could be detected with 80% power is 0.50% for Paranoia and Hallucinations, 
0.65% for Anhedonia, 0.78% for Cognitive Disorganisation, and 0.45% for Parent-rated 
Negative Symptoms.  
5.2.9 – Meta-genome-wide association study 
To evaluate the effect of mega-analysis rather than meta-analysis, the four PEs were also 
analysed post hoc within each sample and then meta-analysed using inverse-variance 
weighting in METAL (Willer, Li, & Abecasis, 2010). To evaluate the effect of randomly 
splitting ties when normalising the phenotypic data, additional post hoc meta-GWASs of 
normalised specific PEs, but averaging tied observations, were also carried out using 
METAL. The results of this analysis are considered less robust due to the remaining 
skew of the dependent variables, particularly for Paranoia and Hallucinations, and 
Parent rated Negative Symptoms.  
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Table 5.1. Power to detect association at genome-wide significance for mega-
genome-wide association analyses of psychotic experience traits. 
Psychotic Experience N r2 Power 
Paranoia and Hallucinations 7970 0.005 0.81 
Paranoia and Hallucinations 7970 0.01 1.00 
Anhedonia 6068 0.005 0.52 
Anhedonia 6068 0.01 0.99 
Cognitive Disorganisation 5083 0.005 0.34 
Cognitive Disorganisation 5083 0.01 0.95 
Parent-rated Negative Symptoms 8763 0.005 0.88 
Parent-rated Negative Symptoms 8763 0.01 1.00 
Note. N = effective sample size after accounting for related individuals (Minica et al., 2014); 
r2, variance explained in the outcome by a tagged SNP.  
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5.2.10 – Replication analysis of genetic associations 
After the TEDS+CATSS+ALSPAC sample had been analysed, genotypic data for 
additional TEDS participants became available as a result of a second wave of 
genotyping of further individuals in 2016. These individuals were used as a replication 
sample for any variants or genes associated with adolescent PEs at significance. This 
replication sample was imputed using the haplotype reference consortium data via the 
Sanger imputation server (McCarthy et al., 2016). Eva Krapohl, a member of the TEDS 
team, led the imputation process. The imputed genotypic data was converted to hard-
call format (certainty threshold of 0.9) in PLINK. Replication analyses were performed 
using the same procedure as the discovery analyses. 
5.2.11 – Gene-region association analysis 
MAGMA (de Leeuw, Mooij, Heskes, & Posthuma, 2015), using the mean of the X2, 
aggregated the association of SNPs within specified gene regions based on the summary 
statistics of the PE GWASs. This summary statistic approach was used as it is 
computationally efficient and the multiple linear principal component regression model 
doesn’t account for the presence of related individuals. The mean X2 approach is 
equivalent to those employed in VEGAS, PLINK’s --set model, and SKAT when using 
inverse-variance weights. Genetic variants were assigned to genes based on the NCBI 
37.3 build with a 10kb annotation window used around genes, resulting in 17,226 genes 
being tested. LD was calculated using the combined TEDS, ALSPAC, and CATSS sample. 
To account for multiple testing, p-values were Bonferroni corrected using the number of 
genes tested. 
5.2.12 – Predicted differential gene expression analysis 
Like complex phenotypes, the expression (transcription) of a given gene is regulated by 
the interplay of genetic and environmental factors. Genetic variants associated with 
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differential gene expression are called eQTLs (expression quantitative trait loci). 
Depending on the variance in the expression of a gene explained by tagged genetic 
variation, it is possible to predict the expression of a gene based on the genotype of 
individuals at eQTL sites. The gene expression predicted by eQTL variation is called 
‘genetically regulated expression’, and is distinct from gene expression differences that 
are a consequence of the phenotype of interest, and distinct from gene expression 
differences due to other factors (including environmental). 
PrediXcan (Gamazon et al., 2015) was used to predict genetically regulated expression 
levels in the prefrontal cortex of individuals in TEDS, ALSPAC and CATSS. This was 
achieved using a tissue-specific additive gene-expression prediction models that have 
been trained using the reference transcriptomic dataset called GTEX Tissue Expression, 
http://www.gtexportal.org/home/) project. Linear regression was then used to test for 
an association between predicted gene-expression levels and individual PEs, using GEE 
to control for related individuals. Due to the small sample size used to create the 
prediction models for the frontal cortex (N = 92), the expression levels of many genes 
could not be reliably predicted. After removal of genes with expression levels showing 
no variance, the total number of genes with predicted expression levels was 2,769. To 
account for multiple testing, p-values were Bonferroni corrected using the number of 
genes tested. 
Given the relatively poor ability to predict gene expression in the frontal cortex, and the 
19.2% overlap between eQTLs for the blood and brain (McKenzie, Henders, Caracella, 
Wray, & Powell, 2014), it was of interest to test for differential gene expression in whole 
blood. Gene expression prediction models for whole blood were from the DGN 
(Depression Genes and Networks) reference (N=922). This analysis enabled the 
prediction of 10,699 genes. This analysis of differential gene expression in blood was 
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post-hoc and for comparison with the frontal cortex results. To help interpret the 
results, p-values were Bonferroni corrected to account for multiple testing. 
5.3 – Results 
5.3.1 – Descriptive of individual psychotic experience scores 
Descriptive statistics for the raw PE sum scores within each sample are shown in Table 
5.2. The relationships between age, sex and the raw PE measures in each sample are 
presented in Tables 5.3 and 5.4. The correlation between adolescent PEs and anxiety 
symptoms, depressive symptoms and cognitive ability in the TEDS sample are presented 
in Table 5.5. The correlations between self-reported depressive symptoms and PEs in 
TEDS, ALSPAC and CATSS are presented in Table 5.6. The median correlation between a 
given scale before and after normalisation when randomly splitting ties was 0.92 (Table 
5.7), dependent on skew of the original scale.  
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Table 5.2. Descriptive statistics for raw psychotic experience domain sum scores in 
each sample.  
TEDS        
Specific PE μ σ Range Skew α N N sibs 
Paranoia and 
Hallucinations 
0.43 0.51 0 - 3.90 2.03 0.73 2994 827 
Anhedonia 3.19 1.54 0 - 9.80 0.53 0.79 2988 821 
Cognitive 
Disorganization 




0.88 1.19 0 - 9.33 2.35 0.84 2995 833 
        
ALSPAC        
Specific PE μ σ Range Skew α N N sibs 
Paranoia and 
Hallucinations 
0.27 0.51 0 - 4.17 2.78 0.67 3591 0 




1.57 1.11 0 - 7.00 0.61 0.61 4019 0 
        
CATSS        
Specific PE μ σ Range Skew α N N sibs 
Paranoia and 
Hallucinations 
0.20 0.43 0 - 5.00 3.92 0.73 2080 849 
Cognitive 
Disorganization 




0.57 0.95 0 - 8.50 2.64 0.75 3084 1395 
Note. These figures are based on the individuals remaining after quality control and were 
used in all subsequent genetic analyses. μ, mean; σ, standard deviation; N, Number of 
genotyped individuals after exclusions; N sibs, number of siblings pairs within N; TEDS, Twins 
Early Development Study; ALSPAC, Avon Longitudinal Study of Parents and Children; CATSS, 




Table 5.3. Pearson’s correlation between raw PE sum scores and age. 
  TEDS ALSPAC CATSS 
Paranoia and 
Hallucinations 
0.030 0.004 -0.038 
Anhedonia -0.018 -0.025 NA 
Cognitive 
Disorganisation 




-0.043 0.001 -0.042 
Note. These figures are based on the individuals remaining after quality control and were 
used in all subsequent genetic analyses. TEDS, Twins Early Development Study; ALSPAC, 




Table 5.4. Mean sex differences for untransformed psychotic experience sum 
scores. 
TEDS      
  Males Females 
p 
  µ SD µ SD 
Paranoia and 
Hallucinations 
0.408 0.497 0.441 0.527 0.081 
Anhedonia 3.630 1.544 2.866 1.459 4.85x10-41 
Cognitive 
Disorganisation 
3.237 2.622 4.254 2.888 2.78x10-23 
Parent-rated 
Negative Symptoms 
0.990 1.246 0.794 1.134 1.11x10-5 
      
ALSPAC      
  Males Females 
p 
  µ SD µ SD 
Paranoia and 
Hallucinations 
0.180 0.418 0.327 0.559 3.34x10-19 
Anhedonia 1.259 1.116 1.537 1.218 1.87x10-12 
Parent-rated 
Negative Symptoms 
1.681 1.122 1.467 1.083 7.77x10-10 
      
CATSS      
  Males Females 
p 
  µ SD µ SD 
Paranoia and 
Hallucinations 
0.154 0.381 0.233 0.461 1.94x10-5 
Cognitive 
Disorganization 
1.824 0.939 2.048 0.998 4.24x10-11 
Parent-rated 
Negative Symptoms 
0.628 0.981 0.525 0.909 2.64x10-3 
Note. Mean difference p-values were estimated using the two sample t-test. These figures 
are based on the individuals remaining after quality control and were used in all subsequent 
genetic analyses. TEDS, Twins Early Development Study; ALSPAC, Avon Longitudinal Study of 
Parents and Children; CATSS, Child and Adolescent Twin Study in Sweden. μ, mean. 
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Table 5.5. Pearson correlation between PEs and anxiety symptoms, depressive 
symptoms and cognitive ability in TEDS. 
Column1 Depression





0.457** 0.396** 0.199** 0.152** -0.071* 
Anhedonia 0.106** -0.109** 0.110** 0.070** 0.085* 
Cognitive 
Disorganisation 
0.525** 0.493** 0.252** 0.243** -0.091* 
Parent-rated 
Negative Symptoms 
0.195** 0.052* 0.498** 0.491** -0.079* 
Note. * = p ≤ 0.05, ** = p ≤ 0.001. a = Between 2146 – 2162 individuals in analyses. b = 
Between 925 – 928 individuals in analyses. (P) = Parent-report. These figures are based on 
unrelated TEDS individuals with genetic data.  
 
 
Table 5.6. Pearson correlation between PEs and self-reported depressive 
symptoms in TEDS, ALSPAC and CATSS. 
 TEDSa ALSPACb CATSSc 
Paranoia and Hallucinations 0.457** 0.358** 0.293** 
Anhedonia 0.106** 0.801** NA 
Cognitive Disorganisation 0.525** NA 0.454** 
Parent-rated Negative Symptoms 0.195** 0.211** 0.271** 
Note. * = p ≤ 0.05, ** = p ≤ 0.001. a = Between 2147 – 2162 individuals in analyses. b = 
Between 2958 – 3505 individuals in analyses. c = Between 1214 – 1777 individuals in 
analyses. These figures are based on unrelated individuals with genetic data.  
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Table 5.7. Pearson’s correlations between raw sum scores and scores after inverse-
rank based normalisation splitting ties randomly. 
Sample Psychotic Experience Correlation 
TEDS Paranoia and Hallucinations 0.887 
TEDS Anhedonia 0.990 
TEDS Cognitive Disorganisation 0.971 
TEDS Parent-rated Negative Symptoms 0.858    
ALSPAC Paranoia and Hallucinations 0.771 
ALSPAC Anhedonia 0.955 
ALSPAC Parent-rated Negative Symptoms 0.979    
CATSS Paranoia and Hallucinations 0.723 
CATSS Cognitive Disorganisation 0.992 
CATSS Parent-rated Negative Symptoms 0.810 
 
5.3.2 – Mega-genome-wide association study of specific adolescent psychotic experiences 
The mega-GWAS identified no genome-wide significant variation for the Paranoia and 
Hallucinations, Cognitive Disorganisation, or parent-rated Negative Symptoms domains. 
The mega-GWAS of Anhedonia identified one SNP (rs149957215) associated at genome-
wide significance (p = 3.76x10-8) within a gene called indoleamine 2,3-dioxygenase 2 
(IDO2) (Figure 5.1). This SNP was imputed in all three samples with an average 
imputation quality (INFO) of 0.89 and minor allele frequency of 0.013. Examination of 
rs149957215 in the gnomeAD database (Lek et al., 2016) reported a similar minor allele 
frequency among European individuals (with and without Finnish individuals) and good 
genotype quality, supporting that imputation of this variant was accurate (results 
available here http://gnomad.broadinstitute.org/variant/8-39872495-C-A). Due to 
limited LD with rs149957215, neighbouring genetic variation showed no significant 
evidence of association. However, the association between rs149957215 and Anhedonia 
did not replicate in the independent TEDS replication sample (N = 2,359 incl. 635 MZ 
pairs), showing a non-significant association (p=0.81) in the opposite direction. The 
replication sample provided a power of 0.86 to detect an association of the same 
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magnitude (r2 = 0.47%) at nominal significance. rs149957215 was well imputed in the 
replication sample with a MACH r2 = 0.93.  
The absence of more genome-wide significant associations indicates that the variance 
explained by individual genetic variants are substantially smaller than the r2 values that 
could have been detected with 80% power (r2 of 0.45% - 0.78%). 
The mega-GWASs of the four psychotic experience domains returned several loci 
achieving a suggestive significance of p<1x10-5 (Table 5.8, Figures 5.2-5.5). There was no 
evidence of confounding with lambdas of 0.99–1.01 and LD-score regression intercept of 
1.00 in all analyses (Figure 5.6). 
The association statistics of genome-wide significant genetic markers in the previous 
TEDS only GWAS of Chapter 2 are in Table 5.9. The direction of effect remained 
consistent in the mega-GWASs. However, no variant remained genome-wide significant. 
rs7830364 within CSMD1 remained nominally significant.  
The direction and p-value of suggestive loci from the PEs GWASs are compared to those 
in the most recent schizophrenia, bipolar disorder, and major depressive disorder 
GWASs in Tables 5.10-5.12 respectively. Of the 29 independent suggestive loci, two 
achieved nominal significance in the schizophrenia GWAS (both with same direction of 
effect), three achieved nominal significance in the bipolar disorder GWAS (two with 
same direction of effect), and one achieved nominal significance in the major depression 
GWAS (with same direction of effect).  
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Table 5.8. Independent loci achieving suggestive significance (p < 1x10-5) in mega-genome-wide association study of psychotic experience 
domains. 
Paranoia and Hallucinations        
CHR SNP BP A1 A2 MAF BETA SE p Nearest Gene 
16 rs8064063 7214065 C T 0.290 0.086 0.017 7.18x10-7 RBFOX1 
2 rs7584721 230401082 A G 0.078 0.144 0.030 1.23x10-6 DNER 
1 rs113892704 26675261 A G 0.198 -0.093 0.020 3.82x10-6 AIM1L 
5 rs1392391 173683914 A G 0.122 0.111 0.024 4.80x10-6 HMP19 
8 rs17749393 96553216 G A 0.071 0.138 0.031 6.18x10-6 C8orf37−AS1 
2 rs72919716 78897267 G A 0.207 -0.089 0.020 7.72x10-6 REG3G 
8 rs77291092 67335395 A C 0.064 -0.140 0.031 8.49x10-6 RRS1-AS1           
Anhedonia         
CHR SNP BP A1 A2 MAF BETA SE p Nearest Gene 
8 rs149957215 39872495 A C 0.013 -0.417 0.076 3.76x10-8 IDO2 
13 rs78013746 61682703 A C 0.027 0.255 0.054 2.37x10-6 MIR3169 
6 rs200488 27795109 T C 0.018 0.297 0.063 2.89x10-6 HIST1H4K 
11 rs117907077 11033989 A G 0.024 -0.286 0.062 3.27x10-6 ZBED5−AS1 
6 rs2531815 28436060 T C 0.287 0.092 0.020 4.36x10-6 ZSCAN23 
20 rs6033026 11059873 G A 0.240 -0.095 0.021 5.39x10-6 LOC339593 
15 rs7164838 34967574 A G 0.317 0.088 0.019 5.55x10-6 GJD2 
11 rs2169485 41079587 G A 0.178 -0.109 0.024 6.02x10-6 LRRC4C 
10 rs11195810 113835240 A G 0.017 0.297 0.066 6.72x10-6 GPAM 
14 rs12897386 72471862 C T 0.256 0.093 0.021 7.62x10-6 RGS6 
9 rs62545506 73241253 T G 0.104 -0.132 0.030 8.15x10-6 TRPM3 
14 rs34420225 94290014 A C 0.212 -0.100 0.022 9.38x10-6 PRIMA1 
15 rs74519172 55010305 T C 0.065 0.159 0.036 9.76x10-6 UNC13C 
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Table 5.8 cont. 
Cognitive Disorganisation        
CHR SNP BP A1 A2 MAF BETA SE p Nearest Gene 
13 rs1961120 28833372 C G 0.386 -0.099 0.020 9.00x10-7 PAN3 
2 rs200022365 186855226 T TTTA 0.432 0.097 0.021 2.30x10-6 LOC101927217 
2 rs80033666 170682319 C T 0.089 -0.156 0.034 3.35x10-6 METTL5 
2 rs1517844 192405134 C A 0.400 0.091 0.020 3.95x10-6 NABP1 
1 rs6665300 65429558 C T 0.014 0.376 0.082 4.16x10-6 JAK1 
4 rs1911103 126449558 T C 0.077 -0.164 0.036 5.58x10-6 MIR2054 
2 rs7588854 80339218 A G 0.169 0.119 0.026 6.67x10-6 CTNNA2 
3 rs185642755 85127281 C T 0.012 -0.361 0.081 8.39x10-6 CADM2           
Parent-rated Negative Symptoms       
CHR SNP BP A1 A2 MAF BETA SE p Nearest Gene 
4 rs4400001 38212771 A C 0.391 0.080 0.015 2.26x10-7 TBC1D1 
8 rs72334712 108862133 CT C 0.046 0.165 0.034 1.34x10-6 RSPO2 
11 rs530272 30519602 C T 0.017 0.267 0.056 2.20x10-6 MPPED2 
2 2:212086966:C:A 212086966 A C 0.037 0.181 0.039 4.26x10-6 ERBB4 
16 rs10500326 4918326 T G 0.226 -0.082 0.018 5.42x10-6 UBN1 
12 rs11063280 4760229 G A 0.267 0.078 0.017 5.75x10-6 LOC101928989 
11 rs12418804 81598184 G C 0.064 0.140 0.031 6.11x10-6 LOC101928989 
6 rs77105684 71903122 G A 0.026 -0.199 0.044 6.58x10-6 OGFRL1 
2 rs114733161 211978580 A C 0.035 0.181 0.041 8.34x10-6 ERBB4 
Note. CHR, chromosome number; BP, base-pair position; A1, allele 1 (test allele); A2, allele 2; MAF, minor allele frequency; BETA, unstandardized effect size; 




















Figure 5.6. Quantile-quantile plot of psychotic experience domain mega-GWASs. 
Note. A, Paranoia and Hallucinations; B, Anhedonia; C, Cognitive Disorganisation; D, Parent-
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Table 5.9. Combined sample (TEDS, ALSPAC and CATSS) association results for genome-wide significant SNPs in TEDS only GWAS of Chapter 
2. 
Psychotic Experience Variant ID 
TEDS only GWAS TEDS+ALSPAC+CATSS GWAS 
A1 BETA SE p A1 BETA SE p 
Cognitive Disorganisation rs7830364 G -1.22 0.21 1.24x10-8 G -0.15 0.07 0.03 
Cognitive Disorganisation rs7845752 T -1.65 0.30 2.98x10-8 C -0.11 0.07 0.11 
Parent-rated Negative Symptoms rs7587811 C 0.56 0.10 7.01x10-8 C 0.08 0.06 0.23 
Note. A1, Allele 1 (test allele); BETA, unstandardized effect size; SE, standard error; TEDS, Twins Early Development Study; ALSPAC, Avon Longitudinal Study 
of Parents and Children; CATSS, Child and Adolescent Twin Study in Sweden; GWAS, genome-wide association study. 
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Table 5.10. Suggestive loci from psychotic experience GWASs in the latest 
schizophrenia GWAS. 
Paranoia and Hallucinations     
CHR Variant ID BP PSNP r2 P_SCZ 
Direction 
(PE/SCZ) 
3 rs73135634 84961810 rs73135634 * 1.17x10-3 -/- 
17 rs1008621 70362731 rs1008621 * 0.650 +/+        
Anhedonia      
CHR Variant ID BP PSNP r2 P_SCZ 
Direction 
(PE/SCZ) 
8 rs149957215 39872495 rs149957215 * 0.339 -/+ 
13 rs78013746 61682703 rs78013746 * 0.229 +/- 
6 rs200488 27795109 rs200488 * 0.159 +/+ 
11 rs117907077 11033989 rs117907077 * 0.982 -/+ 
6 rs2531815 28436060 rs2531815 * 0.950 +/+ 
20 rs6033026 11059873 rs6033026 * 0.952 -/+ 
15 rs7164838 34967574 rs7164838 * 0.668 +/+ 
11 rs2169485 41079587 rs2169485 * 0.960 -/+ 
10 rs11195810 113835240 rs11195810 * 0.796 +/- 
14 rs12897386 72471862 rs35727014 1 0.180 +/+ 
9 rs62545506 73241253 rs62545506 * 0.341 -/- 
14 rs34420225 94290014 rs34420225 * 0.270 -/+ 
15 rs74519172 55010305 rs74519172 * 0.952 +/-        
Cognitive Disorganisation     
CHR Variant ID BP PSNP r2 P_SCZ 
Direction 
(PE/SCZ) 
13 rs1961120 28833372 rs1961120 * 0.973 -/- 
2 rs200022365 186855226 rs12622553 0.999 0.748 +/- 
14 rs7147064 47560742 rs7147064 * 0.028 -/- 
2 rs7588854 80339218 rs7588854 * 0.008 +/- 
2 rs80033666 170682319 rs80033666 * 0.851 -/- 
4 rs1506348 126450002 rs1506348 * 0.403 -/+ 
3 rs185642755 85127281 rs185642755 * 0.225 -/- 
1 rs6665300 65429558 rs79912581 1 0.930 +/+        
Parent-rated Negative Symptoms     
CHR Variant ID BP PSNP r2 P_SCZ 
Direction 
(PE/SCZ) 
5 rs147205145 36033829 rs147205145 * 0.023 +/+ 
4 rs4400001 38212771 rs4583770 1 0.663 +/+ 
8 rs72334712 108862133 rs10112933 1 0.546 +/- 
8 rs35428606 101649797 rs35428606 * 0.338 -/- 
7 rs62457829 29549919 rs62457829 * 0.613 +/+ 
Note: CHR, chromosome number; BP, base-pair position; PSNP, proxy variant in 
schizophrenia dataset; strength of linkage disequilibrium between index SNP in PE study and 
proxy in schizophrenia dataset; P_SCZ, p-value of proxy SNP in schizophrenia dataset; 
Direction (PE/SCZ), direction of effect for index and proxy variants in the PE GWASs and 
schizophrenia GWAS respectively.  
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Table 5.11. Suggestive loci from psychotic experience GWASs in the latest bipolar 
disorder GWAS. 
Paranoia and Hallucinations     
CHR Variant ID BP PSNP r2 P_BIP 
Direction 
(PE/BIP) 
3 rs73135634 84961810 rs9836020 0.944 0.111 -/- 
17 rs1008621 70362731 rs1008621 * 0.040 +/+        
Anhedonia       
CHR Variant ID BP PSNP r2 P_BIP 
Direction 
(PE/BIP) 
8 rs149957215 39872495 NA NA NA -/NA 
13 rs78013746 61682703 rs12583135 0.522 0.004 +/+ 
6 rs200488 27795109 rs1010261 0.900 0.848 +/- 
11 rs117907077 11033989 rs6484605 0.989 0.006 -/+ 
6 rs2531815 28436060 rs2531815 * 0.195 +/- 
20 rs6033026 11059873 rs6033026 * 0.968 -/- 
15 rs7164838 34967574 rs7164838 * 0.132 +/+ 
11 rs2169485 41079587 rs2169485 * 0.810 -/- 
10 rs11195810 113835240 rs11195810 * 0.895 +/+ 
14 rs12897386 72471862 rs12897386 * 0.629 +/- 
9 rs62545506 73241253 rs12001853 0.991 0.709 -/+ 
14 rs34420225 94290014 rs11624417 0.979 0.463 -/+ 
15 rs74519172 55010305 rs8027123 0.221 0.188 +/+        
Cognitive Disorganisation     
CHR Variant ID BP PSNP r2 P_BIP 
Direction 
(PE/BIP) 
13 rs1961120 28833372 rs9319424 0.997 0.204 -/- 
2 rs200022365 186855226 rs12622553 0.999 0.059 +/- 
14 rs7147064 47560742 rs7147064 * 0.263 -/- 
2 rs7588854 80339218 rs1319228 0.975 0.171 +/- 
2 rs80033666 170682319 rs3754913 0.909 0.337 -/+ 
4 rs1506348 126450002 rs1506348 * 0.067 -/+ 
3 rs185642755 85127281 NA NA NA -/NA 
1 rs6665300 65429558 rs17127174 1 0.841 +/+        
Parent-rated Negative Symptoms     
CHR Variant ID BP PSNP r2 P_BIP 
Direction 
(PE/BIP) 
5 rs147205145 36033829 NA NA NA +/NA 
4 rs4400001 38212771 rs4554086 1 0.907 +/+ 
8 rs72334712 108862133 rs10112933 1 0.873 +/+ 
8 rs35428606 101649797 rs2155882 0.997 0.361 -/+ 
7 rs62457829 29549919 rs1059182 0.896 0.593 +/- 
Note: CHR, chromosome number; BP, base-pair position; PSNP, proxy variant in bipolar 
disorder dataset; strength of linkage disequilibrium between index SNP in PE study and 
proxy in bipolar disorder dataset; P_BIP, p-value of proxy SNP in bipolar disorder dataset; 
Direction (PE/BIP), direction of effect for index and proxy variants in the PE GWASs and 
bipolar disorder GWAS respectively.  
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Table 5.12. Suggestive loci from psychotic experience GWASs in the latest major 
depression GWAS. 
Paranoia and Hallucinations     
CHR Variant ID BP PSNP r2 P_MDD 
Direction 
(PE/MDD) 
3 rs73135634 84961810 rs9847448 0.944 0.491 -/+ 
17 rs1008621 70362731 rs1008622 0.999 0.859 +/+        
Anhedonia       
CHR Variant ID BP PSNP r2 P_MDD 
Direction 
(PE/MDD) 
8 rs149957215 39872495 NA NA NA -/NA 
13 rs78013746 61682703 rs7991819 0.521 0.962 +/- 
6 rs200488 27795109 rs1010261 0.900 0.034 +/- 
11 rs117907077 11033989 rs16908726 0.963 0.251 -/+ 
6 rs2531815 28436060 rs2531815 * 0.082 +/- 
20 rs6033026 11059873 rs6033026 * 0.130 -/- 
15 rs7164838 34967574 rs7164838 * 0.218 +/+ 
11 rs2169485 41079587 rs2169485 * 0.057 -/- 
10 rs11195810 113835240 rs12254157 0.929 0.493 +/+ 
14 rs12897386 72471862 rs12883063 0.999 0.308 +/+ 
9 rs62545506 73241253 rs12001853 0.991 0.011 -/- 
14 rs34420225 94290014 rs11624417 0.979 0.242 -/- 
15 rs74519172 55010305 NA NA NA +/NA        
Cognitive Disorganisation     
CHR Variant ID BP PSNP r2 P_MDD 
Direction 
(PE/MDD) 
13 rs1961120 28833372 rs9319424 0.997 0.686 -/- 
2 rs200022365 186855226 rs12618471 0.998 0.142 +/- 
14 rs7147064 47560742 rs7147064 * 0.287 -/+ 
2 rs7588854 80339218 rs1017632 0.905 0.352 +/+ 
2 rs80033666 170682319 rs3754913 0.909 0.133 -/- 
4 rs1506348 126450002 rs1506348 * 0.889 -/- 
3 rs185642755 85127281 NA NA NA -/NA 
1 rs6665300 65429558 rs17127171 0.994 0.835 +/+        
Parent-rated Negative Symptoms     
CHR Variant ID BP PSNP r2 P_MDD 
Direction 
(PE/MDD) 
5 rs147205145 36033829 NA NA NA +/NA 
4 rs4400001 38212771 rs6835249 0.747 0.443 +/+ 
8 rs72334712 108862133 rs11987403 1 0.952 +/- 
8 rs35428606 101649797 rs2155882 0.997 0.201 -/+ 
7 rs62457829 29549919 rs1059182 0.896 0.980 +/+ 
Note: CHR, chromosome number; BP, base-pair position; PSNP, proxy variant in major 
depression dataset; strength of linkage disequilibrium between index SNP in PE study and 
proxy in major depression dataset; P_MDD, p-value of proxy SNP in major depression 
dataset; Direction (PE/ MDD), direction of effect for index and proxy variants in the PE 
GWASs and major depression GWAS respectively.  
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5.3.3 – Results from mega-analysis and meta-analysis GWAS 
Meta-analysis results when using the same PEs data as in the mega-analysis (i.e. ties 
randomly split during normalisation) were almost identical to those of the mega-
analyses. The p-value correlations between all SNPs in the four mega- and meta- GWASs 
were between 0.972 and 0.996, with slightly lower correlations for PE traits that were 
originally more skewed. The genome-wide significant SNP in the Anhedonia mega-
GWAS (rs149957215) remained significant (1.611x10-8) in the meta-analysis, with p-
values of 1.01x10-5 and 4.247x10-4 in the TEDS and ALSPAC samples alone. 
5.3.4 – Evaluating the effect of randomly splitting ties over averaging ties 
Averaging tied observations during normalisation was only partially effective, with 
some PE scales showing a remaining skew greater than 1 (Table 5.13). Meta-analysis 
results when using PE measures that were normalised with ties averaged contained 
many highly significant associations. Phenotypes that were more skewed showed more 
significant associations, particularly in the smaller samples. The large number of highly 
genome-wide significant associations, and their relationship with increased skew and 
decreased sample size suggest that many of the significant associations were spurious. 
For Anhedonia, which had the lowest average skew, the only genome-wide significant 
variant was rs149957215 (p = 1.64x10-8), the same genome-wide significant variant 









Table 5.13. Skew of psychotic experiences after normalisation when averaging tied 
observations. 
Psychotic Experience Sample Skew 
Paranoia and Hallucinations TEDS 0.375 
Paranoia and Hallucinations ALSPAC 1.145 
Paranoia and Hallucinations CATSS 1.334 
Anhedonia TEDS 0.030 
Anhedonia ALSPAC 0.219 
Anhedonia CATSS NA 
Cognitive Disorganisation TEDS 0.431 
Cognitive Disorganisation ALSPAC NA 
Cognitive Disorganisation CATSS 0.157 
Parent-rated Negative Symptoms TEDS 0.556 
Parent-rated Negative Symptoms ALSPAC 0.207 
Parent-rated Negative Symptoms CATSS 0.912 
 
5.3.5 – Gene region association from MAGMA 
Regional gene-based analysis using MAGMA identified no gene that was significantly 
associated with any PE domain after Bonferroni correction for multiple testing. The top 
ten most associated genes for each PE domain are listed in Table 5.14.  
5.3.6 – Differential predicted gene expression from PrediXcan 
Analysis of predicted frontal cortex gene expression associated with PE domains 
showed HACD2 as significantly differentially expressed for Cognitive Disorganisation 
(Bonferroni corrected p = 6.83x10-4). However, the association between HACD2 and 
Cognitive Disorganisation was not replicated in the independent replication sample, 
showing a non-significant association in the opposite direction. The top ten genes 
showing differential expression for each psychotic experience domain are listed in Table 
5.15. 
Analysis of predicted gene expression in blood did not identify any significant 
association with PEs after Bonferroni correction of multiple testing. However, HACD2 
and CIB2 were the most significantly differentially expressed genes for Cognitive 
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Disorganisation and Anhedonia respectively. Overall the correlation between 
association statistics from blood and brain was ~0, even when only comparing genes 
that were nominally significant genes in the brain (or vice versa).  
This indicates that the predicted gene expression levels in the blood and brain are 
substantially different for the majority of genes. Indeed, when using just overlapping 
genes on chromosome 1 (n=157), the mean correlation was 0.23 and ranged from -0.92 
– 0.99. These results demonstrate the large range in eQTL overlap for a given gene 
between the blood and brain.  
The fact that the top associated genes showed similar results in both the blood and brain 
could indicate that genes associated with adolescent PEs have similar eQTL-mediated 
regulation in the blood and brain. Alternatively, these genes might just be more reliably 
imputed in both the brain and blood due to a high heritability of their expression.  
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Table 5.14. Top ten genes associated with psychotic experience domains using 
MAGMA. 
Paranoia and Hallucinations    
CHR Gene Symbol NSNPS z p Corrected p 
5 SGCD 1574 4.105 2.018x10-5 0.348 
18 MC2R 109 3.676 1.184x10-4 1.000 
12 MGAT4C 1987 3.645 1.336x10-4 1.000 
1 OR10K2 57 3.640 1.365x10-4 1.000 
20 PROCR 86 3.434 2.975x10-4 1.000 
16 CALB2 66 3.414 3.202x10-4 1.000 
11 RSF1 298 3.395 3.429x10-4 1.000 
1 OR10K1 48 3.344 4.136x10-4 1.000 
14 MLH3 63 3.311 4.652x10-4 1.000 
14 ACYP1 46 3.296 4.913x10-4 1.000       
Anhedonia     
CHR Gene Symbol NSNPS z p Corrected p 
14 ABHD12B 36 4.045 2.619x10-5 0.451 
15 MAPKBP1 91 3.957 3.789x10-5 0.653 
10 BNIP3 37 3.657 1.275x10-4 1.000 
22 CECR5 43 3.634 1.397x10-4 1.000 
14 PYGL 126 3.615 1.501x10-4 1.000 
10 PPP2R2D 73 3.607 1.547x10-4 1.000 
15 C15orf27 199 3.592 1.644x10-4 1.000 
12 IGFBP6 40 3.588 1.664x10-4 1.000 
19 ZNF43 143 3.551 1.920x10-4 1.000 
15 JMJD7 76 3.530 2.080x10-4 1.000       
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Table 5.14 cont. 
Cognitive Disorganisation    
CHR Gene Symbol NSNPS z p Corrected p 
13 CLYBL 482 4.112 1.958x10-5 0.337 
4 RUFY3 248 3.856 5.773x10-5 0.994 
12 ASUN 100 3.822 6.613x10-5 1.000 
19 PSG4 1 3.792 7.480x10-5 1.000 
9 NR5A1 8 3.625 1.443x10-4 1.000 
11 CEP295 31 3.588 1.667x10-4 1.000 
7 PEX1 57 3.567 1.807x10-4 1.000 
3 TFDP2 551 3.545 1.964x10-4 1.000 
9 ADGRD2 10 3.527 2.100x10-4 1.000 
4 GRSF1 112 3.468 2.626x10-4 1.000       
Parent-rated Negative Symptoms   
CHR Gene Symbol NSNPS z p Corrected p 
12 NDUFA9 134 4.192 1.380x10-5 0.238 
20 SDCBP2 30 4.036 2.722x10-5 0.469 
2 CD28 76 3.793 7.430x10-5 1.000 
11 FUT4 23 3.619 1.479x10-4 1.000 
5 FST 53 3.545 1.966x10-4 1.000 
1 SPAG17 351 3.488 2.433x10-4 1.000 
11 DNHD1 138 3.309 4.681x10-4 1.000 
19 SLC8A2 30 3.229 6.213x10-4 1.000 
16 UBN1 101 3.207 6.717x10-4 1.000 
7 GHRHR 33 3.165 7.762x10-4 1.000 
 Note: CHR, chromosome number; NSNPS, Number of genetic variants within the gene 
region; Corrected p, Bonferroni corrected p-value.  
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Table 5.15. Top ten differentially-expressed genes for psychotic experience 
domains based on predicted gene expression levels. 
Paranoia and Hallucinations    
Gene Symbol Beta SE p Corrected p 
LY6D -0.342 0.097 4.15x10-4 1.000 
LRRIQ1 -0.430 0.132 1.12x10-3 1.000 
FAHD1 0.113 0.036 1.62x10-3 1.000 
PLPPR2 -0.315 0.104 2.42x10-3 1.000 
STMND1 1.111 0.375 3.08x10-3 1.000 
KRT81 0.222 0.076 3.70x10-3 1.000 
COMMD2 0.209 0.073 4.26x10-3 1.000 
SPATA13 0.248 0.088 4.73x10-3 1.000 
ZNHIT6 0.234 0.083 4.84x10-3 1.000 
PSMB8 0.131 0.048 5.96x10-3 1.000      
Anhedonia     
Gene Symbol Beta SE p Corrected p 
CIB2 -1.207 0.317 1.42x10-4 0.392 
INTS1 -0.192 0.054 3.58x10-4 0.991 
FAM198A 0.247 0.073 7.63x10-4 1.000 
ACKR2 -0.483 0.146 9.69x10-4 1.000 
STRN -2.089 0.641 1.11x10-3 1.000 
AGO2 0.252 0.082 2.16x10-3 1.000 
TEAD2 -0.258 0.087 3.07x10-3 1.000 
CBLN4 -0.715 0.248 3.94x10-3 1.000 
NA 0.643 0.225 4.34x10-3 1.000 
ZNF514 -0.243 0.086 4.47x10-3 1.000      
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Table 5.15 cont. 
Cognitive Disorganisation    
Gene Symbol Beta SE p Corrected p 
HACD2 -0.154 0.029 1.06x10-7 2.93x10-4 
RASAL2 0.193 0.054 3.87x10-4 1.000 
AP4S1 -0.162 0.048 8.25x10-4 1.000 
LRBA -0.420 0.128 9.76x10-4 1.000 
NOL6 0.348 0.108 1.29x10-3 1.000 
RAD51C 0.077 0.025 2.42x10-3 1.000 
SLTM 0.241 0.080 2.51x10-3 1.000 
RAB43 0.210 0.070 2.56x10-3 1.000 
NFS1 -0.210 0.070 2.60x10-3 1.000 
BRIX1 -0.277 0.092 2.70x10-3 1.000      
Parent-rated Negative Symptoms   
Gene Symbol Beta SE p Corrected p 
RNASEL -1.093 0.305 3.45x10-4 0.956 
AKAP3 -0.119 0.033 3.67x10-4 1.000 
STXBP5L -0.138 0.040 4.92x10-4 1.000 
EIF5A -0.580 0.176 9.76x10-4 1.000 
MAPK8IP1 2.362 0.725 1.11x10-3 1.000 
ADSS -0.166 0.054 2.18x10-3 1.000 
HNRNPC -1.618 0.530 2.28x10-3 1.000 
LRRC25 1.118 0.371 2.62x10-3 1.000 
WDR17 0.791 0.266 2.97x10-3 1.000 
MRE11A -0.122 0.041 3.04x10-3 1.000 
 Note. Corrected p, Bonferroni corrected p-value.  
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5.4 – Discussion 
This chapter performed mega-GWASs of four specific PE measures across three 
European adolescent samples in an attempt to identify associated genetic loci. This is 
the largest GWAS to date of PEs, and the first to use quantitative measures of specific 
PEs. The only genetic variant that achieved genome-wide significance was in the mega-
GWAS for anhedonia, which was within the gene IDO2. Across the four specific PEs, 29 
LD independent loci were associated at suggestive significance (p=1x10-5). Several 
genetic variants achieving suggestive significance in the mega-GWASs were within or 
proximal to genes with prior evidence of association with related outcomes or plausible 
biological pathways. A full table of suggestive loci with annotation is provided in Table 
5.16. This chapter also performed two gene-based analyses (MAGMA and PrediXcan) to 
identify genes associated with specific adolescent PEs. MAGMA returned no significantly 
associated genes. PrediXcan identified one gene showing significant predicted 
differential gene expression in the prefrontal cortex for Cognitive Disorganisation called 
HACD2.  
The genome-wide significant SNP for Anhedonia was within the protein-coding gene 
IDO2. IDO2 is a key enzyme in the regulation of the kynurenine pathway, which upon 
stimulation by proinflammatory cytokines, converts tryptophan into kynurenine. It has 
been reported that increased metabolism of tryptophan to kynurenine is associated 
with increased depressive symptoms via the increased production of cytotoxic 
kynurenine metabolites (Dantzer, O’Connor, Lawson, & Kelley, 2011; A.-M. Myint et al., 
2007; Wichers et al., 2005). In fact, a previous study has reported a significant 
correlation between kynurenine production and anhedonia in an adolescent sample 
(Gabbay, Ely, Babb, & Liebes, 2012). These previous studies suggest the association 
between IDO2 and anhedonia is plausible. However, this finding should be interpreted 
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with caution as the SNP was imputed in all three samples, only just achieved genome-
wide significance, and failed to replicate in a sufficiently powered independent sample. 
Comparison of the mega- and meta- GWAS approaches showed highly similar results 
when based on the same normalised phenotypic data. When an alternative approach 
was tried, namely of meta-analysing non-normal phenotypic data, the skew in the 
phenotypic data led to spurious associations. This was somewhat unexpected, as the 
GEE method used to account for the presence of related individuals should provide 
heteroskedasticity-robust standard errors. One explanation for the spurious 
associations resulting from skewed phenotypic data is that the heteroskedasticity-
robustness of GEE only holds under asymptotic conditions, explaining the increased 
number of spurious associations in the smaller samples. Together these comparisons 
show that the mega-GWAS approach using normalised traits (randomly splitting ties) 
provides robust estimates of association. 
MAGMA identified no gene region significantly associated with any PE trait after 
controlling for multiple testing. The most significant association was between CLYBL 
and Cognitive Disorganisation (Bonferroni corrected p = 0.11). The CLYBL protein is 
involved in glucose metabolism with both malate synthase and beta-methylmalate 
synthase activity (Strittmatter et al., 2014). CLYBL has been previously implicated in 
attention deficit hyperactivity disorder (ADHD)(Lasky‐Su et al., 2008), supporting its 
role in cognition-related neurodevelopmental disorders.  This gene has also been 
associated with anticitrullinated peptide antibodies-negative rheumatoid arthritis 
(Bossini-Castillo et al., 2014). 
Analysis of predicted gene-expression in the frontal cortex highlighted one gene with a 
significant inverse relationship with Cognitive Disorganisation called HACD2 (3-
Hydroxyacyl-CoA Dehydratase 2). It is a protein-coding gene involved in fatty acid 
metabolism. A previous mouse study reported prenatal stress to cause decreased 
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HACD2 expression in the frontal cortex of offspring (Zucchi et al., 2013). Human studies 
have demonstrated an association between prenatal stress, impaired cognitive 
development (Laplante et al., 2004; Niederhofer & Reiter, 2004) and schizophrenia 
(Selten, van der Graaf, van Duursen, Gispen-de Wied, & Kahn, 1999; van Os & Selten, 
1998). A possible model unifying these results is that HACD2 down regulation mediates 
the association between prenatal stress, cognitive development and schizophrenia. 
However, this association should be interpreted with caution, as it was not replicated in 
the independent TEDS replication sample.  
The comparison of predicted gene expression in the prefrontal cortex and blood 
demonstrates the large range in eQTL overlap for a given gene between the blood and 
brain. The fact that the top associated genes showed similar results in both the blood 
and brain could indicate that genes associated with adolescent PEs have similar eQTL-
mediated regulation in the blood and brain. Alternatively, these genes might just be 
more reliably imputed in both the brain and blood due to a high heritability of their 
expression.  
This study has tested for both variant- and gene- level associations for a broad range of 
specific PE traits across three European and adolescent samples. The measures 
assessing each PE domain within each sample have been carefully harmonised to ensure 
both content validity and comparability of the scales across the samples (Chapter 4). 
Alongside careful harmonisation of genotypic data across the three samples, this 
process has enabled combined analysis across the three samples enabling the largest 
GWAS of adolescent PEs to date. Although it requires replication, this study has 
provided the first genome-wide significant association for an adolescent PE. 
Furthermore, the use of eQTL reference datasets, this study has identified the first gene 
significantly associated with adolescent PEs.  
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Although this study has been successful in a number of ways, it demonstrates the on-
going challenge of insufficient power to detect genome-wide significant genetic markers. 
This lack of power can be interpreted in a number of ways. Two likely interpretations 
are: 1) individual genetic variants have very small effect sizes requiring larger samples 
to detect associations at significance, or 2) the phenotypic variance within and across 
samples explained by tagged genetic variation (SNP-heritability) is very small. One 
approach to investigate this power issue is by estimating the phenotypic variance of PEs 
within and across samples that can be explained by common genetic variation. This is 





Table 5.16. Annotation of suggestive loci with prior evidence of association in neuropsychiatric phenotypes. 




Nearest gene annotation 
8 rs149957215 IDO2 (within) 
Key enzyme in kynurenine pathway (Fatokun, Hunt, & Ball, 2013). The kynurenine pathway has 
been implicated in major depression, bipolar disorder, schizophrenia (A. M. Myint, 2012), suicidal 
behaviour (Bryleva & Brundin, 2017), and antidepressant response (Réus et al., 2015). 
11 rs2169485 LRRC4C (within) 
Binds netrin G1, which is involved in axon guidance (Lin, Ho, Gurney, & Rosenthal, 2003). 
LRRC4C is associated with temperament in bipolar disorder (Greenwood, Akiskal, Akiskal, Study, & 
Kelsoe, 2012), antipsychotic response in schizophrenia (McClay et al., 2011), methylation 
difference in schizophrenia (Viana et al., 2017), autism, intellectual disability (Sangu et al., 2017). 
14 rs12897386 RGS6 (within) 
RGS6 has been associated with schizophrenia (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014), and maintenance of dopaminergic neurons (Bifsha, Yang, Fisher, & 
Drouin, 2014). 
9 rs62545506 TRPM3 (within) 
Apart of the transient receptor potential channel (TRP) gene family. TRPs are cation-selective 
channels important for cellular calcium signalling and homeostasis. The TRPM3 region has been 
repeatedly associated bipolar disorder (Serretti & Mandelli, 2008), and chronic fatigue syndrome 
(Nguyen, Staines, Nilius, Smith, & Marshall-Gradisnik, 2016). A micro-RNA within TRPM3 has been 
associated with schizophrenia (Cammaerts et al., 2015). 
14 rs34420225 PRIMA1 (35kb) 
Transports and anchors acetylcholinesterase to neuronal membranes. Associated with major 
depression (Sabunciyan et al., 2012), borderline personality disorder (Teschler, Gotthardt, 
Dammann, & Dammann, 2016), caffeine related sleep disturbance (Byrne et al., 2012), and 
epilepsy(Hildebrand et al., 2015). 
15 rs74519172 UNC13C (90kb) 
Associated with attentions deficit hyperactivity disorder (ADHD) (Elia et al., 2010) and post-
traumatic stress disorder (PTSD) (Ashley-Koch et al., 2015). 
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Table 5.16 cont. 








MDGA2 (and its paralog MDGA1) regulate inhibitory synapse development (Pettem, Yokomaku, 
Takahashi, Ge, & Craig, 2013). MDGA2 has been previously associated with autism (Bucan et al., 
2009), neuroticism (van den Oord et al., 2008), and harm avoidance (Heck et al., 2011). MDGA1 has 





This gene acts as a linker between the cadherin adhesion receptors and the cytoskeleton to 
regulate cell-cell adhesion and differentiation in the nervous system (Abe, Chisaka, Van Roy, & 
Takeichi, 2004). It regulates morphological plasticity of synapses and cerebellar and hippocampal 
lamination during development (Park, Falls, Finger, Longo-Guess, & Ackerman, 2002). This gene has 
been associated with ADHD (Poelmans, Pauls, Buitelaar, & Franke, 2011), alcohol addiction (Song & 
Zhang, 2014), impulsivity in native Americans (Ehlers et al., 2016), excitement seeking (Terracciano 
et al., 2011), and smoking in schizophrenia (Mexal et al., 2008). 
4 rs1506348 FAT4 (40kb) 
FAT4 is a cadherin that maintains planar cell polarity as well as in inhibition of YAP1-mediated 
neuroprogenitor cell proliferation and differentiation (Cappello et al., 2013). There is evidence of 
association between FAT4 and cognitive performance (Need et al., 2009), and a combined major 




Encodes a member of the synaptic cell adhesion molecule 1 family. Important for synapse 
organisation, providing regulated trans-synaptic adhesion (Pellissier, Gerber, Bauer, Ballivet, & 
Ossipow, 2007). CADM2 has been associated with executive function and processing speed 
(Ibrahim-Verbaas et al., 2016), lifetime cannabis use (Stringer et al., 2016), a range of personality 
traits (Boutwell et al., 2017), and autism (Casey et al., 2012). 
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Within the nexin gene family, which is are involved in intracellular trafficking. A frameshift 
mutation in SNX31 was identified in a schizophrenic patient (Balan et al., 2014). Several other SNX 
genes have been implicated in neuronal or psychiatric phenotypes. A related protein, SNX27, 
contributes to excitatory synaptic dysfunction via modulation of glutamate receptor recycling in 
Down syndrome (X. Wang et al., 2013). Reduced expression of SNX7 was associated with positive 
psychotic symptoms and reduced executive function in bipolar disorder (Sellgren et al., 2016). 
SNX3 has been associated with schizophrenia (K.-C. Huang, Yang, Lin, Tsao, & Lee, 2014; Mladinov 
et al., 2016). 
7 rs62457829 CHN2 (within) 
CHN2 encodes a guanosine triphosphate (GTP)-metabolising protein. This gene has been 
associated with schizophrenia in men (Hashimoto et al., 2005), atypical psychosis (Kanazawa et al., 
2013), and smoking cessation (Uhl et al., 2008). 
Note. Prior evidence of association in neuropsychiatric phenotypes was determined by scanning functional annotations and related articles on the NCBI 
Gene and GeneCards search engines. 
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5.5 – Appendix 
Supplementary Table 5.1. Measures of Paranoia and Hallucinations in TEDS, 




Leading statement: How often have you thought… 
Response options: 0 = Not at all, 1 = Rarely, 2 = Once a month, 3 = Once a week, 4 = Several 
times a week, 5 = Daily   
Item 1: I might be being observed or followed? 
Item 2: I can detect coded messages about me in the press/TV/internet? 
Item 3: People might be conspiring against me? 
Item 4: Hear noises or sounds when there is nothing about to explain them? 
Item 5: Hear sounds or music that people near you don't hear? 
Item 6: Hear voices commenting on what you're thinking or doing? 
Item 7: See things that other people cannot? 
Item 8: See shapes, lights, or colours even though there is nothing really there?   
Note: In order to keep the same ratio of items assessing hallucinations to 
paranoia the same across samples, items 4,5 and 6 were averaged to 
create a composite auditory hallucinations item, and items 7 and 8 were 




Part A response options: 0 = No, never, 1 = Yes, maybe, 2 = Yes, definitely 
Part B response options: 0 = Not at all, 1 = Once or twice, 2 = Less than once a month, 3 = More 
than once a month, 4 = Nearly every day   
Item 1a: Some people believe that other people can read their thoughts. Have 
other people ever read your thoughts? 
Item 1b: How often have other people read your thoughts since your 15th 
birthday? 
Item 2a: Have you ever thought you were being followed or spied on? 
Item 2b: How often has this happened since your 15th birthday? 
Item 3a: Have you ever believed that you were being sent special messages 
though the television or the radio, or that a programme had been 
arranged just for you alone? 
Item 3b: How often has this happened since your 15th birthday? 
Item 4a: Have you ever seen something or someone that other people could not 
see? 
Item 4b: How often have you seen something or someone that other people could 
not see since your 15th birthday? 
Item 5a: Have you ever heard voices that other people couldn’t hear 
Item 5b: How often have you heard voices that other people couldn’t hear since 
your 15th birthday?   




Leading statement: Have you ever… 
Response options: 0 = Never or rarely, 1 = Sometimes, 2 = Often, 3 = Very Often   
Item 1: Thought you were being followed or spied on? 
Item 2: Thought you were being sent special messages through the television? 
Item 3: Thought other people could read your thoughts? 
Item 4: Seen things other people cannot see? 








Response options: 0 = Very false for me, 1 = Moderately false for me, 2 = Slightly false for me, 
3 = Slightly true for me, 4 = Moderately true for me, 6 = Very true for me   
Item 1: When something exciting is coming up in my life, I really look forward to it. 
(R) 
Item 2: When I'm on my way to an amusement park, I can hardly wait to ride the 
rollercoasters. (R) 
Item 3: When it think about eating my favourite food, I can almost taste how good 
it is. (R) 
Item 4: I don’t look forward to things like eating out at restaurants. 
Item 5: I get so excited the night before a major holiday I can hardly sleep. (R) 
Item 6: When I think of something tasty, like chocolate biscuit, I have to have one. 
(R) 
Item 7: Looking forward to a pleasurable experience is in itself pleasurable. (R) 
Item 8: I look forward to a lot of things in my life. (R) 
Item 9: When ordering something off a menu, I imagine how good it will taste. (R) 
Item 10: When I hear about a new movie starring my favourite actor, I can't wait to 




Response options: 0 = No, never, 1 = Yes, sometimes, 2 = Yes, often, 3 = Yes, nearly always   
Item 1: Have you felt that you experience few or no emotions at important events, 
such as on your birthday? 
Item 2: Have you felt that you are lacking 'get up and go'? 
Item 3: Have you felt that you have only a few hobbies or interests?   
Leading statement: In the past two weeks… 
Response options: 0 = Not true, 1 = Sometimes true, 2 = True   
Item 4: I have been having fun. (R) 
Item 5: I didn't enjoy anything at all. 
Item 6: I felt so tired that I just sat around and did nothing. 
Item 7: I have had a good time. (R) 
Note. R, reverse coded. 
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Response options: 0 = Yes, 1 = No   
Item 1: Are you easily confused if too much happens at the same time? 
Item 2: Do you frequently have difficulty in starting to do things? 
Item 3: Are you a person whose mood goes up and down easily? 
Item 4: Do you dread going into a room by yourself where other people have 
already gathered and are talking? 
Item 5: Do you find it difficult to keep interested in the same thing for a long time? 
Item 6: Do you find it difficult in controlling your thoughts? 
Item 7: Are you easily distracted from work by daydreams? 
Item 8: Do you ever feel that your speech is difficult to understand because the 
words are all mixed up and don't make sense? 
Item 9: Are you easily distracted when you read or talk to someone? 
Item 10: Is it hard for you to make decisions? 
Item 11: When in a crowded room, do you often have difficulty in following a 




Response options: 0 = Never, 1 = Rarely, 2 = Sometimes, 3 = Often, 4 = Very often   
Item 1: How often do you have trouble wrapping up the fine details of a project, 
once the challenging parts have been done? 
Item 2: When you have a task that requires a lot of thought, how often do you 
avoid or delay getting started? 
Item 3: How often do you have difficulty keeping your attention when you are 
doing boring or repetitive work? 
Item 4: How often do you have difficulty concentrating on what people say to you, 
even when they are speaking to you directly?  




Supplementary Table 5.4. Measures of Parent-rated Negative Symptoms in TEDS, 




Leading statement: My child… 
Response options: 0 = Not at all true, 1 = Somewhat true, 2 = Mainly true, 3 = Definitely true   
Item 1: Usually gives brief, one word replies to questions, even if encouraged to say 
more. 
Item 2: Often does not have much to say for him/herself. 
Item 3: Has few or no friends.  
Item 4: Is often inattentive and appears distracted. 
Item 5: Often does not pay attention when being spoken to. 
Item 6: Often sits around for a long time doing nothing. 
Item 7: Has a lack of energy and motivation. 
Item 8: Has very few interests or hobbies. 
Item 9: Often fails to smile or laugh at things others would find funny. 
Item 10: Seems emotionally "flat", for example, rarely changes the emotions he/she 




Response options: 0 = Often, 1 = Sometimes, 2 = Hardly ever, 3 = Never   
Item 1: How often does he/she tell you about things that happen at 
school/college/work? 
Item 2: How often does he/she tell you about things that happen while he’s/she’s 
been out?   
  
Response options: 0 = No, 1 = Yes   
Item 3: Thinking back over the last month, has she been feeling tired or felt she had 
no energy?   
Leading statement: In the past 6 months… 
Response options: 0 = Not true, 1 = Somewhat true, 2 = Certainly true, NA = Don’t know   
Item 4: He/She did not respond when told to do something. 
Item 5: He/She has at least one good friend. ® 
Item 6: He/She is easily distracted, his/her concentration wanders. 




Leading statement: How accurate are the following statements for your child in the past six 
months?  
Response options: 0 = Not true, 1 = Somewhat true, 2 = Very or often true   
Item 1: Refuses to talk 
Item 2: Secretive, keeps things to self 
Item 3: Has trouble making or keeping friends 
Item 4: Withdrawn, doesn't get involved with others 
Item 5: Fails to finish things he/she should do 
Item 6: Can’t concentrate, can’t pay attention for long 
Item 7: Underactive, slow moving, or lacks energy 
Item 8: Feels tired without good reason 
Item 9: Stares blankly   
Response options: 0 = No, 1 = Yes, to a certain degree, 2 = Yes   
Item 10: Does the twin have difficulties expressing emotions and reactions with 
facial gestures, prosody, or body language? 
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Chapter 6 - Estimating the SNP-heritability of 
specific adolescent psychotic experiences using TEDS, 
ALSPAC and CATSS 
6.1 – Introduction 
The amount of variance for a given trait explained by additive and common genetic 
variation on a microarray (with or without imputation) is called the SNP-heritability (or 
chip-based heritability) (Yang, Benyamin, McEvoy, Gordon, Henders, Nyholt, et al., 
2010). As mentioned in Section 1.4.4, the SNP-heritability is important for determining 
the amount of power a genome-wide analysis of common variation will have to detect 
genome-wide significant variation. The SNP-heritability is also informative of the 
underlying genetic architecture of a trait. 
As described in Section 1.5.1, two popular methods for estimating the SNP-heritability of 
a phenotype are genomic-relatedness-matrix restricted maximum likelihood (GREML) 
(Yang, Benyamin, McEvoy, Gordon, Henders, & Others, 2010) in Genome-wide Complex 
Trait Analysis (GCTA) (Yang et al., 2011), and linkage disequilibrium (LD)-score 
regression (Bulik-Sullivan et al., 2015). 
One previous study has estimated the SNP-heritability of specific adolescent PEs 
(Sieradzka et al., 2015), as described in Chapter 1. This study used GREML to estimate 
the SNP-heritability for the six specific PE traits captured by the SPEQ (Specific 
Psychotic Experiences Questionnaire) based on 2,152 unrelated individuals within TEDS 
(Twins Early Development Sample). This study used three versions of GREML: GREML-
SC (single component), GREML-MS (MAF-stratified), and GREML-SC based on LD-
pruned genotypic data. The results were fairly consistent across the different GREML-
methodologies, concluding that GREML-MS was recommended. GREML-MS returned 
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evidence of SNP-heritability for Cognitive Disorganisation (23%), Grandiosity (10%) 
and Anhedonia (32%). GREML-MS estimates were close to zero for Paranoia (6%). 
GREML-MS estimates for Hallucinations, and Parent-rated Negative Symptoms were 0%. 
However, due to the limited sample size, these estimates had large standard errors of 
25%.  
In this chapter, the phenotypic variance of each specific PE was estimated using both 
GREML in GCTA and LD-score regression. This was performed within and across 
samples to estimate the phenotypic variance explained by common genetic variation 
within a homogenous sample, but also across samples. Based on the findings of 
Sieradzka et al., 2015 (Sieradzka et al., 2015), Paranoia and Hallucinations and Parent-
rated Negative Symptom PE domains were predicted to have lower SNP-heritability 
estimates than Anhedonia and Cognitive Disorganisation PE domains. 
6.2 – Methods 
6.2.1 – Samples 
The three samples used in this chapter have been originally described in Section 4.2.1. 
The exclusion criteria applied within each sample have been detailed in Section 4.2.2. 
6.2.2 – Measures 
The PE measures used in this chapter are based on the results of Chapter 4. The final 
measures used, and calculation of individual PE scores, are detailed in Sections 5.2.2-
5.2.5. As in the previous chapter, the PE scores were normalised using inverse rank-
based transformation (randomly splitting tied observations). The following covariates 
were then regressed out of the normalised PE scores: sex, age, age2, sex*age, sex*age2, 
study, and the top 8 principal components of ancestry. 
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6.2.3 – DNA collection, genotyping, imputation, and quality control 
The details of DNA collection, genotyping, and imputation are in Section 5.2.6 and 5.2.7. 
6.2.4 – Estimation of SNP-heritability 
The SNP-heritability was estimated using the combined sample (including TEDS, 
ALSPAC and CATSS) to provide estimates of phenotypic variance across the three 
samples that could be accounted for by common genetic variation (mega-SNP-
heritability). If the environmental variance within each sample is equal (although 
heterogeneous), then we can assume a common value of SNP-heritability. Given the 
presence of heterogeneity between the three samples, an estimate of SNP-heritability 
using a combined sample (mega-SNP-heritability) is likely to be downward biased due 
to an increase in phenotypic variance between individuals that is not attributable to 
common genetic variation. As such, estimates of SNP-heritability were also calculated 
within each sample and then inverse variance meta-analysed to provide estimates of 
SNP-heritability in a homogenous sample (meta-SNP-heritability). 
6.2.4.1 - GREML-methodologies 
6.2.4.1.1 – GREML-SC 
GREML was performed using a single component (GREML-SC), meaning that one GRM, 
based on all tagged genetic variation was used. However, GREML-SC estimates of SNP-
heritability may be downward biased if the causal variants have a different minor allele 
frequency (MAF) spectrum than the variants used in the analysis (Speed, Hemani, 
Johnson, & Balding, 2012; Wray et al., 2013).  
6.2.4.1.2 – GREML-MS 
GREML-MS (MAF-stratified)(S Hong Lee et al., 2013), using multiple GRMs based on 
different MAF bins, is an alternative approach that is robust to a difference in the MAF 
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spectrum between causal variants and those used in the analysis. However, GREML-MS 
requires larger samples than GREML-SC and therefore GREML-MS could only be 
performed when combining the three samples (mega-GREML-MS).  
6.2.4.1.3 – GREML-LDMS 
GREML-LDMS (LD-score and MAF stratified) (Yang et al., 2015) is an alternative method 
that controls for both difference in MAF spectrum between causal and tagged variants, 
and region specific heterogeneity in LD. GREML-LDMS has larger sample size 
requirements than GREML-MS and so it was also performed in the combined sample 
only (mega-GREML-LDMS). 
6.2.4.1.4 – Incorporating related individuals in GREML analysis 
All GREML-analyses included both unrelated and related individuals using a method 
proposed by Zaitlen and colleagues that enables the simultaneous estimation of SNP-
heritability and family-based narrow sense heritability (Zaitlen et al., 2013). GRMs were 
adjusted for prediction error as recommended by the software developers (Yang, 
Benyamin, McEvoy, Gordon, Henders, & Others, 2010). 
6.2.4.1.5 – Comparison of constrained and unconstrained GREML estimates 
The default in GCTA is to constrain estimates of variance explained to between zero and 
one. If the estimates are unconstrained, in scenarios where the true SNP-heritability is 
close to zero or above one, estimates of SNP-heritability can be negative or above one 
respectively. In addition to the default constrained estimates of variance explained 
unconstrained estimates were also calculated using the --reml-no-constrain option. This 
was to assess in which scenarios constrained and unconstrained estimates differ. 
 236 
When analysing the ALSPAC sample alone for meta-GREML analyses, individuals that 
were cryptically related were removed using a threshold of 0.05 as recommended by the 
developers of GCTA (Yang, 2016). 
To investigate the effect of normalising the dependent variable (PEs) on the SNP-
heritability, within sample GREML-SC SNP-heritability estimates were also calculated 
using untransformed PE residuals. 
6.2.4.2 – LD-score regression 
LD-score regression was based on summary statistics from mega- and meta- genome-
wide analyses in Chapter 5. There was no evidence of confounding in any analysis 
(Figure 5.6) so the intercept was constrained to 1. As advised by the developers of LD-
score regression, the effective sample size was used in LD-score regression analyses, 
thus matching the sample in the GWAS. The effective sample size was calculated as 
follows: 2*sample size / 1+correlation between siblings (Minica et al., 2014). 
In summary SNP-heritability was estimated using five approaches: meta-GREML-SC, 
mega-GREML-SC, mega-GREML-MS, meta-LD-score regression, and mega-LD-score 
regression. 
6.3 – Results 
6.3.1 – Comparison of within (meta-) and across (mega-) sample estimates of SNP-
heritability 
SNP-heritability estimates from constrained meta-GREML-SC and meta-LDSC were 
between 2.8-8.8% and 6.6-21.5% respectively suggesting some variance in PEs is 
explained by common additive genetic effects (Table 6.1). SNP-heritability estimates 
from mega-GREML-SC and mega-LDSC were between 0.0-5.0% and -0.2-13.6% 
respectively (Table 6.1). No meta- or mega-GREML-SC SNP-heritability estimates were 
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significantly non-zero (Table 6.1). However, the meta- and mega-LDSC SNP-heritability 
estimates for Anhedonia and Cognitive Disorganisation, and the meta-LDSC SNP-
heritability estimate for Parent-rated Negative Symptoms, were significantly non-zero 
(Table 6.1).  
Estimates of SNP-heritability from GREML-SC and LD-score regression for each sample 
individually are in Tables 6.2 and 6.3 respectively. 
6.3.2 – Comparison of different GREML methodologies 
6.3.2.1 – Comparison of GREML-SC, -MS and –LDMS estimates 
This comparison was only possible for mega-SNP-heritability estimates due to sample 
size restrictions for GREML analyses using stratified GRMs. Mega-GREML-MS estimates 
were 0.1% - 6.5%, on average 58% greater than mega-GREML-SC estimates, which were 
0.0% - 5.0% (Table 6.4). For traits with available estimates, mega-GREML-LDMS 
estimates were 10% - 11.1%, on average 54% larger than mega-GREML-MS estimates, 
which were 4.9% - 6.5% (Table 6.4). Mega-GREML-LDMS estimates were only possible 
for Anhedonia and Cognitive Disorganisation. Over stratification of the low SNP-
heritability for Paranoia and Hallucinations and Parent-rated Negative Symptoms led to 
over half the components being constrained to 1x10-6 and the analysis terminating. 
6.3.2.2 – Comparison of constrained and unconstrained GREML estimates 
Unconstrained SNP-heritability estimates were consistently lower than constrained 
estimates (Table 6.5). Estimates from unconstrained mega-GREML-SC and -MS for 
Paranoia and Hallucinations, and Parent-rated Negative Symptoms were negative. 
Comparing constrained and unconstrained estimates from mega-GREML-SC, -MS and -
LDMS for Anhedonia and Cognitive Disorganisation showed that as the analysis became 
more stratified (i.e. a larger number of components) the difference between constrained 
and unconstrained estimates increased. For example, the difference between 
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constrained and unconstrained SNP-heritability estimates for Anhedonia was 0.3% 
when using GREML-MS, and 3% when using GREML-LDMS. Comparison of constrained 
and unconstrained meta-GREML estimates showed that when the SNP-heritability was 
close to zero, meta-analysis of constrained estimates were larger than those from 
unconstrained (Table 6.6). 
6.3.2.3 – Effect of phenotypic normalisation on GREML estimates  
Comparison of within sample GREML-SC SNP-heritability estimates when using 
normalised and untransformed PEs showed that normalisation typically had no effect on 
SNP-heritability estimates (Table 6.7). The largest discrepancy between normalised and 
non-normalised estimates was for Paranoia and Hallucinations in the CATSS sample, 
which was a difference of 7.1%. 
6.3.3 – Distribution of genetic effects across MAF bins 
A breakdown of mega-GREML-MS SNP-heritability estimates into MAF bins is in Table 
6.8. For both Anhedonia and Cognitive Disorganisation over half the variance was 
explained by genetic variants with a MAF less than 5% with the remainder of variance 
explained coming from more common genetic variants. The low SNP-heritability in 
Paranoia and Hallucinations was accounted for by genetic variants within MAF bins 0.1-
0.2 and 0.4-0.5. Due to the very low SNP-heritability estimate for Parent-rated Negative 
Symptoms, it is difficult to identify different contributions across the MAF spectrum. 
6.3.4 – Comparison of LD-score regression and GREML estimates 
SNP-heritability estimates from mega- and meta-LD-score regression (Table 6.1) were 
typically larger than those from GREML-SC, -MS and –LDMS (Table 6.1 and 6.5). For 
example, unconstrained estimates of SNP-heritability for Anhedonia were 3.3% from 
mega-GREML-SC, 4.6% from mega-GREML MS, and 7% from mega-GREML LDMS, 
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whereas mega-LD-score regression estimated the SNP-heritability for Anhedonia as 
9.6%.
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Table 6.1. Mega- and meta- SNP-heritability estimates for specific PEs from GREML and LD-score regression. 
PE 
Mega-GREML-SC Meta-GREML-SC Mega-LDSC Meta-LDSC 
SNP-h2 SE p SNP-h2 SE p SNP-h2 SE p SNP-h2 SE p 
Paranoia and 
Hallucinations 
1.00x10-6 0.03 0.5 0.028 0.05 0.293 -8.20x10-3 0.039 0.417 0.066 0.068 0.168 
Anhedonia 0.033 0.039 0.198 0.088 0.055 0.057 0.096 0.053 0.036 0.204 0.078 4.51x10-3 
Cognitive 
Disorganisation 
0.05 0.046 0.138 0.059 0.063 0.176 0.136 0.068 0.022 0.215 0.085 5.79x10-3 
Parent-Rated 
Negative Symptoms 
1.00x10-6 0.026 0.5 0.059 0.045 0.096 -0.028 0.035 0.216 0.119 0.061 0.026 
Note: SNP-h2 = SNP-heritability. 
Table 6.2. Within sample GREML-SC estimates of SNP-heritability for specific PEs. 
PE 
TEDS ALSPAC CATSS 
SNP-heritability SE SNP-heritability SE SNP-heritability SE 
Paranoia and 
Hallucinations 
1.00x10-6 0.098 0.048 0.066 1.00x10-6 0.127 
Anhedonia 0.144 0.095 0.059 0.068 NA NA 
Cognitive 
Disorganisation 
0.125 0.098 NA NA 0.013 0.083 
Parent-Rated 
Negative Symptoms 




Table 6.3. Within sample LD-score regression estimates of SNP-heritability for specific PEs. 
PE 
TEDS ALSPAC CATSS 
SNP-heritability SE SNP-heritability SE SNP-heritability SE 
Paranoia and 
Hallucinations 
0.111 0.130 0.023 0.092 0.129 0.163 
Anhedonia 0.440 0.135 0.085 0.096 NA NA 
Cognitive 
Disorganisation 
0.189 0.131 NA NA 0.234 0.112 
Parent-rated 
Negative Symptoms 
0.063 0.136 0.133 0.083 0.133 0.121 
 
 
Table 6.4. SNP-heritability estimates for specific psychotic experiences from mega-GREML-SC, -MS and -LDMS. 
PE 
mega-GREML-SC mega-GREML-MS mega-GREML-LDMS 
SNP-heritability SE SNP-heritability SE SNP-heritability SE 
Paranoia and 
Hallucinations 
1.00x10-6 0.030 0.021 0.032 NA NA 
Anhedonia 0.033 0.039 0.049 0.040 0.100 0.053 
Cognitive 
Disorganisation 
0.050 0.046 0.065 0.047 0.111 0.061 
Parent-Rated 
Negative Symptoms 
1.00x10-6 0.026 9.15x10-3 0.028 NA NA 
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Table 6.5. Constrained and unconstrained estimates of SNP-heritability from GREML analyses. 
PE 
Mega-GREML-SC Mega-GREML-MS Mega-GREML-LDMS 
Constrained Unconstrained Constrained Unconstrained Constrained Unconstrained 
Paranoia and 
Hallucinations 
1.00x10-6 -3.14x10-2 0.021 -0.015 NA NA 
Anhedonia 0.033 0.033 0.049 0.046 0.100 0.070 
Cognitive 
Disorganisation 
0.050 0.050 0.065 0.044 0.111 0.063 
Parent-Rated 
Negative Symptoms 
1.00x10-6 -2.43x10-2 9.15x10-3 -4.20x10-2 NA NA 
 
Table 6.6. Constrained and unconstrained meta-GREML-SC estimates of SNP-heritability for specific psychotic experiences. 
PE 
Constrained Unconstrained 
SNP-heritability SE SNP-heritability SE 
Paranoia and 
Hallucinations 
0.028 0.050 2.95x10-4 0.050 
Anhedonia 0.088 0.055 0.088 0.055 
Cognitive 
Disorganisation 
0.059 0.063 0.059 0.063 
Parent-Rated 
Negative Symptoms 
0.059 0.045 0.029 0.044 
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Table 6.7. Within sample GREML-SC SNP-heritability estimates for normalised and untransformed specific psychotic experiences. 
PE 
TEDS ALSPAC CATSS 
Normalised Untransformed Normalised Untransformed Normalised Untransformed 
Paranoia and 
Hallucinations 
1.00x10-6 1.00x10-6 0.048 0.038 1.00x10-6 0.071 
Anhedonia 0.144 0.143 0.059 0.081 NA NA 
Cognitive 
Disorganisation 
0.125 0.116 NA NA 0.013 0.014 
Parent-Rated 
Negative Symptoms 





Table 6.8. MAF-breakdown of mega-GREML-MS SNP-heritability estimates. 
Paranoia and 
Hallucinations 
MAF bin V(G)/Vp SE 
 <0.05 1.00x10
-6 0.020 
 0.05 - 0.10 1.00x10
-6 0.015 
 0.10 - 0.20 8.10x10
-3 0.021 
 0.20 - 0.30 1.00x10
-6 0.017 
 0.30 - 0.40 1.00x10
-6 0.017 
 0.40 - 0.50 0.013 0.015 
 All 0.021 0.032 
    
Anhedonia MAF bin V(G)/Vp SE 
 <0.05 0.027 0.028 
 0.05 - 0.10 4.99x10
-3 0.022 
 0.10 - 0.20 2.89x10
-3 0.026 
 0.20 - 0.30 1.00x10
-6 0.018 
 0.30 - 0.40 0.014 0.023 
 0.40 - 0.50 1.00x10
-6 0.019 
 All 0.049 0.040 
    
Cognitive 
Disorganisation 
MAF bin V(G)/Vp SE 
 <0.05 0.040 0.031 
 0.05 - 0.10 1.00x10
-6 0.025 
 0.10 - 0.20 1.98x10
-3 0.030 
 0.20 - 0.30 0.010 0.027 
 0.30 - 0.40 0.013 0.025 
 0.40 - 0.50 1.00x10
-6 0.023 
 All 0.065 0.047 




MAF bin V(G)/Vp SE 
 <0.05 1.00x10
-6 0.019 
 0.05 - 0.10 1.88x10
-3 0.013 
 0.10 - 0.20 1.00x10
-6 0.018 
 0.20 - 0.30 5.14x10
-3 0.017 
 0.30 - 0.40 2.13x10
-3 0.015 




Note. MAF bin, minor allele frequency range of genetic variation in variance component; 
V(G)/Vp, phenotypic variance explained by variance component.  
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6.4 – Discussion 
This chapter has estimated the SNP-heritability of specific PEs in a number of ways to 
assess the variance in PEs explained by common genetic variation, and to compare 
different methodologies. 
Although there was some discrepancy between the methods used to estimate the mega-
SNP-heritability estimates for specific PEs, there was consistent evidence of non-zero 
variance explained by common genetic factors for both Anhedonia and Cognitive 
Disorganisation. Conversely, all mega-SNP-heritability estimates for Paranoia and 
Hallucinations, and Parent-rated Negative Symptoms suggest little or no phenotypic 
variance in common across the three samples can be explained by common genetic 
variation. This pattern of results is congruent with the findings of Sieradzka et al., 2015 
(Sieradzka et al., 2015). 
For the following reasons, this study deems the most accurate estimates of SNP-
heritability for adolescent PEs are those of constrained meta-GREML-SC, providing 
estimates of 3% - 9%. LD-score regression is less appropriate when based on GWAS 
summary statistics with a mean chi-square of less than 1.02, and therefore GREML 
estimates were thought to be more reliable. Meta-SNP-heritability estimates are 
proposed to be more accurate as they are the average SNP-heritability estimates for a 
homogenous sample. It is unclear whether constrained estimates are more accurate 
than unconstrained, but given that a negative SNP-heritability is not realistic, 
constrained estimates were thought to be accurate. 
In comparison to the twin heritability estimates for adolescent PEs of ~30%-50% 
(Zavos et al., 2014), the SNP-heritability estimates of 3% - 9% means that common 
genetic variation accounts for ~10% - 19% of the twin-based heritability. The 
discrepancy between the twin- and SNP-based heritability is well known. One reason for 
this discrepancy is that SNP-based heritability estimates only consider common additive 
 246 
genetic effects, whereas twin-based heritability includes common additive genetic 
effects as well as the effects of rare genetic variation. However, the twin- and SNP-based 
heritability discrepancy for physical and cognitive phenotypes are in general smaller 
than the missing heritability for behavioural phenotypes (Trzaskowski, Dale, & Plomin, 
2013). The increased discrepancy between twin heritability estimates and SNP-based 
heritability estimates is particularly prevalent for behavioural traits, as opposed to 
diagnostic categories (Cross-Disorder Group of the Psychiatric Genomics Consortium, 
2013; Thapar & Harold, 2014). A number of explanations have been put forward 
including increased non-additive genetic effects that are hidden in twin studies by 
inflated twin similarity, increased gene-environment interaction, or assortative mating 
leading to larger additive genetic effects (Thapar & Harold, 2014; Trzaskowski, Dale, et 
al., 2013). Although each of these are reasonable explanations, they are yet to be 
formally tested. The discrepancy between twin- and SNP-based heritability for 
adolescent PE is larger than that of schizophrenia, which has a twin heritability is ~80% 
(Cardno & Gottesman, 2000; P. F. Sullivan, Kendler, & Neale, 2003) and SNP-heritability 
from GREML-MS is 30% (S Hong Lee et al., 2013). 
One feature of Paranoia and Hallucinations, and Parent-rated Negative Symptoms that 
may contribute to their low SNP-heritability is that they were originally highly skewed. 
The process of randomly separating ties and subsequent rank-based normalisation of 
the dependent variable will decrease the correlation between phenotypic similarity and 
genotypic similarity, which could therefore lead to downward biased estimates of SNP-
heritability. This may explain why traits that were originally close to normality 
(Anhedonia and Cognitive Disorganisation) have larger estimates of SNP-heritability. 
Comparison of SNP-heritability estimates when using transformed or untransformed 
PEs demonstrated that the normalisation process rarely had an effect on SNP-
heritability estimates. However, it has been reported that GREML underestimates the 
 247 
SNP-heritability of skewed traits (Nivard et al., 2016). Further simulation studies are 
required to investigate the effect of skew on estimates of SNP-heritability. 
The phenotypic variance that cannot be explained by genetic or shared environmental 
factors is attributed to non-shared environmental factors which include measurement 
error. Therefore, the stability of the phenotype being measured will influence its 
heritability estimate. The degree of measurement error will decrease heritability 
estimates from both SNP- and twin based approaches and is therefore unlikely to 
explain the difference between these estimates. Nonetheless, strategies to decrease 
measurement error and increase the heritability of adolescent PEs should be employed 
to improve statistical power in future genetic studies. One strategy would be to use 
measures across multiple time points as genetic factors play an important role in the 
stability of behaviours across time (Hannigan, Walaker, Waszczuk, McAdams, & Eley, 
2017). Adolescent PEs have been reported to have a test-retest reliability of 0.65-0.74 
across a 9-month period (Ronald et al., 2014) suggesting that use of PE measures across 
multiple time points could increase heritability estimates. Other strategies for 
decreasing measurement error and increasing heritability have been discussed 
elsewhere (Cheesman et al., 2017). 
Mega-SNP-heritability estimates from GREML varied in range of 0% - 10% depending on 
whether estimates were constrained to be between 0% - 100%, or whether the genetic 
data was stratified to account for known sources of confounding. Although constraining 
estimates is the default of the software and limits results to only realistic outcomes, if 
the true heritability is low, constraining estimates may inflate the total or average 
heritability estimates when performing stratified or meta- GREML analyses. However, 
constrained estimates from GREML-LDMS were most similar to estimates from LD-score 
regression. This agreement between methods could suggest that constrained estimates 
are more accurate. 
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The standard errors of meta-SNP-heritability estimates were consistently larger than 
those of mega-SNP-heritability estimates for both GREML and LD-score regression 
methodology. For GREML methodologies this difference occurs due to meta-analysis not 
utilising the relationships between individuals across samples. For LD-score regression 
this difference may be a result of non-linear relationship between statistical power and 
sample size. 
The comparison of meta- and mega- SNP-heritability estimates provide insight into the 
extent of heterogeneity between samples. Constrained SNP-heritability estimates across 
the three samples (mega-SNP heritability) were approximately a third smaller than 
estimates from meta-analysis of within sample estimates (meta-SNP heritability). This 
indicates some degree of heterogeneity between the three samples that will lead to 
reduced statistical power when testing for associations across samples. However, the 
phenotypic variance in common between the three samples may capture a core aspect 
of each PE trait. The extent of heterogeneity between samples did vary for different PEs. 
Cognitive Disorganisation showed the least heterogeneity, as the mega- and meta-SNP 
heritability estimates were very similar (5% and 6% respectively). In contrast, Parent-
rated Negative Symptoms showed the largest extent of heterogeneity with meta-SNP-
heritability of 6% but a mega-SNP-heritability of 0%. However it is difficult to compare 
the differences in SNP-heritability estimates as the standard errors were often 
overlapping. Due to sample size restrictions, it was not possible to assess genetic 
heterogeneity between samples by estimating the genetic correlation between measures 
within each sample. 
In summary, this chapter has provided evidence that within a homogenous sample, 
adolescent PEs can in part be explained by common genetic variation. However, across 
the different samples used in this chapter, the presence of heterogeneity across samples 
leads to lower estimates of SNP-heritability. PE traits that were originally more skewed 
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showed smaller SNP-heritability estimates, possibly reflecting the reduced statistical 
power when normalising skewed traits. Further work should investigate the effect on 




Chapter 7 - Assessing the genetic relationship 
between specific adolescent psychotic experiences in 
TEDS, ALSPAC and CATSS samples, and major 
psychiatric disorders 
7.1 – Introduction 
Investigating the aetiology of adolescent psychotic experiences (PEs) is important for 
two key reasons: understanding the complex interplay of genetic and environmental 
factors across development underlying adolescent behavioural traits, and providing 
insight into the factors affecting mental health. As previously described in Section 1.2.2, 
adolescent PEs have been identified as risk factors for a number of health related factors 
and outcomes including suicide attempts and ideation, and substance abuse in 
adolescence (Cederlöf et al., 2016; Kelleher et al., 2013, 2014), and psychotic and non-
psychotic psychiatric disorders in adulthood (McGrath et al., 2016; Poulton et al., 2000; 
S. A. Sullivan et al., 2014; Van Os et al., 2009; Welham et al., 2009). The relationships 
between adolescent PEs and schizophrenia, bipolar disorder, and major depression are 
the focus of this chapter due to past epidemiological links, their ostensible connection in 
terms of similarity of phenotype (e.g. paranoia, anhedonia), and the availability of well 
powered genome-wide association summary statistics for schizophrenia, bipolar 
disorder and major depression. Although there is a robust phenotypic relationship 
between adolescent PEs and these psychiatric disorders, evidence of shared genetic 
factors is limited (described in Section 1.5.3). This chapter will investigate the common 
genetic association between adolescent PEs and psychiatric disorders using common 
genotyped variation.  
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Before considering the evidence of a genetic association between two phenotypes, we 
must first demonstrate that the two phenotypes of interest can be partly explained by 
genetic variation. As described in Section 1.5.1, twin studies can be used to estimate the 
phenotypic variance explained by all genetic factors (additive, dominant, epistatic), and 
gene-environment correlation and interaction effects (Plomin et al., 2013). Although 
twin-based heritability estimates are informative, SNP-based heritability estimates are 
of greater relevance to our ability to test for a common genetic association between two 
traits. Schizophrenia, bipolar disorder and major depression have all been reported as 
showing a strong common genetic basis based on analysis in GCTA (Genome-wide 
Complex Trait Analysis) (Cross-Disorder Group of the Psychiatric Genomics Consortium, 
2013) and LD (linkage disequilibrium)-score regression (Bulik-Sullivan et al., 2015). In 
the previous chapter, the SNP-heritability of specific adolescent PEs was estimated 
within and across three samples: TEDS (Twins Early Development Study), ALSPAC 
(Avon Longitudinal Study of Parents and Children), and CATSS (Child and Adolescent 
Twin study in Sweden). 
As previously described in Section 1.6, two samples have been used to investigate the 
common genetic association between adolescent PEs and schizophrenia using a 
schizophrenia polygenic risk score (PRS) derived from the schizophrenia PGC2 
(Psychiatric Genomics Consortium 2) GWAS. The first study (Sieradzka et al., 2014), 
using the TEDS sample, reported no positive association between the schizophrenia PRS 
and any of the six specific PEs. In fact there was evidence of a negative association for 
several of the specific PE domains. This study reported similar findings using the PGC 
bipolar disorder PRS. The second study (H. J. Jones et al., 2016), using the ALSPAC 
sample, reported a significant positive association between the schizophrenia PRS and 
negative symptoms, but identified no association with positive symptoms (including 
paranoia, hallucinations and delusions). The mixed findings for negative symptoms 
could be explained by a number of differences between the studies. One reason may be 
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that the SNP-heritability of the negative symptom measures used in these two studies 
differed. Although the measures used in these previous PRS studies vary from those 
used in the last chapter, evidence from the previous chapter indicates the SNP-
heritability for negative symptoms is higher in ALSPAC than it is in the TEDS sample. 
There has been no published analysis assessing the relationship between adolescent PEs 
in the CATSS sample and the schizophrenia PRS. 
There has been no previous study assessing the common genetic association between 
adolescent PEs and major depression. 
This chapter aims to improve upon these previous studies by assessing the common 
genetic overlap between schizophrenia, bipolar disorder, and major depression, and a 
broad range of quantitative and specific adolescent PE domains across multiple samples. 
This was achieved using both PRS-based analysis and LD-score regression. Given the 
previously reported positive association between adolescent PEs and these psychiatric 
disorders on a phenotypic level, a positive genetic association was predicted. 
7.2 – Methods 
7.2.1 – Samples  
The three samples used in this chapter have been described in Section 4.2.1. The 
exclusion criteria applied within each sample have been detailed in Section 4.2.2. 
7.2.2 – Measures 
The measures used in this chapter are based on the results of Chapter 4. The final 
measures used and calculation of individuals PE scores are detailed in Sections 5.2.2 -
5.2.5. Therefore, the PE scores used in analyses were normally distributed and 
uncorrelated with the following covariates: sex, age, age2, sex*age, sex*age2, study, and 
the top 8 principal components of ancestry. 
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7.2.3 – Genotypic data 
The details of DNA collection, genotyping, and imputation are in Section 5.2.6 and 5.2.7. 
7.2.4 – Polygenic risk score analysis 
The polygenic risk score for an individual is typically calculated as the sum of risk alleles 
that individuals carries, weighted by the effect size. Using PRSice (Euesden, Lewis, & 
O’Reilly, 2015), polygenic risk scores (PRSs) of schizophrenia, bipolar disorder, and 
major depression were calculated in the adolescent sample using the log of the odds 
ratios from the latest Psychiatric Genomics Consortium GWAS of schizophrenia (PGC2) 
(Ripke et al., 2014), bipolar disorder (PGC Bipolar Disorder Working Group, 2011), and 
major depression (Ripke, Wray, et al., 2013). LD was controlled for using LD-based 
clumping using the typical r2-cutoff of 0.1 within a 250-kb window (Palla & Dudbridge, 
2015; Purcell et al., 2007). For each individual, scores were generated using SNPs with 
the following p-value thresholds (pTs) to define alleles included in the polygenic risk 
scores: 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5. Linear regression was performed in R, 
using generalized estimating equations (GEE) with an exchangeable correlation matrix 
to account for related individuals (Minică et al., 2015). 
Logistic regressions comparing PRSs in low and high psychotic experience domain 
groups (defined as bottom and top 25% of raw psychotic experience sum scores) were 
performed to confirm the results of linear analyses using normalised PE traits.  
The linear associations between the PRSs for schizophrenia, bipolar disorder and major 
depression, and specific PEs were also calculated within each sample to highlight the 




7.2.5 – Analysis of non-linear polygenic risk score effects 
Quantile plots and local polynomial regression were used to examine the linearity of 
associations. If there was evidence of a non-linear relationship, then the non-linear 
relationship was formalised by performing linear regression in a subset of individuals. 
7.2.6 – Analysis of within sample polygenic risk score effects 
To demonstrate consistency with previous studies using TEDS and ALSPAC samples, and 
to investigate differences between all three samples, polygenic risk score associations 
were also performed within each sample separately. 
7.2.7 – Estimation of genetic covariance 
To estimate the genetic covariance between psychotic experience domains and 
schizophrenia, bipolar disorder, and major depression, both LD-score regression and 
AVENGEME (Additive Variance Explained and Number of Genetic Effects Method of 
Estimation) were used (Bulik-Sullivan et al., 2015; Palla & Dudbridge, 2015).  
AVENGEME uses the results of polygenic risk score analyses across multiple significance 
thresholds to estimate the model parameters including the genetic covariance. 
AVENGEME estimates 95% confidence intervals using the profile likelihood method. To 
improve the accuracy of the estimates of genetic covariance derived from the 
AVENGEME analysis, the SNP-heritability of liability for schizophrenia, bipolar disorder, 
and major depression were constrained to the LD-score regression estimates of SNP-
heritability (see Table 7.1). The prevalence of schizophrenia, bipolar disorder and major 
depression were set to 0.01, 0.01, and 0.15 respectively (Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013). When specifying the sample size of the PE 
sample, the effective sample size was used to account for the presence of related 
individuals. The effective sample size was calculated as follows: 2*sample size / 
1+correlation between siblings (Minica et al., 2014). 
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There was no evidence of confounding or sample overlap in the mega-GWAS summary 
statistics, as such the heritability-intercept was constrained to 1 and the genetic 
covariance intercept was set to 0 in LD-score regression. These parameters were 
constrained to reduce the standard error of estimates of genetic covariance and 
correlation. 
Power calculations using the ‘polygenescore’ function in AVENGEME showed the power 
to detect moderate levels of genetic covariance varied from 0.09 to 0.85, mainly 
dependent on the estimated SNP-heritability of each PE (Supplementary Tables 7.1-7.3). 
LD-score regression’s power is dependent on the sample sizes used to calculate 
summary statistics for both phenotypes, whereas AVENGEME can provide 
unidirectional estimates that are only dependent on the size of the discovery sample. As 
a result, LD-score regression analysis will have less power due to the relatively small 
sample size used to calculate summary statistics for adolescent PEs. Therefore, in these 
analyses, LD-score regression is thought to have less power. 
7.2.8 – Estimation of genetic correlation 
LD-Score regression automatically estimates the genetic correlation when calculating 
the genetic covariance. As described above, the heritability-intercept was constrained to 
1 and the genetic covariance intercept was set to 0 in LD-score regression. 
Genetic covariance estimates from AVENGEME were standardised into genetic 
correlations using the following formula:  
rG12 = cov(G12)/sqrt(Vg1*Vg2), 
where cov(G12) equals the genetic covariance estimate of either AVENGME, and Vg1 and 
Vg2 equal the SNP-heritability estimate of phenotype 1 and 2 respectively. SNP-
heritability estimates for schizophrenia, bipolar disorder and major depression were 
estimated by LD-score regression on a liability scale using the same PGC summary 
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statistics. Mega-LD-score regression estimates of SNP-heritability for specific PEs were 
used (Chapter 6). It is not currently possible to calculate the error of genetic correlation 




Table 7.1. Parameters used in AVENGEME analysis. 






SCZ 77096 0.447 0.01 0.2618 102323 
Paranoia and 
Hallucinations 7970 






SCZ 77096 0.447 0.01 0.2618 102323 Anhedonia 6068 
SCZ 77096 0.447 0.01 0.2618 102323 
Cognitive 
Disorganization 5083 





        
BD 16731 0.443 0.01 0.2548 67299 
Paranoia and 
Hallucinations 7970 
BD 16731 0.443 0.01 0.2548 67299 Anhedonia 6068 
BD 16731 0.443 0.01 0.2548 67299 
Cognitive 
Disorganization 5083 





        
MDD 18759 0.493 0.15 0.1919 63107 
Paranoia and 
Hallucinations 7970 
MDD 18759 0.493 0.15 0.1919 63107 Anhedonia 6068 
MDD 18759 0.493 0.15 0.1919 63107 
Cognitive 
Disorganization 5083 





Note. Psych, psychiatric disorder; SCZ, schizophrenia; BD, bipolar disorder; MDD, major 
depression; N1, Number of individuals in discovery sample; Samp, proportion of cases in 
training sample; Prev, prevalence of disorder in general population; SNP-h21, LDSC estimate 
of SNP-heritability on a liability scale in training sample; nSNP, number of LD-independent 
genetic variants overlapping between discovery and target samples; N2, effective sample size 





7.3 – Results 
7.3.1 - Polygenic risk score association 
The schizophrenia PRS significantly and positively predicted Anhedonia (p = 0.030 at pT 
= 0.10), Cognitive Disorganization (p = 0.035 at pT = 0.01) and Parent-rated Negative 
Symptoms (p = 5.41x10-3 at pT = 0.05) (Table 7.2; Figure 7.1). The bipolar disorder PRS 
significantly and negatively predicted Paranoia and Hallucinations only (p = 2.47x10-3 at 
pT = 0.010) (note opposite direction to expected) (Table 7.2; Figure 7.1). The major 
depression PRS significantly and positively predicted Anhedonia (p = 0.010 at pT 0.5) 
and Parent-rated Negative Symptoms (p = 8.29x10-3 at pT = 0.001) (Table 7.2; Figure 
7.1). Figures 7.2-7.4 and Supplementary Tables 7.4-7.6 show the full results of these 
analyses. 
Logistic regression comparing PRSs in low and high psychotic experience domain 
groups (defined as bottom and top 25% of raw psychotic experience sum scores) were 
congruent with linear analyses (Supplementary Table 7.7, Figure 7.5). 
7.3.2 – Non-linear effects in Paranoia and Hallucinations scale 
Quantile plots showing the mean PRS within subsets of the PE distributions highlighted 
one non-linear relationship between the schizophrenia PRS and Paranoia and 
Hallucinations (Figures 7.6-7.7). No other PE-psychiatric disorder PRS quantile plot 
showed a non-linear relationship. The non-linear relationship between the 
schizophrenia PRS and Paranoia and Hallucinations was U-shaped with the point of 
inflection at the median. The majority of individuals (81%) below the median had a raw 
score of zero. Post-hoc removal of individuals with a raw Paranoia and Hallucinations 
score of zero led to the schizophrenia PRS positively predicting Paranoia and 
Hallucinations (p = 7.90x10-3 at pT = 0.001) (Table 7.2; Figure 7.1; Supplementary Table 
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7.4). Logistic regression comparing low and high groups of non-zero scoring individuals 
supported these findings (Supplementary Table 7.7, Figure 7.5). 
7.3.3 - Within sample results 
Within sample PRS associations with specific PEs are shown in Supplementary Figures 
7.1-7.3. Within sample analyses show the positive association between the 
schizophrenia PRS and Anhedonia, and Parent-rated Negative Symptoms is mainly 
driven by the ALSPAC sample (Supplementary Figure 7.1). The positive association 
between schizophrenia and Cognitive Disorganisation is mainly driven by CATSS 
(Supplementary Figure 7.1). The positive association between schizophrenia PRS, and 
Paranoia and Hallucinations after excluding zero scorers is driven by both TEDS and 
ALSPAC (Supplementary Figure 7.1). For bipolar disorder and major depression, the 





Figure 7.1. Polygenic risk scores for schizophrenia, bipolar disorder, and major 
depression predict adolescent psychotic experience domains.  
Note. This figure shows results for polygenic risk scores at the most predictive p-value 
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Table 7.2. Schizophrenia, bipolar disorder, and major depression polygenic risk 
scores predicting psychotic experience domains in adolescents.  
Schizophrenia      
Specific PE β SE p r2 pT 
Paranoia and Hallucinations -0.005 0.011 0.664 0.002% 0.2 
Paranoia and Hallucinations 
excl. zero-scorers 0.031 0.012 7.90x10-3 0.094% 0.001 
Anhedonia 0.028 0.013 0.030 0.079% 0.10 
Cognitive Disorganisation 0.029 0.014 0.035 0.083% 0.01 
Parent-rated Negative 
Symptoms 0.030 0.011 5.41x10-3 0.088% 0.05 
      
Bipolar Disorder      
Specific PE β SE p r2 pT 
Paranoia and Hallucinations -0.034 0.011 2.47x10-3 0.115% 0.01 
Anhedonia -0.017 0.013 0.178 0.030% 0.100 
Cognitive Disorganisation -0.013 0.014 0.333 0.017% 0.001 
Parent-rated Negative 
Symptoms -0.009 0.011 0.388 0.008% 0.5 
      
Major Depression      
Specific PE β SE p r2 pT 
Paranoia and Hallucinations 0.006 0.011 0.589 0.004% 0.1 
Anhedonia 0.033 0.013 0.010 0.109% 0.5 
Cognitive Disorganisation 0.018 0.014 0.189 0.033% 0.05 
Parent-rated Negative 
Symptoms 0.028 0.011 8.29x10-3 0.078% 0.001 
    
Note. This table shows results for polygenic risk scores at the most predictive p-value 
threshold for each trait. Specific PE, specific psychotic experience; β, standardised beta 









Figure 7.2. Schizophrenia polygenic risk score predicting psychotic experience 
domains in adolescence.  
Note. *, p ≤ 0.05; **, p ≤ 0.01. Linear regression results are shown for polygenic risk scores at 
all p-value thresholds. Figure corresponds to results shown in Supplementary Table 7.4. 
Error bars indicate 95% confidence intervals. 
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Schizophrenia PRS predicting Parent−rated Negative Symptoms
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Figure 7.3. Bipolar disorder polygenic risk score predicting psychotic experience 
domains in adolescence.  
Note. *, p ≤ 0.05; **, p ≤ 0.01. Linear regression results are shown for polygenic risk scores at 
all p-value thresholds. Figure corresponds to results shown in Supplementary Table 7.5. 
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Bipolar Disorder PRS predicting Parent−rated Negative Symptoms
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Figure 7.4. Major depression polygenic risk score predicting psychotic experience 
domains in adolescence.  
Note. *, p ≤ 0.05; **, p ≤ 0.01. Linear regression results are shown for polygenic risk scores at 
all p-value thresholds. Figure corresponds to results shown in Supplementary Table 7.6. 
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Figure 7.5. Schizophrenia, bipolar disorder, and major depression polygenic risk 
score mean differences between low- and high-scoring psychotic experience 
domain groups. 
Note. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; PRS, polygenic risk score. Polygenic risk scores 
were adjusted to control for covariate effects. Low- and high-scoring groups determined as 
the bottom and top 25% of raw psychotic experience domain sum scores. This plot shows 
mean differences for polygenic risk scores at the most predictive p-value threshold for each 
trait. Significance of mean difference was determined using logistic regression (results 
shown in Supplementary Table 7.7). Error bars indicate the standard error of the mean. 
 
 














































































































































Major Depression PRS predicting Adolescent Psyc hotic Experiences
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Figure 7.6. Local polynomial regression of schizophrenia polygenic risk score (p-
value threshold of p<0.3) and Paranoia and Hallucinations.  
Note. The red line indicates the schizophrenia polygenic risk score (left y-axis) of individuals 
across the Paranoia and Hallucinations distribution. Histogram in background shows number 




Figure 7.7. Mean schizophrenia polygenic risk score (SCZ PRS) in six quantiles of 
Paranoia and Hallucinations scores.  
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7.3.4 – Estimates of genetic covariance 
Table 7.3 presents the AVENGEME estimates of genetic covariance, which were highly 
congruent with the PRS analysis results. AVENGEME pools evidence across p-value 
thresholds tested from PRS analysis. As such, even when there is consistent but non-
significant evidence of association at individual p-value thresholds, AVENGEME genetic 
covariance estimates can be significant. Consequently, there were two significant results 
that were not shown by the PRS analyses; between the Anhedonia PE domain and 
bipolar disorder (genetic covariance = -0.022, 95%CI = -0.041 – -0.002), and the 
Cognitive Disorganization PE domain and major depression (genetic covariance = 0.033, 
95%CI = 0.005 – 0.062). 
Table 7.3 presents estimates of genetic covariance from LD-score regression. LD-score 
regression mirrored over half of the significant associations shown between the 
equivalent polygenic risk scores and psychotic experience domains in Table 7.2. The 
genetic covariance between the schizophrenia PRS and non-zero scorers on Paranoia 
and Hallucinations could not be estimated because the genome-wide association 
analysis included zero scorers. Unlike for the equivalent results in Table 7.2, the genetic 
covariance between schizophrenia and anhedonia psychotic experience domain, and 
between major depression and parent-rated negative symptoms domain, were not 
significant. 
7.3.5 – Estimates of genetic correlation 
Genetic correlations between Anhedonia and Cognitive Disorganisation with 
schizophrenia, bipolar disorder, and major depression are in Table 7.4 (Genetic 
correlation estimates were not possible for Paranoia and Hallucinations, and Parent-
rated Negative Symptoms as the mega-LDSC SNP-heritability estimates were negative).  
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It is not currently possible to estimate the errors of genetic correlations derived from 
AVENGEME estimates of genetic covariance. Consistent with the genetic covariance 
results from LD-score regression, genetic correlation estimates were significant 
between Cognitive Disorganisation and schizophrenia (LD-score regression: rG = 0.205, 
SE = 0.090, p= 0.023; AVENGEME: rG = 0.134), and Anhedonia and major depression 
(LD-score regression: rG = 0.432, SE = 0.193, p= 0.025; AVENGEME: rG = 0.477). 
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Table 7.3. Genetic covariance between each psychotic experience domain and 
schizophrenia, bipolar disorder, and major depression. 







95% CI cov(G) SE p 
Paranoia and 
Hallucinations 
-0.002 -0.013 0.008 -0.003 0.014 0.844 
P and H excl. zero-
scorers 
0.019 0.011 0.029 NA NA NA 
Anhedonia 0.024 0.013 0.038 0.021 0.016 0.184 
Cognitive 
Disorganisation 
0.025 0.013 0.040 0.054 0.018 3.52x10-3 
Parent-rated 
Negative Symptoms 
0.025 0.015 0.036 0.047 0.014 5.57x10-4 
       







95% CI cov(G) SE p 
Paranoia and 
Hallucinations 
-0.032 -0.048 -0.018 -0.045 0.022 0.039 
Anhedonia -0.022 -0.041 -0.002 0.008 0.028 0.767 
Cognitive 
Disorganisation 
0.008 -0.013 0.029 0.021 0.028 0.451 
Parent-rated 
Negative Symptoms 
-0.010 -0.026 0.006 0.009 0.021 0.669 
       







95% CI cov(G) SE p 
Paranoia and 
Hallucinations 
0.004 -0.018 0.026 0.013 0.020 0.523 
Anhedonia 0.065 0.037 0.094 0.061 0.023 7.50x10-3 
Cognitive 
Disorganisation 
0.033 0.005 0.062 0.015 0.028 0.594 
Parent-rated 
Negative Symptoms 
0.023 0.010 0.042 0.031 0.020 0.119 
Note. PE, psychotic experience; cov(G), genetic covariance; CI, confidence interval; 
AVENGEME, additive variance explained and number of genetic effects method of 
estimation; LDSC, linkage-disequilibrium score regression.  
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Table 7.4. Estimates of genetic correlation between specific adolescent psychotic 
experiences, and schizophrenia, bipolar disorder, and major depression. 
Psych PE 
AVENGEME LDSC 
rG rG SE p 
SCZ Paranoia and Hallucinations NA NA NA NA 
SCZ P and H excl. zero-scorers NA NA NA NA 
SCZ Anhedonia 0.154 0.097 0.074 0.188 
SCZ Cognitive Disorganisation 0.134 0.205 0.090 0.023 
SCZ 
Parent-rated Negative 
Symptoms NA NA NA NA 
            
BD Paranoia and Hallucinations NA NA NA NA 
BD Anhedonia -0.138 0.038 0.128 0.768 
BD Cognitive Disorganisation 0.041 0.087 0.116 0.452 
BD 
Parent-rated Negative 
Symptoms NA NA NA NA 
            
MDD Paranoia and Hallucinations NA NA NA NA 
MDD Anhedonia 0.477 0.432 0.193 0.025 
MDD Cognitive Disorganisation 0.204 0.096 0.182 0.600 
MDD 
Parent-rated Negative 
Symptoms NA NA NA NA 
Note. Psych, psychiatric disorder; SCZ, schizophrenia; BD, bipolar disorder; MDD, major 
depression; PE, psychotic experience; P and H excl. zero-scorers, Paranoia and Hallucinations 
excluding zero-scorers; rG, genetic correlation; AVENGEME, additive variance explained and 
number of genetic effects method of estimation; LDSC, linkage-disequilibrium score 
regression.  
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7.4 – Discussion 
This study has tested for a common genetic overlap between a broad range of 
adolescent PEs and schizophrenia, bipolar disorder and major depression in the largest 
sample to date.  This is the first study to find significant genetic overlap between 
schizophrenia and such a wide range of PEs. 
Results showed significant and positive genetic covariance between schizophrenia and 
Paranoia and Hallucinations (in non-zero scorers only), Anhedonia, Cognitive 
Disorganisation, and Parent-rated Negative Symptoms. LD-score regression results were 
congruent with those of AVENGEME. The best fitting schizophrenia PRSs predicted 
between 0.08 – 0.09% of the variance in Paranoia and Hallucinations (in non-zero 
scorers only), Anhedonia, Cognitive Disorganisation, and Parent-rated Negative 
Symptoms. Although only a small amount variance in PEs was explained by the 
schizophrenia PRS, genetic correlation estimates, where possible, were approximately 
0.15. 
The use of quantitative measures of PEs allowed investigation of non-linear effects. Our 
study finds evidence that Paranoia and Hallucinations during adolescence are only 
associated with schizophrenia genetic risk if the individual reports at least some degree 
of paranoia or hallucinations. Individuals reporting no Paranoia and Hallucinations can 
exist anywhere on the schizophrenia genetic liability spectrum. This finding requires 
further investigation with longitudinal data. An explanation may lie in the fact that age 
of onset of paranoia and hallucinations varies widely among individuals: our study was 
focused on PEs in mid to late adolescence.  
The combined analysis of three samples has provided a larger sample size than previous 
studies and as a result more power to detect associations at significance. Furthermore, 
the use of multiple samples means the overall effects observed are more generalizable 
and likely to hold true for other samples. The within sample results relating to 
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schizophrenia are consistent with those of previous studies in TEDS and ALSPAC (H. J. 
Jones et al., 2016; Sieradzka et al., 2014), but the combined analysis of a broad range of 
specific and quantitative measures has provided some solidity to previously mixed 
findings, and has offered several new insights into the relationship between adolescent 
PEs and schizophrenia. These new insights include the genetic association between the 
schizophrenia and non-zero Paranoia and Hallucinations, Anhedonia, and Cognitive 
Disorganisation. 
In addition to testing for a common genetic association between adolescent PEs and 
schizophrenia, this study also examined the common genetic relationship between 
adolescent PEs and major depression and bipolar disorder. 
Significant and positive genetic covariance between major depression and Anhedonia, 
Cognitive Disorganisation, and Parent rated Negative Symptoms was found, and LD-
score regression results were consistent in direction of effect, although not all estimates 
were significant. The genetic correlation between major depression and Anhedonia was 
significant with estimates ~0.45. This finding is in accordance with a previous study 
reporting that subclinical depressive symptoms (including anhedonia) are a strong 
predictor of major depressive episodes in adulthood (Pine, Cohen, Cohen, & Brook, 
1999). Anhedonia is present as a symptom of both schizophrenia and depression in 
psychiatric diagnoses, and our research shows that as a trait dimension in adolescence it 
shares common genetic underpinnings with both schizophrenia and depression. 
Contrary to our hypothesis, significant negative genetic covariance was found between 
bipolar disorder and Paranoia and Hallucinations, and Anhedonia. The significant 
negative genetic covariance between bipolar disorder and Paranoia and Hallucinations 
conflicts with previous reports of increased paranoia, hallucinations, and delusions 
prior to the onset of bipolar disorder (McGrath et al., 2016). Although the negative 
association is somewhat surprising, the absence of a positive association is less so given 
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that the bipolar disorder PRS can only explain 2.83% of the variance in bipolar disorder 
(PGC Bipolar Disorder Working Group, 2011). 
The previous chapter estimated the SNP-heritability of adolescent PEs, with zero SNP-
heritability estimates when looking across the three samples for Paranoia and 
Hallucinations, and Parent-rated Negative Symptoms. Given these zero SNP-heritability 
estimates, it is somewhat counterintuitive that these traits can have a significant genetic 
covariance with other phenotypes. However, when estimating the SNP-heritability 
within each sample separately, thereby removing the between sample heterogeneity, 
the SNP-heritability estimates for Paranoia and Hallucinations, and Parent-rated 
Negative Symptoms were 3% and 5 % respectively. Therefore, the effects within each of 
the samples could drive the genetic covariance observed in this study. Another 
explanation is that the across sample SNP-heritability of Paranoia and Hallucinations, 
and Parent-rated Negative Symptoms are not zero, but are very close to zero. 
It should be noted that the significant genetic covariance estimates reported here could 
be partly explained by the presence of adolescents with diagnosed relatives. If an 
adolescent has a relative with schizophrenia for example, the adolescent may have 
increased PEs due to their shared environment with the relative. Future studies should 
investigate the effect of parental diagnosis on the genetic covariance between 
adolescent PEs and psychiatric disorders.  
Collectively these findings provide evidence of a common genetic overlap between a 
broad range of adolescent PEs, schizophrenia and major depression, suggesting that 
investigating the common genetic basis of adolescent PEs could provide insight into the 
development of these major psychiatric disorders. However, given the heterogeneity 
between within-sample PRS analysis results, the relationship between specific 
adolescent PE and adult psychiatric disorders should be further explored.  The clinical, 
theoretical and genetic implications of these findings will be considered in the following 
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chapter. Furthermore, schizophrenia polygenic risk appears to be only predictive of 
Paranoia and Hallucinations among individuals reporting at least some experiences of 
paranoia or hallucinations. This relationship was observed in all three samples and 
should be further investigated to understand the factors underlying it. 
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7.5 – Appendix 
Supplementary Tables: 
Supplementary Table 7.1. Power calculations for genetic covariance analysis 
between PEs and schizophrenia.  
PE N1 h21 N2 h22 rG Alpha Power 
Paranoia and 
Hallucinations 
77096 0.2618 7970 0.028 0.2 0.05 0.26 
Anhedonia 77096 0.2618 6068 0.088 0.2 0.05 0.52 
Cognitive 
Disorganization 
77096 0.2618 5083 0.059 0.2 0.05 0.33 
Parent-rated 
Negative Symptoms 
77096 0.2618 8763 0.059 0.2 0.05 0.52 
Paranoia and 
Hallucinations 
77096 0.2618 7970 0.028 0.3 0.05 0.51 
Anhedonia 77096 0.2618 6068 0.088 0.3 0.05 0.85 
Cognitive 
Disorganization 
77096 0.2618 5083 0.059 0.3 0.05 0.63 
Parent-rated 
Negative Symptoms 
77096 0.2618 8763 0.059 0.3 0.05 0.85 
Note. PE, psychotic experience; N1, sample size of discovery sample; h21, SNP-heritability of 
disorder in training sample on a liability scale; N2, sample size of target sample; h22,  SNP-
heritability of psychotic experience in target sample. Set as meta-GREML-SC estimate from 
Chapter 6; rG, genetic correlation. Estimates calculated using AVENGEME, assuming 100,000 
LD independent genetic markers overlap between samples, 70% of genetic markers have no 
effect on the training trait, and an alpha of 0.05.  
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Supplementary Table 7.2. Power calculations for genetic covariance analysis 
between PEs and bipolar disorder.  
PE N1 h21 N2 h22 rG Alpha Power 
Paranoia and 
Hallucinations 
16731 0.2548 7970 0.028 0.2 0.05 0.09 
Anhedonia 16731 0.2548 6068 0.088 0.2 0.05 0.16 
Cognitive 
Disorganization 
16731 0.2548 5083 0.059 0.2 0.05 0.11 
Parent-rated 
Negative Symptoms 
16731 0.2548 8763 0.059 0.2 0.05 0.15 
Paranoia and 
Hallucinations 
16731 0.2548 7970 0.028 0.3 0.05 0.15 
Anhedonia 16731 0.2548 6068 0.088 0.3 0.05 0.30 
Cognitive 
Disorganization 
16731 0.2548 5083 0.059 0.3 0.05 0.19 
Parent-rated 
Negative Symptoms 
16731 0.2548 8763 0.059 0.3 0.05 0.29 
Note. PE, psychotic experience; N1, sample size of discovery sample; h21, SNP-heritability of 
disorder in training sample on a liability scale; N2, sample size of target sample; h22,  SNP-
heritability of psychotic experience in target sample. Set as meta-GREML-SC estimate from 
Chapter 6; rG, genetic correlation. Estimates calculated using AVENGEME, assuming 100,000 
LD independent genetic markers overlap between samples, 70% of genetic markers have no 
effect on the training trait, and an alpha of 0.05.  
 278 
Supplementary Table 7.3. Power calculations for genetic covariance analysis 
between PEs and major depression. 
PE N1 h21 N2 h22 rG Alpha Power 
Paranoia and 
Hallucinations 
18759 0.1919 7970 0.028 0.2 0.05 0.09 
Anhedonia 18759 0.1919 6068 0.088 0.2 0.05 0.14 
Cognitive 
Disorganization 
18759 0.1919 5083 0.059 0.2 0.05 0.10 
Parent-rated 
Negative Symptoms 
18759 0.1919 8763 0.059 0.2 0.05 0.14 
Paranoia and 
Hallucinations 
18759 0.1919 7970 0.028 0.3 0.05 0.14 
Anhedonia 18759 0.1919 6068 0.088 0.3 0.05 0.26 
Cognitive 
Disorganization 
18759 0.1919 5083 0.059 0.3 0.05 0.17 
Parent-rated 
Negative Symptoms 
18759 0.1919 8763 0.059 0.3 0.05 0.25 
Note. PE, psychotic experience; N1, sample size of discovery sample; h21, SNP-heritability of 
disorder in training sample on a liability scale; N2, sample size of target sample; h22,  SNP-
heritability of psychotic experience in target sample. Set as meta-GREML-SC estimate from 
Chapter 6; rG, genetic correlation. Estimates calculated using AVENGEME, assuming 100,000 
LD independent genetic markers overlap between samples, 70% of genetic markers have no 
effect on the training trait, and an alpha of 0.05.  
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Supplementary Table 7.4. Schizophrenia polygenic risk score predicting psychotic 
experience domains at 8 p-value thresholds. 
Paranoia and Hallucinations   
pT β SE p r2 
0.001 0.002 0.011 0.889 0.000% 
0.01 -0.001 0.011 0.926 0.000% 
0.05 0.001 0.011 0.915 0.000% 
0.1 -0.002 0.011 0.824 0.001% 
0.2 -0.005 0.011 0.664 0.002% 
0.3 -0.002 0.011 0.848 0.000% 
0.4 -0.002 0.011 0.832 0.001% 
0.5 -0.002 0.011 0.892 0.000% 
Paranoia and Hallucinations (excl. zero-scorers)  
pT β SE p r2 
0.001 0.031 0.012 0.008 0.094% 
0.01 0.026 0.012 0.025 0.067% 
0.05 0.019 0.012 0.098 0.037% 
0.1 0.017 0.012 0.156 0.028% 
0.3 0.015 0.012 0.208 0.022% 
0.4 0.012 0.012 0.311 0.014% 
0.5 0.011 0.012 0.336 0.013% 
0.2 0.010 0.012 0.404 0.010% 
Anhedonia     
pT β SE p r2 
0.001 0.021 0.013 0.104 0.043% 
0.01 0.025 0.013 0.050 0.063% 
0.05 0.022 0.013 0.083 0.050% 
0.1 0.028 0.013 0.030 0.079% 
0.2 0.028 0.013 0.034 0.076% 
0.3 0.023 0.013 0.077 0.052% 
0.4 0.024 0.013 0.059 0.059% 
0.5 0.027 0.013 0.039 0.071% 
Cognitive Disorganisation   
pT β SE p r2 
0.001 0.024 0.014 0.081 0.057% 
0.01 0.029 0.014 0.035 0.083% 
0.05 0.028 0.014 0.048 0.076% 
0.1 0.026 0.014 0.065 0.067% 
0.2 0.024 0.014 0.082 0.059% 
0.3 0.028 0.014 0.048 0.077% 
0.4 0.027 0.014 0.056 0.072% 
0.5 0.028 0.014 0.050 0.076% 
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Supplementary Table 7.4 cont. 
Negative Symptoms    
pT β SE p r2 
0.001 0.019 0.011 0.078 0.034% 
0.01 0.026 0.011 0.015 0.067% 
0.05 0.030 0.011 0.005 0.088% 
0.1 0.025 0.011 0.021 0.061% 
0.2 0.026 0.011 0.014 0.069% 
0.3 0.027 0.011 0.012 0.073% 
0.4 0.024 0.011 0.023 0.059% 
0.5 0.024 0.011 0.027 0.057% 
 Note. pT, p-value threshold used to select genetic variation included in risk score; β, 
standardised beta value.  
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Supplementary Table 7.5. Bipolar disorder polygenic risk score predicting psychotic 
experience domains at 8 p-value thresholds. 
Paranoia and Hallucinations     
pT β SE p r2 
0.001 -0.022 0.011 0.051 0.049% 
0.01 -0.034 0.011 0.002 0.115% 
0.05 -0.028 0.011 0.014 0.076% 
0.1 -0.026 0.011 0.019 0.069% 
0.2 -0.021 0.011 0.062 0.043% 
0.3 -0.019 0.011 0.095 0.035% 
0.4 -0.019 0.011 0.094 0.035% 
0.5 -0.020 0.011 0.077 0.039% 
Anhedonia     
pT β SE p r2 
0.001 0.007 0.013 0.600 0.004% 
0.01 0.010 0.013 0.448 0.009% 
0.05 -0.013 0.013 0.304 0.017% 
0.1 -0.017 0.013 0.178 0.030% 
0.2 -0.011 0.013 0.385 0.013% 
0.3 -0.014 0.013 0.269 0.021% 
0.4 -0.011 0.013 0.391 0.012% 
0.5 -0.011 0.013 0.399 0.012% 
Cognitive Disorganisation     
pT β SE p r2 
0.001 -0.013 0.014 0.333 0.017% 
0.01 -0.001 0.014 0.937 0.000% 
0.05 0.008 0.013 0.541 0.007% 
0.1 0.005 0.013 0.725 0.002% 
0.2 -0.001 0.013 0.964 0.000% 
0.3 0.006 0.013 0.665 0.003% 
0.4 0.006 0.013 0.670 0.003% 
0.5 0.004 0.013 0.754 0.002% 
Parent-rated Negative Symptoms     
pT β SE p r2 
0.001 -0.009 0.011 0.425 0.007% 
0.01 0.002 0.011 0.837 0.000% 
0.05 0.003 0.011 0.786 0.001% 
0.1 -0.002 0.011 0.858 0.000% 
0.2 -0.005 0.011 0.626 0.003% 
0.3 -0.007 0.011 0.506 0.005% 
0.4 -0.006 0.011 0.551 0.004% 
0.5 -0.009 0.011 0.388 0.008% 
Note. pT, p-value threshold used to select genetic variation included in risk score; β, 
standardised beta value.  
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Supplementary Table 7.6. Major depression polygenic risk score predicting 
psychotic experience domains at 8 p-value thresholds. 
Paranoia and Hallucinations   
pT β SE p r2 
0.001 0.002 0.011 0.861 0.000% 
0.01 -0.002 0.011 0.835 0.001% 
0.05 0.002 0.011 0.877 0.000% 
0.1 0.006 0.011 0.589 0.004% 
0.2 -0.002 0.011 0.892 0.000% 
0.3 0.004 0.011 0.687 0.002% 
0.4 0.000 0.011 0.980 0.000% 
0.5 0.001 0.011 0.926 0.000% 
Anhedonia     
pT β SE p r2 
0.001 0.003 0.013 0.794 0.001% 
0.01 0.019 0.013 0.135 0.037% 
0.05 0.022 0.013 0.083 0.048% 
0.1 0.023 0.013 0.069 0.053% 
0.2 0.024 0.013 0.062 0.057% 
0.3 0.029 0.013 0.025 0.082% 
0.4 0.032 0.013 0.014 0.100% 
0.5 0.033 0.013 0.010 0.109% 
Cognitive Disorganisation   
pT β SE p r2 
0.001 -0.012 0.014 0.403 0.014% 
0.01 0.010 0.014 0.479 0.009% 
0.05 0.018 0.014 0.189 0.033% 
0.1 0.015 0.014 0.285 0.021% 
0.2 0.007 0.014 0.610 0.005% 
0.3 0.014 0.014 0.316 0.019% 
0.4 0.014 0.014 0.296 0.021% 
0.5 0.015 0.014 0.276 0.022% 
Parent-rated Negative Symptoms   
pT β SE p r2 
0.001 0.028 0.011 0.008 0.078% 
0.01 0.020 0.011 0.061 0.040% 
0.05 0.021 0.011 0.051 0.044% 
0.1 0.013 0.011 0.226 0.018% 
0.2 0.012 0.011 0.271 0.014% 
0.3 0.014 0.011 0.187 0.021% 
0.4 0.012 0.011 0.283 0.013% 
0.5 0.012 0.011 0.273 0.014% 
Note. pT, p-value threshold used to select genetic variation included in risk score; β, 
standardised beta value.  
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Supplementary Table 7.7. Comparison of schizophrenia, bipolar disorder, and 
major depression polygenic risk scores in low and high psychotic experience 
domain groups.  
Schizophrenia    
PE OR CI 95% p 
Paranoia and Hallucinations 0.997 0.049 0.894 
P and H excl. zero-scorers 1.077 0.077 0.059 
Anhedonia 1.073 0.067 0.039 
Cognitive Disorganization 1.110 0.070 3.82x10-3 
Parent-rated Negative 
Symptoms 
1.084 0.059 7.42x10-3 
 
   
Bipolar Disorder    
PE OR CI 95% p 
Paranoia and Hallucinations 0.903 0.050 5.90x10-5 
Anhedonia 0.967 0.068 0.338 
Cognitive Disorganization 0.999 0.071 0.968 
Parent-rated Negative 
Symptoms 
0.974 0.058 0.384 
 
   
Major Depression    
PE OR CI 95% p 
Paranoia and Hallucinations 1.032 0.050 0.218 
Anhedonia 1.102 0.067 4.59x10-3 
Cognitive Disorganization 1.061 0.071 0.099 
Parent-rated Negative 
Symptoms 
1.062 0.058 0.042 
Note. PE, psychotic experience; P and H excl. zero-scorers, Paranoia and Hallucinations 
excluding zero scorers; OR, odds ratio; CI 95%, 95% confidence interval of odds ratio. Low 
and high groups were defined as the bottom and top 25% of raw psychotic experience 
domain sum scores. This table shows results when using polygenic risk scores at the most 
predictive p-value threshold for each trait. Linear regression results for the same p-value 





Supplementary Figure 7.1. Schizophrenia (SCZ) PRS predicting specific adolescent 
PEs within TEDS, ALSPAC and CATSS samples.  
Note. This figure shows results for polygenic risk scores at the most predictive across sample 
p-value threshold for each trait. TE, effect size; seTE, Effect size standard error; 95%-CI, 95% 
confidence intervals. Error bars represent 95% confidence intervals. 
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Supplementary Figure 7.2. Bipolar disorder (BD) PRS predicting specific adolescent 
PEs within TEDS, ALSPAC and CATSS samples.  
Note. This figure shows results for polygenic risk scores at the most predictive across sample 
p-value threshold for each trait. TE, effect size; seTE, Effect size standard error; 95%-CI, 95% 




Supplementary Figure 7.3. Major depression (MDD) PRS predicting specific 
adolescent PEs within TEDS, ALSPAC and CATSS samples.  
Note. This figure shows results for polygenic risk scores at the most predictive across sample 
p-value threshold for each trait. TE, effect size; seTE, Effect size standard error; 95%-CI, 95% 






Chapter 8 - Discussion 
This chapter will first provide a short reintroduction of the pre-existing literature 
surrounding adolescent psychotic experiences (PEs) that motivated the overarching 
aims of this thesis. Second, a brief overview of the six empirical chapters will be 
provided. Finally, key points relating to this thesis will be discussed in a wider context, 
including the genetic architecture of adolescent PEs, the relationship between 
adolescent PEs and schizophrenia, bipolar disorder, and major depression, and the 
pooling of information across multiple samples. 
8.1 – Motivation for this thesis 
The following section will summarise information discussed in Sections 1.2.1, 1.2.2, 
1.5.2, 1.5.3, and 1.6.1.  
Adolescent PEs have been phenotypically associated with psychotic and non-psychotic 
psychiatric disorders in adulthood, as well as several aspects of adolescent mental 
health. Adolescent PEs have been shown to exist as quantitative and specific traits, 
typically separating into positive, cognitive and negative symptoms domains. Twin 
studies estimates that a third to half of the variance in adolescent PEs are accounted for 
by genetic factors. One previous study has provided evidence that for some PEs, 
approximately half of this heritability is explained by common genetic variation. There 
has been one genome-wide association study (GWAS) of adolescent PEs, which returned 
no genome-wide significant variation (p < 5x10-8). Family-based studies have reported 
that adolescent PEs may share genetic factors with schizophrenia and affective 
disorders. The common genetic relationship between adolescent PEs and psychiatric 
disorders has been explored using two samples for schizophrenia, and one sample for 
bipolar disorder. For schizophrenia, studies suggested no common genetic relationship 
between positive or cognitive PEs and schizophrenia, but there were mixed findings 
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relating to negative symptoms. For bipolar disorder, there was no common genetic 
relationship with adolescent PEs. 
This previous research relating to common genetic variation has provided useful insight 
into the common genetic architecture of adolescent PEs and their relationship with 
some psychiatric disorders. However, these previous studies had several limitations. 
One limitation is the use of binary and non-specific PE measures. This approach reduces 
statistical power due to phenotypic heterogeneity within groups, and doesn’t allow the 
investigation of non-linear effects. Another limitation of these previous studies is the use 
of one moderately small sample (N = 3,483) thus limiting statistical power and the 
findings are less generalizable.  
Given the importance of characterising the common genetic basis of adolescent PEs and 
their relationship with psychiatric disorders, and the limitations of previous studies, this 
thesis had the following specific aims: 1) Harmonise genetic data from samples with 
adolescent PE data to enable combined analysis, 2) Harmonise measures of specific PEs 
between samples, 3) Estimate SNP-heritability of specific PEs. 4) Perform GWAS of 
specific PEs to identify associated genetic variation and biological pathways. 5) Estimate 
the genetic correlation between specific PEs and typically adult-onset psychiatric 
disorders including schizophrenia, bipolar disorder and major depressive disorder. 
8.2 – Summary of methods and results 
8.2.1 – GWAS of specific adolescent PEs in TEDS 
Chapter 2 performed the second ever GWAS of adolescent PEs within the TEDS (Twins 
Early Development Study) sample alone. This study used quantitative and specific 
measures of adolescent PEs to improve statistical power. Another step taken to improve 
statistical power was the inclusion of ungenotyped siblings of monozygotic individuals 
using a generalised estimating equation. Across the six specific PE genome-wide 
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association analyses three independent loci were associated at genome-wide 
significance, two for Cognitive Disorganisation, and one for Parent-rated Negative 
Symptoms. One of the associations for Cognitive Disorganisation was within CSMD1, a 
gene previously associated with schizophrenia. Limitations of this study were sample 
size and lack of a replication sample. Subsequent chapters worked towards using 
multiple samples to investigate the genetic basis of adolescent PEs. 
8.2.2 – Effect of normalising residuals 
In preparation for harmonising data between samples to improve statistical power for 
subsequent analyses, the effect of normalisation before or after correcting for covariates 
was investigated in Chapter 3. Correcting for covariates before normalisation has the 
practical advantage of separating tied observations, improving the efficacy of rank-
based normalisation. However, this chapter showed that normalisation of residuals can 
re-introduce a correlation with covariates, resulting in confounding effects. Rank-based 
normalisation (randomly splitting ties) before correcting for covariates was shown to be 
an alternative approach with many of the practical advantages of the previous approach, 
but without causing confounding. This approach was therefore employed when 
preparing phenotypic data for analysis in subsequent chapters. 
8.2.3 – Harmonisation of PE measures of samples 
In Chapter 4, the items assessing aspects of PEs within each sample were identified with 
the help of clinicians. Using principal components analysis the correlation structure 
between PE items was investigated within each sample to identify specific domains. 
Four comparable domains were identified in each sample confirming the existence of 
distinct and replicable PE domains: Paranoia and Hallucinations, Anhedonia, Cognitive 
Disorganisation, and Parent-rated Negative Symptoms. Items within these domains 
were then used to create scales. 
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8.2.4 – GWAS of specific adolescent PEs in TEDS, ALSPAC, and CATSS 
Chapter 5 aimed to perform a genome-wide association study of these harmonised PE 
measures across the three samples. This involved genotypic harmonisation of the 
samples through careful quality control, imputation to a common reference, and 
estimation of population structure covariates. The four mega-GWASs returned one 
variant achieving genome-wide significance. This genome-wide significant variant for 
Anhedonia was within a biologically plausible gene but was not replicated in the 
replication sample, possibly suggesting that it was a false positive. Gene based 
association analysis was also used to identify associated genes. One gene achieved 
significance but did not replicate in the replication sample. The absence of many 
genome-wide significant associations demonstrated a lack of power possibly due to 
overall sample size, between sample heterogeneity, or a low amount of PE variance that 
can be explained by common genetic variation. 
8.2.5 – Estimating SNP-heritability of specific adolescent PEs in TEDS, ALSPAC, and CATSS 
Chapter 6 aimed to characterise the genetic architecture of adolescent PEs within a 
homogenous sample, but also to estimate the SNP-heritability of PEs across the three 
samples. This chapter provided evidence that ~3-9% of the heritability of adolescent PE 
could be accounted for by common additive genetic variation, with estimates of SNP-
heritability for Anhedonia and Cognitive Disorganisation being significantly non-zero. 
The SNP-heritability was higher for more normally distributed traits (Anhedonia and 
Cognitive Disorganisation) than skewed traits (Paranoia and Hallucinations and Parent-
rated Negative Symptoms). This could reflect differences in underlying genetic 
architecture, or the appropriateness of current methods for estimating SNP-heritability 
of skewed traits. Across-sample (mega) estimates of SNP-heritability were lower than 
within-sample (meta) estimates, suggesting heterogeneity between the samples.  
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8.2.6 – Estimating genetic association between psychiatric disorders and specific adolescent 
PEs in TEDS, ALSPAC, and CATSS 
Chapter 7 aimed to test for evidence of a SNP-based genetic covariance between 
adolescent PEs and schizophrenia, bipolar disorder and major depression. This chapter 
demonstrated significant positive genetic covariance between a range of adolescent PE 
and schizophrenia and major depression, but a negative genetic covariance with bipolar 
disorder. These results were broadly supported by LD-score regression analysis.  
8.3 – Wider implications of research 
8.3.1 – The genetic architecture of adolescent PEs 
This thesis reports that 3%-9% of the variance in adolescent PEs can be explained by 
common genetic variation. Estimates of SNP-heritability varied across specific PE 
domains, with higher estimates for Anhedonia and Cognitive Disorganisation than for 
Paranoia and Hallucinations and Parent-rated Negative Symptoms. These estimates of 
SNP heritability accounted for 10%-19% of the twin-based heritability. This discrepancy 
is a result of several factors as described in Section 6.4. 
The items within Paranoia and Hallucinations and Parent-rated Negative measures were 
more rarely endorsed in comparison to the items within Anhedonia and Cognitive 
Disorganisation measures. This thesis potentially supports a difference in genetic 
architecture between these two groups of PEs as well, with Anhedonia and Cognitive 
Disorganisation showing larger amounts of variance explained by common genetic 
effects than Paranoia and Hallucinations and Parent-rated Negative Symptoms. There 
are a number of possible reasons for this difference. 
The first reason could be a methodological one. Although SNP-heritability estimates 
were calculated using two different methodologies, both were based on normalised PE 
scores. The process of normalisation can introduce artificial variance (i.e. noise) and 
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thereby reduce the proportion of variance that can be explained by common genetic 
variation. Normalisation will have a larger effect on more highly skewed variables, 
which could therefore explain why the more skewed traits show a lower SNP-
heritability. Although GREML SNP-heritability estimates were consistent when using 
untransformed PE scores, it has been reported that GREML underestimates the SNP-
heritability of skewed traits (Nivard et al., 2016). Further simulation studies are 
required to investigate the effect of skew on estimates of SNP-heritability. 
A second reason that SNP-heritability estimates vary between adolescent PEs, in spite of 
similar twin heritability estimates, is that different parts of the minor allele frequency 
spectrum are contributing to their variance. Investigation of rare genetic variation 
associated with adolescent PEs was not within the scope of this thesis. However, a 
future study investigating the contribution of genetic variation with a frequency below 
0.01 would be of interest. 
A third reason for a difference in SNP-heritability between adolescent PEs could be due 
to contributions of non-SNP variation (i.e. CNVs and InDels) varying across PEs. 
Although some CNVs and InDels were available in the genetic data used when 
estimating SNP-heritability, the coverage of non-SNP variation was low. Therefore, it is 
possible that an increased contribution of non-SNP variation for a given PE could lead to 
smaller SNP-heritability estimates. 
8.3.2 – The genetic relationship between adolescent PEs and schizophrenia, bipolar disorder 
and major depression 
This thesis reports a significant genetic covariance between a range of specific 
adolescent PEs and schizophrenia, bipolar disorder, and major depression. This 
supports the notion that adolescent PEs share biological pathways with adult 
psychiatric disorders, and are not merely epiphenomena. As suggested by previous 
epidemiological studies, the genetic association between adolescent PEs, schizophrenia, 
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and major depression was positive. Prior to this thesis, only the positive common 
genetic association between adolescent Negative Symptoms and schizophrenia had been 
demonstrated. The common genetic association between schizophrenia and adolescent 
Paranoia and Hallucinations when excluding zero scorers had not been identified in 
previous studies that used two of the same samples, highlighting the importance of 
investigating non-linear effects. Contrary to previous research (McGrath et al., 2016), 
the genetic association between adolescent PEs and bipolar disorder was negative, 
indicating that genetic variation increasing the presence of adolescent PEs actually 
decrease the risk of developing bipolar disorder. Although the genetic association 
between adolescent PEs and bipolar disorder is not positive, the strength of the 
association implies again that PEs are meaningful to clinical outcomes. 
Although non-zero estimates of genetic covariance are informative, the magnitude of the 
genetic overlap is important as it indicates the amount of variance in one trait that can 
be explained by the genetic variants associated with another. For example, this thesis 
reports that the SNP-based genetic correlation between schizophrenia and Cognitive 
Disorganisation is ~0.15, this means that if all of the SNP-heritability in Cognitive 
Disorganisation could be explained, then ~2.2% of the SNP-heritability of schizophrenia 
could also be explained. When considering the value of studying Anhedonia to gain 
insight into major depression, the genetic correlation of ~0.45 suggests that if the SNP-
heritability of Anhedonia could be fully explained, then 20% of the SNP-heritability of 
major depression could also be explained. This thesis was unable to calculate the 
magnitude of genetic correlation for Paranoia and Hallucinations and Parent-rated 
Negative Symptoms due to the apparent zero heritability (across samples). These 
findings indicate that the common genetic basis of specific adolescent PEs are to some 
degree informative of the common genetic basis of psychiatric disorders. 
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Given the evidence of shared aetiology between certain adolescent PEs and psychiatric 
disorders, in theory adolescent PEs could be used as a predictor for the onset of these 
psychiatric disorders. However, the amount of the total phenotypic variance in 
psychiatric disorders that could be explained by only the common genetic variation 
underlying adolescent PEs is likely to be low in most cases as the SNP-heritability of 
these psychiatric disorders is 19-26%. For example, if all of the SNP-heritability in 
Cognitive Disorganisation could be explained, then ~2.2% of the SNP-heritability of 
schizophrenia could also be explained. Given that common genetic variation only 
accounts for 26% of the variance in schizophrenia, the common genetic variation 
underlying adolescent Anhedonia would explain 0.6% of the total phenotypic variance 
in schizophrenia. For another example, if all of the SNP-heritability of Anhedonia could 
be explained, 20% of the SNP-heritability of major depression could also be explained. 
Given that common genetic variation only accounts for 19% of the variance in major 
depression, the common genetic variation underlying adolescent Anhedonia would 
explain 3.8% of the total phenotypic variance in major depression. Given the sample 
sizes required to fully account for the SNP-heritability of adolescent PEs, using the 
common genetic basis of adolescent PEs alone to predict later psychiatric disorders will 
likely be inefficient. However, given the complex aetiology of common psychiatric 
disorders it is unlikely to find many predictors (apart from family history) with large 
effect size, and therefore, even if the variance explained by the common genetic basis of 
adolescent PEs is small, it could make a useful contribution to the prediction of 
psychiatric disorders in combination with other predictors. Although the non-zero 
genetic covariance estimates presented here indicate that genetic variation associated 
with adolescent PEs may be useful for the prediction of certain adult psychiatric 
disorders, we view strong statements about causality as impossible (Pickrell et al., 
2016). For example, a correlation between two variables might be mediated by a third 
variable that is correlated with both outcomes. The same concept applies to the 
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interpretation of genetic correlation estimates. Therefore, the non-zero genetic 
covariance estimates between PEs and psychiatric disorders indicate an overlap in 
associated heritable factors. 
8.3.3 – The pooling of information across multiple samples 
Pooling information across samples has two key advantages. Firstly, increasing sample 
size improves statistical power to identify associations at significance. This is very 
important when studying the common genetic basis of complex traits, such as 
adolescent PEs, as the effect size of individual genetic variants is very small. Secondly, by 
including multiple samples in an analysis, it reduces the likelihood of identifying sample 
specific effects. Therefore the results from combined sample analyses are likely to be 
more generalisable to other populations. 
This thesis has indicated that increasing sample size does not always increase statistical 
power to detect genetic associations. When studying adolescent PEs in the TEDS sample 
alone, the genome-wide association study (GWAS) identified several genome-wide 
associations. Whereas in the combined sample GWAS, only one genetic association was 
identified at genome-wide significance. In theory, as sample size increases, our ability to 
identify small effect sizes at significance also increases. One reason why fewer genome-
wide significant associations were identified when using larger samples could be that 
the likelihood of detecting false positives increases in smaller samples. Another reason 
may be that combining multiple samples leads to an increase in heterogeneity (thereby 
decreasing effect sizes) that outweighs the increase in statistical power. The comparison 
of within and across sample SNP-heritability estimates in Chapter 6 demonstrates the 
presence of heterogeneity between samples, reducing the variance in PEs that can be 
explained by common genetic variation. The inverse relationship between magnitude of 
effect size and sample size has been seen in other areas of genetics as well. For example, 
a recent RNA sequencing study of schizophrenia that used a sample 10-fold larger than 
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any previous RNA-sequencing study reported that differential gene expression was far 
more subtle (i.e. smaller effect sizes) than previous smaller studies had reported 
(Fromer et al., 2016). Unlike previous smaller RNA-sequencing studies of schizophrenia, 
this large RNA-sequencing identified no gene as significantly differentially expressed 
(Fromer et al., 2016). It is likely that there is a trade off between the increase in sample 
size and the increase in heterogeneity when adding samples to an analysis.  
In terms of improving the generalizability of results, pooling information from multiple 
samples in this thesis has been successful. The harmonisation of the specific PE 
measures within each sample has enabled direct comparison of the results from each 
sample, and the combined analysis across samples has provided more accurate 
estimates of effects. Prior to this thesis, the SNP-heritability of specific adolescent PEs 
had only been estimated in one sample. This thesis estimated the SNP-heritability of 
specific PEs in three samples, highlighting differences in SNP-heritability estimates 
within each sample, but also providing more accurate estimates of SNP-heritability by 
averaging estimates across samples (meta-SNP-heritability). Furthermore, prior to this 
thesis, the relationship between adolescent PEs and schizophrenia had been explored 
using two samples. These samples reported contrasting results that could not be 
directly compared due to differences in the measures used, meaning that an overall 
effect could not be estimated. This thesis enabled the direct comparison of within 
sample effects and provided overall effect size estimates. These are just two examples 
demonstrating the utility of analysing multiple phenotypically harmonised samples. 
8.4 – Considerations for future research 
8.4.1 – Measurement 
A key strength of this thesis was the derivation of psychometrically-sound quantitative 
individual PE domains: these were derived using principal component analysis and had 
content validity. Greater power was achieved compared to past research through 
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combining independent samples. However, as mentioned in the previous section, 
differences between the measures across samples impact the amount of phenotypic 
variance across the three samples that can be explained by common genetic variation. 
One approach to overcome this issue would be to alter the measures within each sample 
to optimise (increase) the across sample (mega-) SNP-heritability.  
8.4.2 – Models for non-normal data 
For the more skewed PE domains, with larger numbers of tied individuals, the process 
of randomly ranking tied individuals during normalisation will have introduced noise 
and thus downward biased SNP-heritability estimates and other parameter estimates. 
Given that normalisation is essential for combined analysis of multiple samples (mega-
analysis) and the standard linear regression, a more powerful approach may be to use a 
model that does not assume normality (or is heteroskedasticity robust) to estimate 
effects within each sample, and then perform meta-analysis of the results. Although 
using more complex models present their own practical limitations, such as often not 
being available in genome-wide analysis software, application of models that do not 
require the normality assumption should be explored further. 
8.4.3 – Genetic relationship between adolescent PEs and other traits/disorders 
This thesis has only investigated the common genetic relationship between adolescent 
PEs and three psychiatric disorders. It would be useful to estimate the genetic 
relationship between adolescent PEs and other phenotypes, to understand the position 
of adolescent PEs in the aetiological landscape of health and disease. Schizophrenia, 
bipolar disorder and major depression were chosen due to past epidemiological links, 
their ostensible connection in terms of similarity of phenotype (e.g. paranoia, 
anhedonia), and the availability of well-powered genome-wide association summary 
statistics. There are other phenotypes that have past epidemiological links with 
adolescent PEs that should also be investigated such as autistic traits (R. B. Jones, 
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Thapar, Lewis, & Zammit, 2012; Taylor, Robinson, et al., 2015) and sleep disturbances 
(Taylor, Gregory, Freeman, & Ronald, 2015; Thompson et al., 2015). Phenotypes that are 
correlated with adolescent PEs on a phenotypic level are expected to also correlate at a 
common genetic level.  
The genetic correlation between two phenotypes can also be used to infer a phenotypic 
association. Given that the genetic correlation between two phenotypes can be 
estimated even when the phenotype has been measured in separate samples, this 
provides an opportunity to identify novel phenotypic associations between adolescent 
PEs and outcomes assessed in separate samples. 
8.4.4 – Developmental stages of PEs 
This thesis has focused on PEs in adolescence for reasons described in Section 1.1 and 
1.2.2. However, investigation of the relationship between PEs in adulthood and 
psychiatric disorders would be of interest as it could shine light on the factors that 
change specific PEs in healthy individuals into symptoms of a pathology. Furthermore, 
the relationship between adolescent PEs and adult PEs would also be of interest. 
8.4.5 – Rare genetic variation 
As previously mentioned in Section 8.3.1, this thesis has focused on common genetic 
variation only. Given that common genetic variation only accounts for a part of the 
variance in adolescent PEs, other sources of variance should also be explored, including 
rarer genetic variation, environmental factors, and the interplay between genetic and 
environmental factors.  
Ideally, investigation of rare genetic variation underlying adolescent PEs would be 
achieved using DNA sequence data. However, a cheaper and more practical way of 
investigating the contribution of rarer genetic variation would be to impute genotype 
array data using a larger genomic reference panel, such as the Haplotype Reference 
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Consortium (McCarthy et al., 2016). Genomic reference panels with large samples can 
more accurately impute rarer genetic variation (J. Huang et al., 2015). 
There have already been several studies investigating the environmental factors 
underlying adolescent PEs, for example cannabis use and stressful life events (Shakoor 
et al., 2015, 2016). To improve power to detect environmental effects and uncover 
interplay between genetic and environmental factors, future studies investigating 
environmental factors could incorporate genetic data in their analyses by stratifying by 
genotype or incorporating interaction effects in the model. 
8.5 – Conclusion and future directions 
In conclusion, this thesis has provided a robust characterisation of the common genetic 
basis of specific adolescent PEs through the harmonisation and combined analysis of 
data from three European samples. It has provided evidence that common genetic 
variation accounts for 3-9% of the variance in adolescent PEs, with some suggestion that 
the rarer PEs may also have a rarer genetic architecture. This thesis has performed the 
largest GWAS of adolescent PEs to date, identifying one genome-wide significant variant 
for Anhedonia. Additionally, predicted gene expression association analysis identified 
one gene significantly associated with Cognitive Disorganisation. This thesis has also 
provided robust evidence of a genetic overlap between adolescent PEs and 
schizophrenia and major depression. 
This thesis has highlighted many research avenues for future studies. First, investigation 
into the different contributions of common genetic variation across specific adolescent 
PEs requires further investigation. Does the genetic architecture of specific adolescent 
PEs vary in terms of the frequency or type of underlying genetic variation? Or is the 
difference in SNP-heritability between specific PEs a reflection of methodological issues 
relating to the skew of traits. Second, although effects were often consistent between the 
different samples used in this thesis, investigation of the heterogeneity between these 
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three samples could help understand instances where effects differed. This process 
could uncover factors underlying observed effects, and could also aid in the planning 
and interpretation of future studies. Third, investigation of the genetic association 
between adolescent PEs and other phenotypes should occur. This thesis has supported 
the notion that adolescent PEs are clinically meaningful, and it would therefore by 
interesting to estimate their genetic (and phenotypic) relationship with other outcomes.  
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